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CHAPTER I 
 
BIOLOGY OF THE POLARIZED EPITHELIUM 
 
Epithelial cells make up the epithelial tissue or epithelium that covers all 
external and internal organs of multicellular organisms. There are four principal 
types of epithelium: simple columnar, simple squamous, transitional, and 
stratified squamous (Lodish, 2003). One of the most important functions of the 
epithelium is the creation of a selectively permeable barrier that separates 
chemically and functionally distinct compartments. This compartmentalization 
allows for different functions and reactions to proceed simultaneously within an 
organism. Accordingly, epithelial cells contain four distinct structural elements to 
create and maintain epithelial polarity: the apical membrane, the tight junction, 
the adherens junction, and the basolateral (BL) membrane (Figure 1) (St 
Johnston and Ahringer, 2010). These cellular regions are biochemically and 
functionally divergent polarized membrane surfaces with distinct protein and lipid 
compositions (Martin-Belmonte and Mostov, 2008). 
 
The Apical Membrane 
The apical membrane is the surface of the cell exposed to the lumen or 
external environment. Because this environment can vary dramatically 
depending on the location of the cell, there is great variety in the composition of 
apical membranes. Apical membranes often contain structural elements that 
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interact with the external environment and these structures vary depending on 
the cell location and function. For example, the apical membranes of intestinal 
and kidney cells contain protrusions of microvilli, collectively termed a brush 
border, which increases the absorptive capacity of the cell (Nambiar et al., 2010). 
The apical membrane is also the location of the primary cilium that acts as a 
“cellular antenna” for a variety of sensory and signaling mechanisms (Singla and 
Reiter, 2006). Because this membrane is the interface between the external 
environment and the interior of an organism, endocytosis at the apical membrane 
is much more regulated then the BL membrane, such that the rate of endocytosis 
at the apical surface is only 20% the rate of endocytosis at the BL surface 
(Mostov et al., 2000).  The apical membrane is enriched in glycosphingolipids, 
which may function to protect the cell from the harsh environment of the lumen, 
and depleted in phosphatidylcholine (Simons and van Meer, 1988; van Meer and 
Simons, 1988). The protein components of the apical membrane include ion 
channels and transporters that regulate nutrient and water uptake as well as 
hydrolases involved in digestive and protective functions (Rodriguez-Boulan and 
Nelson, 1989). Maintaining the appropriate protein and lipid composition of the 
apical membrane is critical for proper cellular function.  
 
Tight Junctions 
Tight junctions perform multiple functions in polarized epithelial cells. Tight 
junctions are the major paracellular barrier between the external and internal 
milieu (Denker and Nigam, 1998). The apical membrane is physically separated  
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Figure 1. Basic schematic of a polarized epithelial cell. Epithelial cells form a 
selectively permeable barrier that facilitates the creation of chemically and 
functionally distinct compartments within an organism. To cope with the disparate 
environments created by this compartmentalization, epithelial cells must 
establish biochemically and functionally diverse membrane surfaces with distinct 
lipid and protein compositions. The apical membrane faces the lumen or external 
environment; the lateral membrane faces neighboring cells; the basal membrane 
faces the ECM. Tight junctions form a selective paracellular barrier that regulates 
intramembrane diffusion. Adherens junctions mediate cell-cell interactions and 
integrins mediate cell-ECM interactions, both involved in mechanical attachment 
and orientation cues.  
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from the lateral membrane by the tight junctions, which act as a fence to prevent 
the diffusion of lipids within the exoplasmic leaflet and maintain the polarity of the 
cell surface (Aijaz et al., 2006). Tight junctions are comprised of the tetraspan 
adhesion proteins occludin and claudin and the single pass transmembrane 
proteins junctional adhesion molecules (JAMs) and coxsackievirus and 
adenovirus receptor (CAR) (Figure 2)	   (Aijaz et al., 2006). These adhesion 
proteins are clustered together at the tight junctions by ZO-1 and ZO-2, which 
bind to the cytoplasmic domains of occludin and the claudins, linking them to the 
underlying actin cytoskeleton (St Johnston and Ahringer, 2010). Together these 
proteins form a “fence” to separate the apical membrane from the lateral 
membrane and a selective paracellular “gate” acting to regulate ion permeability 
(Kohler and Zahraoui, 2005; Marchiando et al., 2010). 
Occludin, the first tight junction protein to be identified, clearly localizes to 
the tight junction but its function is poorly defined	   (Schneeberger and Lynch, 
2004). Occludin is expressed from a single gene that produces five isoforms by 
alternative splicing	  (Aijaz et al., 2006). Occludin consists of four transmembrane 
domains with two extracellular loops and the N- and C- terminal domains both 
localized in the cytoplasm. The C-terminal domain is rich in serine, threonine, 
and tyrosine residues that are phosphorylated and regulate occludin integration 
into the tight junction and occludins barrier function (Raleigh et al., 2011; 
Sakakibara et al., 1997; Schneeberger and Lynch, 2004). Occludin functions as 
part of the intramembrane diffusion barrier, or “fence”, that separates the apical 
and lateral membrane domains (Balda et al., 1996). Increased expression of 
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occludin within a polarized cell line results in an increased transepithelial 
electrical resistance (TEER), suggesting a role in electrical barrier function and 
regulating the paracellular diffusion of small hydrophilic molecules (Aijaz et al., 
2006; McCarthy et al., 1996). However, occludin null mice exhibit normal tight 
junction morphology and normal barrier function in the intestinal epithelium 
(Saitou et al., 2000). The role of occludin in the tight junction will become more 
clearly defined as more is learned about its regulation and interactions with other 
tight junction proteins. 
Claudins are the major structural component of the tight junctions and 
determine the ion selectivity of the paracellular barrier (Balda and Matter, 2008). 
Claudins are tetraspan transmembrane proteins, with 24 family members 
expressed in a tissue-specific manner. The two extracellular loops of claudins, 
the large first loop and the small second loop, have great variability among family 
members and form intercellular hetero- and homotypic interactions in varying 
combinations, creating diverse ion selectivity barriers (Aijaz et al., 2006; Tsukita 
et al., 2001). The C-terminal cytoplasmic domain, the most heterogeneous region 
of the claudin isoforms, can be phosphorylated and contains a PDZ binding-
motif, suggesting a role for the C-terminal domain in claudin isoform regulation 
and targeting	   (Angelow et al., 2008). Over expression of claudins in fibroblasts 
can induce the formation of tight junction strands, supporting the importance of 
claudins in tight junction structure (Furuse et al., 1998). Future studies on how 
the claudin extracellular loops regulate ion selectivity and the regulatory role of 
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the C-terminal domain will reveal how different claudin isoforms function in 
various epithelial tissues.   
The role of the single pass transmembrane proteins JAMs and CAR at the 
tight junction is not clear. Both proteins have two immunoglobulin folds in their 
extracellular domains that form intercellular homophilic interactions	   (Coyne and 
Bergelson, 2005; Ebnet et al., 2004; Tomko et al., 1997). CAR and the four 
isoforms of JAMs (A-D) localize to the tight junctions and interact with ZO-1 
through the PDZ binding motifs within their cytoplasmic domains (Cohen et al., 
2001; Ebnet et al., 2004). Expression of CAR can reduce the passage of 
macromolecules and ions across a cellular monolayer, suggesting a role in tight 
junction permeability	  (Cohen et al., 2001). JAMs associate with polarity proteins 
as well as ZO-1 and may play a role in cell polarity as opposed to tight junction 
permeability	  (Ebnet et al., 2004). Future investigations into these proteins should 
clarify the roles they play at the tight junctions. 
In addition to providing a physical barrier, the tight junction is the location 
of membrane domain orientation cues essential for establishment and 
maintenance of cellular polarity. These membrane domain orientation cues 
define which membrane is apical and which is BL. Three complexes are 
responsible for providing intrinsic membrane domain orientation cues: the 
Crumbs complex, consisting of crumbs (Crb), protein associated with LIN-7 
(PALS1), and PALS1 associated tight junction protein (PATJ); the partitioning 
defect (Par) complex, consisting of Par3, Par6, and atypical protein kinase C 
(aPKC); and the Scribble complex, consisting of scribble, lethal giant larvae (Lgl),  
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Figure 2. Components of the tight junctions and adherens junctions. An 
illustration of the transmembrane and cytoplasmic proteins that comprise the tight 
and adherens junctions. The tight junctions are the paracellular barrier separating 
the external environment from the interstitium and consist of claudins, occludin, 
JAMs, and CAR (not shown). The adherens junctions mediate cell-cell 
interactions through the transmembrane proteins nectin and E-cadherin. E-
cadherin binds the catenins, α- β- and p120, with its cytoplasmic domain and 
mediates actin dynamics. Afadin links nectin to the actin cytoskeleton. Figure 
adapted from (Coradini et al., 2011)  
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and discs large (Dlg) (Pieczynski and Margolis, 2011). In mammalian epithelial 
cells, the Crumbs and Par complexes localize to the apical side of the tight 
junctions while the Scribble complex localizes to the lateral membrane (Figure 3) 
(Margolis and Borg, 2005). Through protein-protein interactions and 
phosphorylation these three complexes antagonize each other to form the 
boundary between the apical and BL domains at the tight junctions. 
 
The Crumbs Complex 
There are three isoforms of Crb in humans (Crb1-3), with Crb3 involved in 
epithelial polarity and tight junction formation. Crb3 is a transmembrane protein 
with PDZ and FERM binding domains and is located on the apical surface and 
tight junctions of polarized epithelial cells (Makarova et al., 2003). Over 
expression of Crb3 results in expansion of the apical membrane and reduction of 
the BL membrane in polarized cells and can lead to the formation of tight 
junctions in non-polarized cells (Fogg et al., 2005; Roh et al., 2003). This 
suggests a role for Crbs3 in defining the apical membrane.  
PALS1 is a cytosolic protein localized to the tight junction and contains six 
distinct protein interacting domains including a PDZ domain and a L27 domain 
important for epithelial polarity (Pieczynski and Margolis, 2011). Crb3 binds the 
PDZ domain of PALS1 while PATJ binds the L27 domain (Bachmann et al., 
2001; Li et al., 2004b). The N-terminus of PALS1 also binds the PDZ domain of 
Par6, linking the Par and Crumbs complexes (Wang et al., 2004). Knockdown of 
PALS1 results in a loss of PATJ expression and reduced interaction of Par6 and  
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Figure 3. Schematic of the three polarity complexes responsible for 
establishment and maintenance of polar membrane domains. The Crumbs 
complex (CRB/Patj/Pals), localized to the apical surface and tight junctions, 
promotes apical membrane expansion. The Scribbled complex (Scrib/Dlg/Lgl) 
localizes to the lateral membrane and promotes lateral membrane expansion. 
The Par complex (Par3/Par6/aPKC) localizes to the tight junctions and acts as 
the mediator between the Crumbs and Scribbled complexes. Figure adapted 
from (Coradini et al., 2011).  
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Crb3 but does not affect Crb3 expression or localization (Straight et al., 2004). 
These data suggest PALS1 is essential in cell polarity by stabilizing PATJ at the 
tight junction and providing a bridge between the Crumbs and Par complexes. 
The main role of PATJ is as a molecular scaffold. PATJ contains 10 PDZ 
domains and a N-terminal L27 domain (Pieczynski and Margolis, 2011). PATJ 
interacts with PALS1 through the L27 domain and with ZO-3 and claudin-1 
thought PDZ domains, directly linking the Crumbs complex with the tight junction 
(Roh et al., 2002a; Roh et al., 2002b). PATJ is also bound by the protein 
angiomotin, which associates with the Cdc42 GTPase-Activating Protein (GAP) 
Rich1, linking the Crumbs complex with Cdc42 regulation at the tight junction 
(Wells et al., 2006). This regulation of Cdc42 at the tight junction may affect the 
ability of Cdc42 to interaction with Par6	  (Garrard et al., 2003). The three proteins 
that make up the Crumbs complex localize to the apical side of the tight junction 
and regulate the identity of the apical membrane (Mellman and Nelson, 2008). 
 
The Par Complex 
 The Par complex (Par3/Par6/aPKC) localizes to the tight junction and 
binds both and acts as mediator between the Crumbs and Scribbled complexes 
(Mellman and Nelson, 2008). Par3 is a multidomain scaffolding protein that 
contains three PDZ domains that bind Par6, aPKC, and JAM tight junction 
proteins. Par3 is required for the localization of the other Par complex proteins 
and is necessary for the formation of tight junctions (Chen and Macara, 2005; 
Pieczynski and Margolis, 2011). There are two Par3 proteins expressed in 
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humans, Par3A and Par3B. Par3A is the most important for polarity and 
expresses three isoforms in epithelial cells (Gao et al., 2002). Localization of 
Par3 to the tight junction and its association with Par6, Par5, aPKC, and the 
Crumbs complex are all regulated by phosphorylation of Par3 by aPKC or the 
polarity kinase Par1 (Pieczynski and Margolis, 2011). Par3 also spatially 
regulates the activity of Rac1 by interacting with the Rac1 guanine nucleotide 
exchange factor (GEF) Tiam1/2 (Chen and Macara, 2005). This enhancement of 
Rac1 activity at the tight junction is necessary for assembly of tight junctions, but 
can be inhibited by Rho kinase phosphorylation of Par3 (Chen and Macara, 
2005; Nakayama et al., 2008). The localization and regulation of Par3 through 
these various phosphorylation events is critical for tight junction formation and 
epithelial polarity.  
Par6 is a multifunction protein that allows the Par complex to interact with 
both the Crumbs and Scribbled complexes. Par6 contains a PDZ domain 
allowing interaction with Crb3 and PALS1 of the Crumbs complex, while through 
an alternative interaction it can also bind Dlg of the Scribbled complex 
(Pieczynski and Margolis, 2011).  These interactions may be regulated by GTP-
Cdc42, which binds the Par6 simi-CRIB and PDZ domains, altering the ability of 
Par6 to bind components of the Crumbs complex (Garrard et al., 2003). Par6 is 
the link between the other component of the Par complex, binding and activating 
aPKC, which phosphorylates Par3 and results in Par3 binding the PDZ and simi-
CRIB domain of Par6 in a tripartite complex (Pieczynski and Margolis, 2011; 
Yamanaka et al., 2001). The platform provided by Par6 for aPKC is critical in 
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locating aPKC within proximity of two substrates important for polarity and tight 
junction formation, Par3 and Lgl (Hirose et al., 2002; Yamanaka et al., 2003). 
aPKC is thought to regulate the location of these two substrates, with 
phosphorylation of Par3 locating it to the tight junction and phosphorylation of Lgl 
incorporating it into the Scribbled complex (Hirose et al., 2002; Pieczynski and 
Margolis, 2011; Plant et al., 2003). The regulatory roles played by aPKC are 
essential for epithelial cell polarity.  
The term “complex” may be inaccurate to describe the association 
between Par3, Par6, and aPKC. They are most likely in constant flux between 
the Crumbs and Scribbled complexes, regulating both complexes through 
recruitment of various proteins and phosphorylation events that mediate the 
establishment of apical and lateral surfaces.  
 
The Scribbled Complex 
The Scribbled complex (Scribbled/Lgl/Dlg) is located along the lateral 
membrane and is required to define the lateral surface through exclusion of 
apical membrane proteins (Bilder and Perrimon, 2000; St Johnston and Ahringer, 
2010). There is little evidence that the Scribbled complex is actually a “complex” 
because not all the components are known to directly interact, with the exception 
of scribbled and Lgl (Kallay et al., 2006). However, the Scribbled complex 
proteins have complete or partial cellular colocalization and mutations of each 
protein in the complex result in a similar phenotype (St Johnston and Ahringer, 
2010). These results suggest that scribbled, Lgl and Dlg work cooperatively.  
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Scribbled is a large cytosolic scaffold protein that contains 16 leucine rich 
repeats (LRRs) and four PDZ domains (Pieczynski and Margolis, 2011). 
Scribbled localization to the lateral membrane is dependent on the LRRs and the 
junctional protein E-cadherin (Navarro et al., 2005). While loss of scribbled has 
been shown to result in expansion of the apical membrane, knockdown of 
scribbled delays, but does not prevent polarization (Bilder and Perrimon, 2000; 
Qin et al., 2005). The main role of scribbled appears to be stabilization of the E-
cadherin-catenin interaction, supporting a role for scribbled as a tumor 
suppressor (Qin et al., 2005).  
Another component of the Scribbled complex, Lgl, interacts with scribbled 
and Par6/aPKC, physically linking the Scribbled and Par complexes. 
Phosphorylation of Lgl by aPKC restricts Lgl to the lateral membrane (Plant et al., 
2003). Lgl and aPKC may antagonize each other since over expression of Lgl 
results in the same phenotype as aPKC knockout and Lgl can rescue the apical 
expansion caused by aPKC over expression (Chalmers et al., 2005).  In addition, 
Lgl has been shown to interact with syntaxin-4, a component of the BL exocytic 
machinery, revealing a possible role for Lgl in BL trafficking and polarity (Musch 
et al., 2002).  
The third component of the Scribbled complex, Dlg, has been linked to the 
complex genetically, but not physically. A direct link between Dlg and scribbled or 
Lgl has yet to be confirmed, although Dlg has been shown to interact with a 
variety of other proteins making the role of Dlg in polarity unclear (Pieczynski and 
Margolis, 2011). Dlg has been demonstrated to interact with APC and scribbled 
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with E-cadherin-catenin, and these associations could link Dlg and scribbled 
(Matsumine et al., 1996; Qin et al., 2005). Future studies may provide a more 
direct link between Dlg and the other components of the Scribbled complex. 
The complexity of the three polarity complexes, Crumbs, Par and 
Scribbled, is immense and we have only a cursory understanding of how these 
three complexes mutually regulate the function and location of each other. 
Currently, the exact mechanisms by which these complexes regulate the different 
membrane domains remain unknown (Mellman and Nelson, 2008). However, as 
more is learned about the different components of these complexes, the pieces 
of the puzzle will fall into place.   
 
The Adherens Junctions 
Below the tight junctions in the lateral membrane of the cell are the 
adherens junctions, which are dynamic mediators of cell-cell contact (Figure 2). 
The adherens junction serves three functions: provide mechanical attachment 
between cells within a monolayer, provide domain orientation cues at points of 
cell-cell contact in establishment of apical BL polarity, and provide junction points 
for the cortical domain polarization in planar cell polarity (Baum and Georgiou 
2011). Adherens junctions are composed of the type-1 transmembrane proteins 
cadherin and nectin, both of which interact with junctional proteins on adjacent 
cells as well as with a number of intracellular proteins through their cytoplasmic 
domains to regulate junctional maintenance, turnover, and function.  
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The core of the adherens junction is E-cadherin, a member of the classical 
cadherin family of transmembrane glycoproteins, which mediates Ca2+-
dependent homophilic interactions with cadherins on adjacent cells (Hartsock 
and Nelson, 2008). The extracellular domain of E-cadherin consists of five 
extracellular cadherin (EC1-EC5) domains that interact in a Ca2+-dependent 
manner (Pokutta et al., 1994; Ringwald et al., 1987). The EC domains can form 
cis- and trans- homophilic interactions, with the trans-interactions being mediated 
through the EC1 domain (Patel et al., 2006). The trans-interactions are reported 
to be weak and are compensated for through the formation of cis-dimers that 
trans-oligomerize with the cis-dimerized cadherins on adjacent cells to form 
strong adherens junctions (Nelson, 2008).  
In addition to intercellular interactions, E-cadherin mediates intracellular 
interactions through its cytoplasmic domain. The cytoplasmic domain of E-
cadherin is bound by p120-catenin in the juxtamembrane region and by β-catenin 
in the C-terminal catenin binding domain (Aberle et al., 1994; Yap et al., 1998).  
A reported function of p120-catenin is to stabilize E-cadherin at the adherens 
junction by regulating E-cadherin turnover. Knockdown of p120-catenin results in 
elimination of E-cadherin and loss of adherens junctions (Davis et al., 2003). 
Alteration or loss of p120-catenin expression has been reported in a number of 
cancers, suggesting p120-catenin can act as a tumor suppressor (Thoreson and 
Reynolds, 2002).  While β-catenin has many implications in cancer via inducing 
transcription of certain oncogenes, its role in adherens junctions may be to link E-
cadherin to the actin cytoskeleton through α-catenin, an association that may be 
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very dynamic (Rimm et al., 1995). In addition, E-cadherin may regulate cytosolic 
levels of β-catenin by sequestering β-catenin to the adherens junctions, a 
process that is regulated by either phosphorylation of E-cadherin to increase β-
catenin binding or by phosphorylation of β-catenin that decreases binding to E-
cadherin (Hartsock and Nelson, 2008). Alpha-catenin does not interact directly 
with E-cadherin, but instead interacts with β-catenin and actin (Aberle et al., 
1994; Rimm et al., 1995). The interaction between these two catenins is thought 
to physically link E-cadherin to the actin cytoskeleton; however, this quaternary 
complex cannot be reconstituted in vitro (Yamada et al., 2005). Alternatively, α-
catenin may regulate actin dynamics at the adherens junctions. Alpha-catenin 
can exist as a monomer, which binds to β-catenin or as a homodimer, which 
binds and bundles actin. When actin is bound by α-catenin, Arp2/3 is forced to 
dissociate from actin thereby preventing actin branching. Accordingly, the 
increased local concentration of α-catenin at the adherens junctions via 
interaction with β-catenin/E-cadherin would promote actin bundling at the cell 
junctions and prevent Arp2/3-induced branching (Drees et al., 2005). Combined, 
these reports support a major function of the adherens junction, in addition to 
providing cell-cell adhesion, as regulator of the local concentration of α- and β-
catenin, which affects actin dynamics and β-catenin induced gene transcription.  
Another component of the adherens junction is the single pass 
transmembrane protein nectin, which contains three Ig-like domains in the 
extracellular region and a PDZ binding motif in the cytoplasmic domain (Takai 
and Nakanishi, 2003). There are four members of the nectin family that form 
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homo-cis-dimers and homo- and hetero- trans-dimers in a Ca2+-independent 
manner (Reymond et al., 2001; Satoh-Horikawa et al., 2000). Nectin is recruited 
to the adherens junctions through interaction with the PDZ domain of the actin 
binding protein afadin (Mandai et al., 1997; Takahashi et al., 1999). Afadin links 
nectin to the actin cytoskeleton and possibly to E-cadherin through an interaction 
with α-catenin (Takai and Nakanishi, 2003). There is also evidence that suggests 
nectin is the initial adhesion molecule to form cell-cell adhesions and recruits E-
cadherin through the afadin-α-catenin interaction to form mature adherens 
junctions (Tachibana et al., 2000). Nectin may provide the physical link between 
the actin cytoskeleton and the adherens junction since a physical link has not 
been established between E-cadherin and actin.   
 
The Basolateral Membrane 
The basal and lateral membranes of the cell are often combined and 
defined as the basolateral (BL) membrane. In a polarized columnar epithelial cell, 
the lateral membrane is the “side” surface of the cell juxtaposed to neighboring 
cells and is the site of cell-cell interactions. The basal membrane is the “bottom” 
surface of the cell and the site of cell-matrix interactions (Figure 1). Cell-matrix 
interactions are critical for cell survival and provide orientation cues	  (Rodriguez-
Boulan and Nelson, 1989). The lateral membrane is enriched in proteins that 
mediate cell-cell interactions and domain orientation cues, as previously 
described, while the basal membrane is devoid of cell-cell interaction proteins 
and enriched in extracellular matrix (ECM) receptors. 
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The cell attaches and interacts with the ECM through focal adhesions that 
mainly consists of the integrin family of cell adhesion receptors. Integrins are 
made up of α- and β-subunits, of which there are 18 α-subunits and 8 β-subunits. 
The α- and β-subunits can form non-covalently linked heterodimers at the cell 
surface to provide the cell with a diverse family of 24 integrin heterodimers. The 
different combinations of α- and β-subunits is what provides integrins with their 
binding diversity (Dubash et al., 2009). The integrin extracellular domain binds to 
different components of the ECM, while the short cytoplasmic domain interacts 
with proteins linked to the actin cytoskeleton. The complexity and diversity of the 
proteins that function on the cytoplasmic side of the focal adhesion is immense, 
with more then 50 proteins identified so far (Zamir and Geiger, 2001).  
Integrins are bidirectional signaling proteins. Intracellular signals can be 
transferred to integrin receptors resulting in activation or inactivation of the ECM 
binding domain (inside-out signaling). The extracellular domain of integrins can, 
in turn, relay a signal it receives from the ECM to the inside of the cell, resulting 
in an intracellular signaling cascade (outside-in signaling) (Hynes, 2002). The 
signals received from an integrin can mediate numerous cell-signaling pathways 
that control cell survival, division, differentiation, and migration (Zaidel-Bar et al., 
2007; Zamir and Geiger, 2001).  
In addition to mediating cell-cell and cell-ECM interaction, BL membrane 
proteins function in cellular communication and homeostasis. The BL membrane 
contains growth factor receptors and ligands that function to mediate signal 
reception and transduction. The BL membrane is the main site for the cell to 
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send and receive information to and from the surrounding interstitium. The BL 
membrane also contains ion channels and ATPases that function to generate an 
ion gradient.	  These channels and pumps work in concert with their counterparts 
in the apical membrane to create a suitable environment for cell and tissue 
homeostasis (Rodriguez-Boulan and Nelson, 1989).  
 
Polarized Sorting Signals 
 In order to maintain these distinct membrane surfaces with specialized 
proteins and functions the polarized cell must sort, deliver, and retain membrane 
components to the correct location for proper cellular function. This is 
accomplished using signals contained within the proteins structure, either in the 
extracellular, transmembrane, or cytoplasmic domains (Carmosino et al., 2010). 
Signals present in the extracellular and transmembrane domains predominantly 
mediate protein delivery to the apical surface, while signals within the 
cytoplasmic domain typically drive proteins to the endosomal system or the BL 
surface and are involved in internalization. Cytoplasmic BL sorting signals have 
been shown to be dominant over extracellular apical sorting signals	  (Weisz and 
Rodriguez-Boulan, 2009).  
Apical sorting signals mainly consist of extracellular protein modifications 
or a transmembrane structural determinant, such as a 
glycosylphosphatidylinositol (GPI) linkage to the membrane. The transmembrane 
or GPI-linkage determinants result in apical sorting of proteins by assisting in the 
incorporation of the protein into lipid rafts. The sphingolipid- and cholesterol-rich 
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lipid rafts tend to possess longer hydrophobic tails, making the raft domains of 
the membrane “taller” than non-raft domains. Proteins with large transmembrane 
domains find it energetically favorable to incorporate into these taller membrane 
domains and are sorted to the apical membrane.  
GPI-anchored proteins are also incorporated into lipid rafts, although GPI-
anchored proteins are present on both the apical and BL surface. An additional 
criterion for apical sorting of GPI-anchored proteins is oligomerization within the 
lipid raft (Paladino et al., 2004; Paladino et al., 2007). Apically targeted GPI-
anchored proteins are reportedly delivered directly to the apical surface and are 
not transcytosed from the BL surface (Paladino et al., 2006).  
Post-translational N- and O-linked glycosylation of the extracellular 
domain has been demonstrated to play a role in apical sorting (Potter et al., 
2006). This was initially demonstrated with growth hormone that is normally 
secreted from both apical and BL surfaces of polarized cells, but is preferentially 
delivered apically when N-glycosylated (Scheiffele et al., 1995). O-glycosylation 
of the juxtamembrane stalk of p75 NGFR is important for its apical delivery	  
(Yeaman et al., 1997). One possible explanation of how glycosylation assists in 
apical delivery is that proper folding and maturation of the protein requires these 
post-translational modifications. Glycosylation may also assist in the recognition 
of the protein by an as yet unidentified sorting receptor (Weisz and Rodriguez-
Boulan, 2009).  
Sorting signals contained within the cytoplasmic domains are composed of 
short linear sequence motifs and are involved in internalization, sorting to the BL 
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surface, and delivery to endosomes. Consensus motifs have been identified, but 
are not always exact, with a few residues being the most important, typically 
bulky hydrophobic or charged residues (Bonifacino and Traub, 2003). The best-
characterized cytoplasmic domain sorting motifs contain critical tyrosine or 
leucine residues.  
Consensus tyrosine-based motifs are [FY]XNPXY and YXXΦ, where Φ is 
a bulky hydrophobic residue (Leu, Ile, Met, or Phe). These motifs have been 
shown to be involved in delivery to the BL surface, the lysosome, and 
internalization (Chen et al., 1990; Gough et al., 1999; Hunziker et al., 1991; 
Marks et al., 1995). The [FY]XNPXY signal has been shown to be critical for the 
rapid internalization of transmembrane proteins, but has not been reported to be 
involved in other intracellular sorting events (Bonifacino and Traub, 2003). 
Transmembrane proteins that contain [FY]XNPXY motifs include low density 
lipoprotein (LDL) receptor, epidermal growth factor receptor (EGFR), insulin 
receptor, and integrin-β1, although not all have been demonstrated to be active 
internalization motifs (Bonifacino and Traub, 2003). The most extensive studies 
of this motif have been on the LDL receptor due to its importance in disease 
(Hobbs et al., 1992). Replacement of the phenylalanine, asparagine, proline, or 
tyrosine residues in the LDL receptor motif resulted in reduced internalization 
(Chen et al., 1990).  The LDL receptor signal is also transplantable, capable of 
replacing the endogenous signal within the transferrin receptor (Collawn et al., 
1991). 
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The YXXΦ motif has also been shown to be involved in BL sorting as well 
as internalization and delivery to the lysosome (Gough et al., 1999; Sorkin et al., 
1996; Thomas et al., 1993). This functional flexibility is conferred by varying the 
localization of the motif within the cytoplasmic domain and by heterogeneous 
composition of the residues that make up the motif with the exception of the 
tyrosine, which is critical (Bonifacino and Traub, 2003; Williams and Fukuda, 
1990). Addition of a glycine residue before the tyrosine specifies lysosomal 
targeting while different residues in the Φ position can also determine localization 
(Gough and Fambrough, 1997; Harter and Mellman, 1992). This motif has been 
shown to interact with the medium subunit (see below) of adaptor proteins 
(Aguilar et al., 2001; Ohno et al., 1995; Owen and Evans, 1998; Rous et al., 
2002).  
Consensus leucine-based sorting motifs are [DE]XXXL[LI], DXXLL, 
EEEXXXXXL, and EEXXXL. Similar to tyrosine-based signals, leucine-based 
sorting signals are diverse in their composition and function, acting as 
endosomal/lysosomal, internalization, and BL sorting signals (Deora et al., 2004; 
Dietrich et al., 1994; Johnson and Kornfeld, 1992b; Matter et al., 1994; Miranda 
et al., 2001). Leucine-based sorting signals were discovered after tyrosine-based 
sorting signals. The first leucine-based signal identified was a di-leucine signal 
[DE]XXXL[LI] in a protein that when truncated to not contain any tyrosine 
residues in the cytoplasmic domain was still delivered to the lysosome 
(Letourneur and Klausner, 1992). These same studies demonstrated the 
importance of both leucine residues for proper lysosome localization with the first 
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leucine more critical than the second. Replacement of the first leucine with an 
isoleucine impairs signal function while replacement of the second leucine with 
an isoleucine maintains a functional signal (Letourneur and Klausner, 1992). The 
acidic residues N-terminal to the di-leucine residues are also important for 
internalization and targeting to the endosomal system, possibly by providing a 
necessary structure for signal recognition or binding to the adaptor protein (Kelly 
et al., 2008; Pond et al., 1995).  
The DXXLL consensus motif is involved in TGN to endosome transport 
and is conserved in all metazoans (Bonifacino and Traub, 2003; Johnson and 
Kornfeld, 1992a). This motif tends to be located toward the carboxy-terminus of 
the cytoplasmic domain, although this localization may not be critical for its 
function (Braulke and Bonifacino, 2009). Both of the leucine residues are critical 
as well as the aspartic acid residue, which cannot even tolerate an isoelectric or 
isosteric substitution (Chen et al., 1997).  
The EEEXXXXXL and EEXXXL mono-leucine motifs are both involved in 
BL sorting of transmembrane proteins (Deora et al., 2004; Wehrle-Haller and 
Imhof, 2001). To date, the EEEXXXXXL motif has been found in only two 
proteins, CD147 and stem cell factor, while the EEXXXL motif exists in 
amphiregulin (AREG) and is described in chapter 2 of this dissertation (Deora et 
al., 2004; Wehrle-Haller and Imhof, 2001). Further studies are needed to 
determine how these motifs function and proteins that recognize these signals. 
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Cargo Adaptor Proteins 
Sorting motifs are recognized by heterotetrameric cargo adaptor protein 
complexes (AP-1A, AP-1B, AP-2, AP-3A, AP-3B, AP-4) and the monomeric 
Golgi-localized, γ-ear-containing Arf-binding proteins (GGAs 1-3), which 
selectively incorporate cargo proteins and facilitate vesicle formation (Robinson, 
2004). The main functions of these adaptor proteins are to bind to the 
membrane, recognize and bind cargo, and recruit clathrin and other proteins 
involved in vesicle formation. The heterotetrameric cargo adaptor proteins are 
300 kDa and are composed of two large subunits (γ/β1, α/β2, δ/β3A, δ/β3B, ε/β4), 
one medium subunit (µ1A, µ1B, µ2, µ3A, µ3B, µ4), and one small subunit (σ1-
σ4) (Figure 4). The large subunits are responsible for binding the heterotetramer  
to the target membrane (γ, α, δ, ε) and binding clathrin though clathrin box motifs 
(β1, β2, β3). The medium subunit contains a binding pocket that recognizes and 
binds the sorting signal within a cargo protein. The small subunit functions to 
stabilize the complex (Owen et al., 2004).  
Adaptor proteins localize to different membranes on the cell surface or 
organelles of the cell, depending on their function (Figure 4 and 5).  Localization 
of adaptor proteins can be directed by membrane phosphoinositide composition. 
For example, AP-2 localization to the phosphatidylinositol (4,5)-bisphosphate 
[PIP2] enriched inner leaflet of the plasma membrane is mediated by the PIP2 
binding sites contained in the α and µ2 subunits of AP-2 (Gaidarov and Keen, 
1999; Jost et al., 1998; Rohde et al., 2002). The µ1B subunit of AP-1B contains a 
three amino acid sequence necessary for localization of AP-1B to the  
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Figure 4. Cargo adaptor proteins. An illustration of the four cargo adaptor 
heterotetramer protein complexes and a GGA monomer protein. Each AP 
complex consists of two large subunits (γ/β1, α/β2, δ/β3A, δ/β3B, ε/β4), one 
medium subunit (µ1A, µ1B, µ2, µ3A, µ3B, µ4), and one small subunit (σ1-σ4). 
Listed below each AP complex is where the AP is localized in the cell and the 
destination of the sorted cargo. Figure adapted from (Braulke and Bonifacino, 
2009).	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phosphatidylinositol 3,4,5-trisphosphate [PI(3,4,5)P3] enriched recycling 
endosomes (Fields et al., 2010). Golgi-associated type II phosphatidylinositol 4 
kinase-α (PI4KIIα) generates phosphatidylinositol 4 phosphate [PI(4)P] at the 
Golgi and is required for recruitment of AP-1 to the Golgi (Wang et al., 2003). In 
addition to phosphoinositides, the ADP-ribosylation factor (ARF) family of small 
GTPases is also involved in membrane recruitment of adaptor proteins (D'Souza-
Schorey and Chavrier, 2006). Activated GTP-bound Arf1 recruits AP-1, AP-4, 
and GGAs to the TGN membrane and AP-3 to the endosomal membrane 
(Boehm et al., 2001; Boman et al., 2000; Ooi et al., 1998; Stamnes and 
Rothman, 1993). Once localized to the proper membrane/organelle the adaptor 
protein can perform its function. 
AP-1 has two isoforms, the ubiquitously expressed AP-1A (γ, β1, µ1A, σ1) 
and epithelial specific AP-1B (γ, β1, µ1B, σ1). These two isoforms differ only by 
their medium subunits, µ1A and µ1B, which are 79% identical (Ohno et al., 
1999).  AP-1A localizes to the trans Golgi network (TGN) and along with the 
GGA proteins is involved in vesicle formation for transport between the TGN and 
endosomes (Doray et al., 2002b). The epithelial specific AP-1B is localized to 
recycling endosomes near the TGN and sorts proteins to the BL surface via two 
routes, biosynthetically and recycling (Figure 5) (Cancino et al., 2007; Folsch et 
al., 2003; Gravotta et al., 2007). In the biosynthetic route, proteins are delivered 
to the recycling endosome from the TGN. Once in the recycling endosome, the 
proteins are recognized by AP-1B and incorporated into vesicles destined for the 
BL surface (Gonzalez and Rodriguez-Boulan, 2009). In the recycling route,  
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Figure 5. Possible routes taken by BL membrane proteins.  There are three 
possible routes taken by a protein to obtain and maintain BL polarity. The direct 
biosynthetic route taken to the BL surface, represented by the black arrow, is 
delivery from the TGN to the BL surface. A second biosynthetic route to the BL 
surface, represented by the green arrows, is via the common recycling 
endosome (CRE) and is AP-1B dependent. The recycling route, represented by 
the red arrows, delivers BL proteins to the CRE after endocytosis and returns 
them back to the BL surface from the CRE. Proteins that follow the red route can 
be delivered to the BL surface in an AP-1B-independent manner but depend on 
AP-1B for recycling back to the BL surface and maintenance of steady-state 
polar distribution. Adaptor proteins AP-1A, AP-3, and AP-4 are located at the 
TGN. AP-1B is localized to the CRE. AP-2 is located at the plasma membrane.  
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proteins are endocytosed from the cell surface and delivered to the recycling 
endosome where they are recognized by AP-1B for return to the BL surface. 
Proteins, such as LDL receptor, transferrin receptor, and AREG that are AP-1B 
dependent for steady state polarized distribution are initially delivered to the BL 
surface via an AP-1B independent biosynthetic route (Cancino et al., 2007; Gan 
et al., 2002; Gravotta et al., 2007). However, over time these proteins lose 
polarity because they are mis-recycled to the apical surface in AP-1B deficient 
cells. The medium µ1B subunit has been demonstrated to contain a tyrosine 
motif binding pocket, mutation of which impairs the BL sorting of some but not all 
AP-1B-dependent BL proteins (Sugimoto et al., 2002).  
AP-2 (α, β2, µ2, σ2), the most well characterized adaptor protein, is 
localized to the plasma membrane and regulates receptor-mediated endocytosis 
(Nakatsu and Ohno, 2003). Yeast two-hybrid and structural analyses of AP-2 
have identified the medium subunit, µ2, as the site of interaction with YXXΦ 
tyrosine-based sorting motifs (Ohno et al., 1995; Owen and Evans, 1998). The 
structural analysis of µ2 revealed a hydrophobic binding pocket that facilitated 
the formation of hydrogen bonds with the tyrosine hydroxyl group in the sorting 
signal. Importantly, it was found that the size and composition of this binding 
pocket precludes the phosphorylation of the tyrosine (Owen and Evans, 1998). 
AP-2 also interacts with di-leucine-based sorting signals [DE]XXXL[LI]. This 
interaction takes place between the two leucine residues and a hydrophobic 
pocket of the σ2 subunit. There is also a positively charged patch of amino acids 
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between the α and σ2 subunits that accommodates hydrophilic residues 
upstream of the leucine residues on the cargo protein (Kelly et al., 2008). 
Sorting signal recognition by AP-2 may be regulated by phosphorylation of 
the adaptor protein. Within the inactive AP-2 complex, the β2 subunit blocks both 
the di-leucine binding interface on the σ2 subunit and the YXXΦ binding pocket 
in the µ2 subunit. When the β2 subunit dissociates from σ2 it reveals the σ2 
binding interface, an event that may be regulated by phosphorylation of tyrosine 
6 on β2. However, the µ2 binding pocket remains blocked (Kelly et al., 2008; 
Traub, 2009). Opening of the µ2 binding pocket is regulated by adaptor- 
associated kinase AAK1-mediated phosphorylation of µ2 on threonine 156 and is 
further stabilized by interaction of µ2 with PIP2 (Honing et al., 2005; Olusanya et 
al., 2001; Ricotta et al., 2002). These two steps allow for a strong binding 
interaction between µ2 and the YXXΦ motif while not enhancing binding of di-
leucine motifs to the σ2 binding interface (Honing et al., 2005). All of this taken 
together suggests these two phosphorylation events may be important regulatory 
mechanisms for motif recognition by AP-2.  
AP-3 has two isoforms, the ubiquitous AP-3A (δ, β3A, µ3A, σ3) and 
neuronal specific AP-3B (δ, β3B, µ3B, σ3) (Nakatsu and Ohno, 2003).  AP-3A is 
localized to endosomes where it is present on budding vesicles enriched in 
lysosomal proteins (Peden et al., 2004). Patients with Hermansky-Pudlak 
syndrome (HPS) have a mutant form of β3A, resulting in an increase in 
lysosomal proteins on the cell surface (Dell'Angelica et al., 1999b). Additionally, 
yeast two-hybrid analysis indicated µ3A preferentially binds tyrosine-based 
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lysosomal targeting motifs, all implicating AP-3A in sorting from the endosome to 
the lysosome (Dell'Angelica et al., 1999b). Unlike AP-1 and AP-2, the role of 
clathrin in AP-3A vesicles is not clear. Components of AP-3 were initially 
identified as not enriched in clathrin-coated vesicles, but were later shown to 
interact with clathrin via β3 (Dell'Angelica et al., 1998; Simpson et al., 1996). 
Subsequent studies quantitated only 46% of AP-3 positive membranes to be 
associated with clathrin coats, compared to 91% of AP-1 positive membranes 
(Peden et al., 2004). Taken together, AP-3A appears to play a role in endosome 
to lysosome transport in clathrin-dependent and clathrin-independent pathways. 
AP-3B has two subunits, β3B and µ3B, that are only expressed in neurons. 
Deletion of  µ3B in mice results in spontaneous epileptic seizures and a reduced 
number of synaptic vesicles in excitatory and inhibitory terminals of the 
hippocampus (Nakatsu et al., 2004). These results indicate a role for AP-3B in 
synaptic vesicle formation.  
AP-4 (ε, β4, µ4, σ4) is ubiquitously expressed at low levels and is located 
at the TGN in an ARF-regulated manner (Boehm et al., 2001; Hirst et al., 1999). 
The µ4 subunit can bind certain canonical YXXΦ motifs, particularly signals 
within lysosomal proteins, although this interaction is not as strong as µ2 or µ3A 
(Aguilar et al., 2001). A novel YXXΦ motif, YX[FYL][FL]E, is tightly bound by µ4, 
while not bound by µ1, µ2, or µ3 (Burgos et al., 2010).  The µ4 binding pocket 
requires the same conserved residues as µ2 to bind canonical YXXΦ motifs, but 
binding to the YX[FYL][FL]E motif takes place on a different face of the µ4 pocket 
than the YXXΦ binding with µ2 (Aguilar et al., 2001; Burgos et al., 2010; Owen 
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and Evans, 1998). AP-4 is the only adaptor protein that does not contain a 
clathrin-binding domain and does not associate with clathrin-coated vesicles as 
determined by EM (Dell'Angelica et al., 1999a; Hirst et al., 1999). AP-4 has been 
speculated to participate in transport from the TGN to the endosomal/lysosomal 
system, however siRNA against µ4 does not impair lysosomal transport (Aguilar 
et al., 2001; Burgos et al., 2010; Simmen et al., 2002). However, AP-4 has been 
shown to sort proteins to the BL surface of polarized MDCK cells, making it and 
AP-1B the only adaptor proteins demonstrated to sort BL proteins (Folsch, 2005; 
Simmen et al., 2002).  
The most recent studies on AP-4 have focused in neuronal cells, which 
similar to epithelial cells, form distinct polarized membrane domains. Proteins 
delivered to the epithelial apical surface are delivered to the neuronal axonal 
domain, whereas proteins that are delivered to the epithelial BL surface are 
delivered to the neuronal somatodendritic domain (Dotti and Simons, 1990; Jareb 
and Banker, 1998). In neurons, AMPA receptors are normally delivered to the 
somatodendritic domain. However, these receptors are not properly delivered in 
mice carrying a null mutation for β4, providing further evidence AP-4 acts as a BL 
sorting adaptor protein (Matsuda et al., 2008). Homozygous deletion of the gene 
encoding the ε subunit results in cerebral palsy due to a deficiency in AP-4 
(Moreno-De-Luca et al., 2011). The difficulties in pinpointing a function for AP-4 
in fibroblasts and epithelial cells and the recent findings in neurons may indicate 
the main function for AP-4 is in the neurons. 
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Golgi-localized, γ-ear-containing Arf-binding proteins (GGAs) are 
monomeric clathrin adaptor proteins involved in TGN to endosomal transport 
(Bonifacino, 2004). There are three ubiquitously expressed GGA proteins 
(GGA1-3) that localize to the TGN in an ARF-dependent manner (Boman et al., 
2000). GGAs consist of three tandem domains, VHS (Vps27, Hrs, Stam), GAT 
(GGA and TOM (target of myb)) and GAE (γ-adaptin ear), connected by two 
linker sequences (Figure 4). The 140-residue VHS domain binds DXXLL motifs 
contained within the cytoplasmic domains of lysosomal proteins (Takatsu et al., 
2001; Zhu et al., 2001). The VHS domain can also bind a DXXLL motif within the 
hinge segment of GGA1 and GGA3, an autoinhibitory mechanism regulated by 
casein kinase 2 (CK2) (Doray et al., 2002a). The VHS domain interaction with the 
DXXLL motif is specific, in that it will not interact with tyrosine- or di-leucine-
based motifs devoid of acidic residues (Puertollano et al., 2001). A short 20-
residue linker connects the VHS and GAT domains. The 150-residue GAT 
domain contains a binding site for GTP-bound ARF proteins, a necessary 
interaction for proper localization of GGAs to the TGN (Dell'Angelica et al., 2000). 
The GAT domain is followed by the long unstructured hinge segment that 
connects the GAT and GAE domains. In addition to containing the 
aforementioned autoregulatory DXXLL domain, the hinge segment also contains 
a clathrin box motif (Zhu et al., 2001). The hinge segment can also bind the γ-ear 
domain of AP-1, indicating an interaction between GGAs and AP-1. Cargo that is 
mutated such that it cannot interact with GGAs is poorly incorporated into AP-1 
vesicles, suggesting a mechanism by which GGAs identify and bind cargo that is 
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then presented to AP-1 for incorporation into vesicles (Doray et al., 2002b). The 
124-residue GAE domain binds the consensus motif DFGXΦ, which is contained 
within the unstructured regions of accessory proteins. The accessory proteins 
may be involved in processes such as membrane deformation and 
tethering/fusion events (Bonifacino, 2004). The current understanding of GGAs 
and their interaction with AP-1 supports the idea that the two work together to 
select cargo destined for the lysosome and provide a foundation for the 
recruitment of accessory and scaffolding proteins to facilitate vesicle biogenesis 
at the TGN.  
 
Polarized Delivery of the EGFR and the EGFR Ligands 
One family of proteins that is distributed to the cell surface in a polarized 
manner is the EGFR and its cognate ligands (Harris et al., 2003). EGFR is a 
transmembrane receptor tyrosine kinase involved in proliferation, migration, and 
cell survival and is critical for epithelial wound repair and homeostasis (Jost et al., 
2000; Konturek et al., 1995; Wells, 1999). Seven mammalian EGFR ligands have 
been identified (EGF, AREG, transforming growth factor-α (TGFα), heparin-
binding EGF-like growth factor (HB-EGF), betacellulin (BTC), epiregulin (EREG), 
and epigen), all of which are produced as type 1 transmembrane proteins and 
delivered to the cell surface where they are cleaved by metalloproteases to 
release a mature soluble ligand (Figure 6) (Harris et al., 2003). The soluble 
ligands can bind and activate the EGFR with differing affinities and intensities in  
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Figure 6. EGFR ligands. There are seven ligands that bind and activate the 
EGFR. All of these ligands are produced as type-1 transmembrane proteins that 
are cleaved from the cell surface by metalloproteases to release a soluble 
mature ligand. Figure adapted from (Harris et al., 2003).  
 
 
 
 
 
 
 
 
	   35	  
a paracrine, autocrine, or juxtacrine manner (Harris et al., 2003; Shoyab et al., 
1989). The cellular signaling pathways activated downstream of the EGFR are 
ligand-dependent (Chung et al., 2005; Luetteke et al., 1999; Luetteke et al., 
1993).  
In polarized epithelial cells, EGFR is selectively delivered to the BL 
surface (Hobert and Carlin, 1995). The EGFR is a large type 1 transmembrane 
glycoprotein with a 622-amino acid extracellular ligand binding domain, 23-amino 
acid transmembrane domain, and a 541-amino acid cytoplasmic domain 
(Carpenter, 1987). The cytoplasmic domain contains a tyrosine kinase domain 
and multiple tyrosine autophosphorylation sites responsible for the biologic 
activity of the receptor (Schlessinger, 2000). The C-terminal region of the EGFR 
cytoplasmic domain contains a canonical YXXΦ internalization signal that is 
recognized by AP-2 (Sorkin et al., 1996). The information responsible for BL 
delivery of the EGFR is also contained within the cytoplasmic  
domain, removal of which results in apical expression of the EGFR (Hobert and 
Carlin, 1995). This BL sorting information is present in the juxtamembrane region 
of the cytoplasmic domain and consists of a non-canonical BL sorting motif within 
a 22-residue stretch and was initially thought to lack a critical tyrosine or di-
leucine motif (Hobert et al., 1997). This 22-residue stretch is predicted to form 
two α-amphipathic helices with three hydrophobic leucine residues on one face 
and charged residues on the opposite face of each helix (Hobert et al., 1997). 
These helices could provide a binding interface similar to what may be present 
within the cytoplasmic domain of AREG. 
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The same group later published a more precise study of the EGFR BL 
sorting motif that narrowed down the critical residues within the 22-residue 
stretch to include two leucine residues within the first helix and a proline rich 
motif consisting of PXXP in the second helix, constituting two separate signals 
with the proline-based motif being the dominant signal (He et al., 2002).  An 
alternative explanation to the proline residues acting as a sorting signal is that 
mutation of the proline residues destroys important structural elements 
necessary for recognition of the two α-amphipathic helices described in the initial 
paper, although there is no evidence to support this hypothesis. Additionally, the 
EGFR was recently demonstrated to be AP-1B-dependent for polar distribution in 
LLC-PK1 cells	  (Ryan et al., 2010). The di-leucine motif was shown to bind AP-1B 
in an in vitro peptide pulldown assay, supporting the leucine residues as the 
critical determinants for polar distribution of the EGFR	  (Ryan et al., 2010).     
The ligand EGF is delivered to both surfaces of MDCK cells, but is 
selectively cleaved by BL metalloproteases, leading to apically retained EGF 
(Dempsey et al., 1997). EGF is the largest of the EGFR ligands, with nine EGF-
like repeats in the extracellular domain and a 154-residue cytoplasmic domain, 
considerably larger than the typical 20 to 40-residue EGFR ligand cytoplasmic 
domain (Table 1)	  (Harris et al., 2003). While EGF is delivered to both surfaces, 
the cytoplasmic domain of EGF contains a PXXP motif, mutation of which results 
in loss of EGF at the BL surface but not the apical surface (Groenestege et al., 
2007). This supports the dogma that PXXP is a bonafide BL sorting signal, 
although EGF also contains di-leucine residues N-terminal to the PXXP, similar 
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to the EGFR. It is possible that these di-leucine residues are the critical residues 
and mutation of the proline simply affects the structure of the cytoplasmic 
domain, a hypothesis unsupported by experimental evidence.  Questions still 
remain regarding the role of proline residues in BL transport, such as can the 
PXXP motif itself provide BL sorting information or must it be in the context of the 
surrounding residues? How do PXXP motifs bind adaptor proteins? More 
analysis of the PXXP motif in the EGF and EGFR cytoplasmic domains is 
needed before a definitive sorting signal can be declared.  
 TGFα is delivered to the BL surface of polarized epithelial cells with the 
help of the myristoylated cargo recognition and targeting (CaRT) protein Naked2 
(NKD2) (Dempsey and Coffey, 1994; Li et al., 2004a). ProTGFα is a 160-amino 
acid type one transmembrane glycoprotein with a 39-residue palmitoylated 
cytoplasmic domain (Table 1)	   (Bringman et al., 1987; Lee et al., 1995). The BL 
sorting motif of TGFα consists of two elements in the cytoplasmic domain, a non-
canonical di-leucine motif and an 8-residue segment of the juxtamembrane 
domain	   (Dempsey et al., 2003). Removal of only the 8-residue juxtamembrane 
segment or site-directed mutagenesis of just the di-leucine residues results in 
loss of polarized delivery. This suggests both regions contain some information 
important for the polarized distribution of TGFα. However, if the cytoplasmic 
domain is truncated to only 8-residues, BL distribution is maintained. This is 
interesting because the truncated mutant lacks the di-leucine motif but does not 
lose polar distribution, whereas site-directed mutagenesis of the two leucine 
residues, which still contains the 8-residue juxtamembrane region, results in loss 
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of polar distribution. How these two regions of the TGFα cytoplasmic domain 
assist in BL delivery is unclear.  
TGFα is palmitoylated on two cysteine residues towards the C-terminus of 
the cytoplasmic domain (Shum et al., 1996). Palmitoylation of the cytoplasmic 
domain	  positions the domain in a unique manner, anchoring the C-terminus into 
the membrane. This orientation could possibly contribute to the interaction 
between TGFα and NKD2, although site-directed mutagenesis of the two 
cysteine residues did not affect NKD2-TGFα interaction by yeast two-hybrid 
analysis	   (Li et al., 2004a). However the interaction between NKD2 and TGFα 
was reduced by site-directed mutagenesis of the di-leucine motif and the 
juxtamembrane domain, supporting the role of these two regions in BL delivery of 
TGFα	  (Li et al., 2004a). TGFα is the only EGFR ligand known to be trafficked by 
NKD2, which functions by coating TGFα-containing vesicles after emergence 
from the TGN and delivering them to the BL corner of polarized MDCK cells 
where they fuse with the plasma membrane in a NKD2 myristoylation-dependent 
manner (Li et al., 2004a). Knockdown of NKD2 by shRNA reduces cell surface 
expression of TGFα and leads to accumulation of TGFα-containing vesicles in 
the cytoplasm (Li et al., 2007). NKD2 is a critical component for the proper 
delivery of TGFα to the BL surface.   
The very C-terminal portion of TGFα contains a PDZ recognition motif that 
is bound by the PDZ protein MAGI-3	   (Franklin et al., 2005). MAGI-3 was 
identified in a yeast two-hybid screen for interacting proteins of the TGFα 
cytoplasmic domain. A model was proposed that different PDZ proteins 
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recognize this motif as TGFα passes through the secretory pathway, “handing 
off” TGFα along the way. In this model the PDZ protein syntenin binds TGFα 
early in the secretory pathway in the endoplasmic reticulum (ER)	   (Fernandez-
Larrea et al., 1999). TGFα is then “handed off” to another PDZ protein, the 
myristoylated and palmitoylated GRASP55, in the cis-Golgi	  (Kuo et al., 2000). At 
this point NKD2 may be next in line to take the TGFα “baton” at the TGN and 
escort TGFα containing vesicles to the BL surface. At the cell surface, TGFα 
interacts with another PDZ protein, MAGI-3, which assists TGFα traffic efficiently 
to the cell surface (Franklin et al., 2005). It is unknown if TGFα is the only EGFR 
ligand to be handed off through the secretory pathway. AREG does contain a 
possible PDZ recognition motif at its C-terminus, but removal of this sequence 
has no effect on AREG delivery and no PDZ domain-containing proteins have 
been identified to interact with the AREG cytoplasmic domain.  
The latest EGFR ligand to be studied for a BL sorting motif is EREG. It 
has been determined through unpublished work in the Coffey lab that EREG is 
delivered to the BL surface of polarized MDCK cells. Removal of the cytoplasmic 
domain results in almost exclusively apical expression of EREG. Replacement of 
the apically expressed NGFR cytoplasmic domain with the EREG cytoplasmic 
domain results in BL expression of NGFR. Cytoplasmic domain truncation 
mutants of EREG revealed a tyrosine motif similar to YXXΦ, with valine in the Φ 
position (Table 1). Site-directed mutagenesis of the single tyrosine in this motif 
resulted in apical expression of EREG, similar to removal of the entire  
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Table 1. The EGFR ligands’ cytoplasmic domains. Amino acid compositions 
of the seven EGFR ligands’ cytoplasmic domains are listed with identified BL 
sorting determinants in bold. The length of each domain is indicated on the right. 
 
 
 
 
 
 
 
 
 
 
	   41	  
cytoplasmic domain. Analysis of the EREG cytoplasmic domain reveals a 
possible PXXP motif similar to EGFR and EGF. However, the EREG motif is at 
the C-terminus of the cytoplasmic domain as opposed to the juxtamembrane 
region and is not downstream of a di-leucine motif like in EGFR and EGF. Site-
directed mutagenesis of this motif did not affect EREG BL delivery, indicating 
PXXP alone is not a BL sorting motif. The location in relation to the membrane 
and surrounding amino acids may be important determinants for PXXP to act as 
a BL sorting signal. However, the fact that PXXP is not functioning as a BL 
sorting signal in EREG supports my theory that mutation of the PXXP motif in 
EGFR and EGF affects the structure of the cytoplasmic domain and that PXXP is 
not an actual signal recognized by adaptor proteins.  
EGFR ligands that have not been studied for BL sorting motifs include HB-
EGF, BTC, and epigen. A cursory analysis of HB-EGF reveals a mono-leucine- 
based signal (EEKVKL) very similar to the one identified in chapter 2 of this 
dissertation for AREG (EERKKL). Future analysis of HB-EGF will determine if 
this signal is involved in BL delivery of HB-EGF. Interestingly, HB-EGF was the 
first ligand identified to be present in exosomes. AREG was later determined to 
be in exosomes and play an important role in cellular invasion	  (Higginbotham et 
al., 2011). The fact that both of these proteins contain an EEXXXL motif could be 
an important determinant of how they are trafficked to exosomes. This motif is 
similar to the DXXLL motif described earlier for targeting to the lysosome, and 
may serve a similar function in diverting proteins from the lysosome to a multi-
vesicular body destined to fuse with the plasma membrane and release 
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exosomes.  If one extends the similarities within the AREG (YEGEAEERKKL) 
and HB-EGF (YDVENEEKVKL) cytoplasmic domains they both contain the 
amino acid sequence YaXaXaabXbL, where “a” represents an acidic residue and 
“b” represents a basic residue. This charged region flanked by tyrosine and 
leucine, two residues shown to be critical in signal recognition, could play an 
important role in the trafficking of these two proteins. 
 
Loss of Polarity in Disease 
Our understanding of how proteins are delivered in a polarized cell is 
critical to understanding the basis for a number of human diseases. When 
proteins important for the function of a cell or organ are not properly delivered, 
the homeostasis of the organism can be disrupted. This is especially true in 
organs vital for overall homeostasis such as the kidney and liver.  
Isolated recessive renal hypomagnesemia is a disorder of the kidney 
characterized by excessive Mg2+ wasting (Groenestege et al., 2007).  In the 
kidney, EGF is delivered to both the apical and BL surface of polarized epithelial 
cells (Dempsey et al., 1997).  A mutation of the PXXP motif to PXXL results in 
loss of BL delivery, restricting the ligand from activating the BL localized EGFR 
(Groenestege et al., 2007). Loss of EGFR signaling prevents activation and cell 
surface expression of the Mg2+ permeable channel TRPM6, reducing Mg2+ 
reabsorption in the distal convoluted tubule and resulting in renal Mg2+ loss 
(Thebault et al., 2009).  Maintenance of Mg2+ homeostasis in the body is critical 
for normal functioning of the immune system, neuromuscular excitability, and 
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neuroprotection; loss of homeostasis can contribute to hypertension and 
metabolic syndrome	  (Cao et al., 2008a).   
Familial hypercholesterolaemia is an inherited disease caused by 
mutations within the LDL receptor. In the liver, the LDL receptor functions in 
removal and catabolism of plasma LDL. Individuals with dysfunctional LDL 
receptors are unable to properly clear cholesterol carrying LDL from the plasma 
and develop premature coronary heart disease	  (Hobbs et al., 1992).  To function 
properly the LDL receptor must be delivered in a polarized manner to the proper 
sinusoidal surface of hepatocytes	  (Koivisto et al., 2001). In 1992 there were more 
than 150 known mutations to the LDL receptor that impaired its function to the 
point of causing hypercholesterolaemia	   (Hobbs et al., 1992). One of the 
mutations is a G34D mutation within the GYXY BL sorting motif in the C-terminal 
portion of the LDL receptor, resulting in receptors that were no longer expressed 
in a polarized manner	  at steady state (Koivisto et al., 2001). Receptors with this 
mutation were delivered to the sinusoidal surface in hepatocytes but were post-
endocytically missorted to the apical surface, resulting in decreased clearance of 
LDL	   (Koivisto et al., 2001). While the receptors were initially delivered to the 
proper cell surface, they were not properly recycled back, resulting in a 
diminished number of receptors available to clear the LDL.  
Diseases like hypercholesterolaemia and renal hypomagnesemia reveal 
the delicate balance of homeostasis in the body and demonstrate how important 
maintenance of polarity is within the cell. The existence of diseases like these 
confirms the need to study the complexities of the polarized epithelial cell. The 
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cell is not a static structure but is in constant flux and renewal. The more we 
learn about each individual component of the cell, like polarized delivery of 
AREG, the closer we get to understanding the entirety of the cell and how it 
functions. 
 
In the following chapters, I will describe how the EGFR ligand AREG is 
trafficked in polarized epithelial cells. In chapter 2, I will demonstrate that AREG 
delivery to the BL surface is driven by a dominant BL sorting signal in the 
cytoplasmic domain. The main sorting signal present in the AREG cytoplasmic 
domain consists of a mono-leucine preceded by an acidic cluster. The steady 
state polarized distribution of AREG is dependent on the epithelial-specific 
adaptor protein AP-1B. The data in chapter 2 support the hypothesis that AP-1B 
facilitates the recycling of AREG to the BL surface and loss of AP-1B results in 
mis-recycling of AREG to the apical surface.  Chapter 2 identifies a novel BL 
sorting signal in the AREG cytoplasmic domain and shows that AREG is the sole 
EGFR ligand dependent on AP-1B for its polarized distribution.  
Chapter 3 will introduce exosomes and discuss AREG in exosomes. 
Exosomal AREG is in a signaling competent topology and AREG is enriched in 
exosomes from cells with a mutant KRAS, suggesting a difference in exosome 
composition between normal and transformed cells. AREG western blots of 
exosome preparations reveal a post-translational modification of AREG not seen 
in AREG IP or total lysate western blots. Hypothesizing this modification is 
ubiquitin, I demonstrate that AREG can be ubiquitylated in vitro and provide 
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supporting data for the hypothesis that ubiquitylation is necessary for efficient 
delivery to exosomes. The data in chapter 3 provide a foundation for future work 
on how AREG is delivered to exosomes and how exosomes may act as a novel 
EGFR ligand signaling platform. 
Chapter 4 will discuss the techniques used to discover AREG-interacting 
proteins. Two methods, a split ubiquitin yeast two-hybrid screen and a 
crosslinked AREG IP mass spectral analysis, were performed to identify 
interacting proteins for AREG. The main focus of these screens was to identify 
proteins involved in the delivery of AREG to the BL surface. Chapter 4 includes 
the list of identified proteins and highlights several interesting candidates for 
future work. While these screens did not uncover any interacting proteins that 
regulate BL delivery of AREG, they do provide a set of data that may prove 
useful in future work in the Coffey lab.  
The data presented in this dissertation expands our knowledge of how 
AREG is trafficked in polarized epithelial cells and opens new areas for future 
study. Now that we know AREG is AP-1B dependent for its polarized distribution, 
identification of the signal recognized by AP-1B will add to our understanding of 
how this critical adaptor protein functions. Identification of the signal recognized 
during AREG endocytosis from the cell surface and regulation of internalization 
will increase our understanding of how EGFR ligands are regulated. Revealing 
that AREG can be ubiquitylated suggests this modification may play an important 
role in regulating AREG. Good science not only answers questions but also 
poses new ones, and I think my work accomplishes both of those tasks. 
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CHAPTER II 
 
THE CYTOPLASMIC DOMAIN OF AMPHIREGULIN CONTAINS A NOVEL 
MONO-LEUCINE-BASED BASOLATERAL SORTING MOTIF 
 
Introduction 
  The AREG gene, localized to chromosomal region 4q13-4q21, encodes a 
252-amino acid type one transmembrane glycoprotein (Plowman et al., 1990). 
The AREG precursor protein consists of a signal sequence, pro-peptide domain, 
heparin-binding domain, EGF-like consensus motif, transmembrane domain, and 
cytoplasmic domain (Figure 7). The 81-residue pro-peptide domain is N-
glycosylated and provides structural elements to the heparin-binding domain 
necessary for proper folding and secretion of mature AREG (Thorne and 
Plowman, 1994). If the pro-peptide is removed from AREG, the protein is not 
properly secreted and is degraded, unless the heparin-binding domain is 
removed as well (Thorne and Plowman, 1994). The heparin-binding domain is 
enriched in basic residues and constitutes the N-terminal region of the mature 
secreted AREG ligand. The ability of the heparin-binding domain to interact with 
heparin-sulfated proteoglycans in the ECM has been proposed to be a factor in 
AREG-induced lung branching morphogenesis and cellular proliferation (Schuger 
et al., 1996). The heparin-binding domain may act to store the ligand in the ECM 
or present the ligand in a fashion that mediates more efficient binding to the 
EGFR. The EGF-like consensus motif consists of six cysteine residues in the 
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Figure 7. Schematic diagram of full-length AREG and amino acid 
composition of the AREG cytoplasmic domain.  AREG is synthesized as a 
252- amino acid type 1 transmembrane glycoprotein. Beginning with a signal 
sequence (1-19), AREG contains an N-glycosylated pro-peptide domain (20-100) 
that is required for proper folding and secretion. Following the pro-peptide is 
mature AREG (101-184) consisting of a heparin-binding domain (HBD) and an 
EGF domain. The EGF domain contains the conserved spacing of six cysteine 
residues that is preserved amongst all EGFR ligands. The 31-amino acid 
cytoplasmic domain (222-252) is aligned with other species with the conserved 
residues highlighted in red. 
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conserved spacing CX7CX4CX10CX1CX8C that form di-sulfide bonds to provide 
the necessary structure for binding and activating the EGFR (Shoyab et al., 
1989). However, AREG does lack a critical leucine residue that is conserved in 
EGF, TGFα, and HB-EGF and may explain the lower binding affinity AREG has 
for the EGFR (Shoyab et al., 1989). The transmembrane domain anchors the 
protein to the membrane while the cytoplasmic domain contains critical 
information necessary for the proper localization of AREG to the BL surface of 
polarized epithelial cells (Brown et al., 2001; Damstrup et al., 1999). Each 
domain within the AREG precursor protein provides a necessary function for 
proper AREG secretion and activation of the EGFR. 
Once delivered to the BL surface, mature soluble AREG, which includes 
the heparin-binding domain and the EGF-like motif, is released from the 
precursor protein by the metalloprotease ADAM17/TACE (Sahin et al., 2004). 
Metalloprotease processing of AREG results in multiple soluble and membrane 
forms (Figure 8) (Brown et al., 1998). The predominant membrane form detected 
in cell lysates is the 50 kDa full length N-glycosylated precursor protein. This 
form can be processed by metalloproteases to produce either a soluble 43 kDa 
form that still contains the pro-protein domain or 28 kDa and 26 kDa membrane 
forms. The 28 kDa and 26 kDa membrane forms no longer contain the pro-
protein domain and differ in size due to processing of the N-terminal 6-residues 
within the heparin-binding domain. Since the pro-protein domain is no longer 
present on these two membrane forms and the pro-protein domain is necessary 
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for proper secretion, this processing event most likely occurs at the cell surface 
(Brown et al., 1998; Thorne and Plowman, 1994).  
The 28 kDa and 26 kDa membrane forms are also the predominant forms 
detected in exosomes (Higginbotham et al., 2011). How AREG is delivered to 
exosomes is a topic of future study and the presence of forms lacking the pro-
protein domain indicates delivery to exosomes may be enhanced by removal of 
the pro-protein domain. The presence of these two forms in exosomes and the 
requirement of the pro-protein domain for proper secretion also indicates the 
route to the exosome is via the cell surface where the removal of the pro-protein 
domain is thought to take place (Brown et al., 1998; Thorne and Plowman, 1994).  
The 28 kDa and 26 kDa membrane forms can be processed to release 21 
kDa and 19 kDa soluble forms, which correspond to the 84- and 78-residue 
soluble bioactive ligands initially identified as AREG (Brown et al., 1998; Shoyab 
et al., 1988; Shoyab et al., 1989). If not released as soluble isoforms, the 
heparin-binding domain of the 28 kDa and 26 kDa membrane forms can be 
removed to produce a 16 kDa membrane form that can be released as a 9 kDa 
soluble form. The 9 kDa soluble form would consist only of the EGF-like motif 
(Brown et al., 1998).  The different biological activities and occurrence in the 
extracellular milieu of these various soluble and membrane forms is unknown. 
The recent work regarding the biologic activity of AREG exosomes verses 
soluble ligand sheds some light on the potency of different AREG forms 
(Higginbotham et al., 2011). However, there is still much more to learn about the 
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regulation of different forms of AREG and the role they play in normal and 
disease states.       
The work in this chapter focuses on the critical residues present in the 
cytoplasmic domain of AREG necessary for the proper localization to the BL 
surface. Previous studies showed that removal of the AREG cytoplasmic domain 
resulted in a non-polar distribution of AREG on the cell surface, indicating that 
the cytoplasmic domain contains important BL sorting information (Brown et al., 
2001). The extracellular domains of EGFR and EGF are heavily glycosylated; 
this glycosylation is likely responsible for their predominant apical distribution 
upon removal of their cytoplasmic domains (Hobert and Carlin, 1995). AREG is 
also glycosylated, but removal of the AREG cytoplasmic domain results in a non-
polar distribution of AREG, suggesting that the glycosylated extracellular domain 
of AREG does not act as a separate apical sorting determinant (Brown et al., 
2001). The data in this chapter demonstrate that the AREG cytoplasmic domain 
contains dominant-acting BL sorting information that is sufficient to redirect the 
apically targeted 75-kDa human nerve growth factor receptor (NGFR) to the BL 
surface. The atypical AREG BL sorting motif consists of a mono-leucine 
preceded by an acidic cluster (EExxxL). In polarized cells that lack the adaptor 
protein AP-1B, AREG is inappropriately recycled from the BL surface to the 
apical surface, distributing AREG in a non-polar fashion at steady state. The 
AREG BL sorting motif sequence configuration and dependence on AP-1B 
differentiates AREG from the only other known proteins to contain a mono-  
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Figure 8. Model proposed by Brown et al. to explain the various membrane 
and soluble forms of AREG detected in cellular lysates and conditioned 
media. The indicated domains of the precursor protein are as follows a) pro-
peptide b) heparin-binding c) EGF-like motif d) transmembrane e) cytoplasmic. 
Proposed processing events: #1) release of the soluble 43 kDa form #2) removal 
of the pro-peptide domain #3) release of the 78- and 84-residue ligands #4) 
removal of the heparin-binding domain #5) release of the 9 kDa soluble form 
lacking the heparin-binding domain (Brown et al., 1998).  
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leucine BL sorting motif, CD147 and stem cell factor (SCF) (Deora et al., 2004; 
Wehrle-Haller and Imhof, 2001). 
 
Materials and Methods 
 
Reagents and Antibodies 
Cell culture media was purchased from Media Tech Inc (Manassas, VA) 
and fetal bovine serum from Hyclone Laboratories (Logan, UT). All chemicals 
were purchased from Sigma (St. Louis, MO) unless otherwise stated.  Sulfo-
NHS-LC-Biotin and micro-BSA protein assay kits were purchased from Pierce 
Biotechnology (Rockford, IL). All electrophoresis reagents were purchased from 
Bio-Rad Laboratories (Hercules, CA). Rainbow markers were purchased from 
Bio-Rad or Fermentas Life Sciences (Glen Burnie, MD). ECL reagents were 
purchased from Perkin Elmer (Waltham, MA). Nitrocellulose was purchased from 
Whatman (Dassel, Germany). DNA mini-prep and cleanup kits were purchased 
from Qiagen Sciences (Hilden, Germany). Protein G agarose beads were 
purchased from Invitrogen (Carlsbad, CA). All conjugated secondary antibodies 
were purchased from Jackson ImmunoResearch Laboratories Inc. (West Grove, 
PA). Labeled phalloidin was purchased from Invitrogen (Eugene, OR). Mouse 
monoclonal antibody 6R1C2.4 against human AREG was previously described 
(Brown et al., 2001; Brown et al., 1998; Piepkorn et al., 1995). Anti-NGFR p75 
(ME20.4) mouse monoclonal antibody was purchased from Santa Cruz 
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Biotechnology, Inc (Santa Cruz, CA). IR-Dye680 streptavidin was purchased 
from LI-COR Biosciences (Lincoln, NE).  
 
Cells and Cell Culture  
MDCK II cells were obtained from Enrique Rodriguez-Boulan (Cornell 
University Medical College, Ithaca, NY). MDCK µ1B KD cells were obtained from 
Enrique Rodriguez-Boulan and previously described (Gravotta et al., 2007).   
LLC-PK1::µ1A and LLC-PK1::µ1B cells were previously described (Folsch et al., 
1999). Cells were cultured as previously described (Dempsey and Coffey, 1994). 
Cells were grown on 12 mm Transwells (0.4 µm pores, Corning Inc.) as 
previously described (Brown et al., 2001).  
 
AREG Constructs  
Human AREG cDNA encoding wild-type pro-AREG was obtained from Dr. 
Greg Plowman (Sugen, Redwood City, CA) (Plowman et al., 1990) and Dr. Gary 
Shipley (Oregon Health Sciences University, Portland, OR) (Cook et al., 1991) 
and expressed in pCB6 (Brown et al., 1998). All untagged constructs were 
expressed in pCB6 (Brewer and Roth, 1991). All EGFP tagged constructs were 
expressed in the Clontech vector pEGFP-N1 (GenBank Accession #U55762). 
Human NGFR cDNA was obtained from Dr. Andre Le Bivic (Monlauzeur et al., 
1995).  A chimera of the extracellular and transmembrane domains of NGFR with 
the cytoplasmic domain of AREG (NGFR-ACD) was constructed by creating a 
BsmI site at the transmembrane-cytoplasmic domain junction of NGFR. The 
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cytoplasmic domain of NGFR was removed with a BsmI/XbaI digest. Using PCR, 
AREG cytoplasmic domain fragment was ligated to the NGFR to create an 
NGFR-ACD chimera. AREG cytoplasmic domain truncations and amino acid 
mutations were obtained by PCR QuikChange® site-directed mutagenesis of 
wild-type pro-AREG in pCB6 as per manufactures instructions (Stratagene 
Catalog# 200518). All DNA constructs were confirmed by sequencing prior to 
use.  
 
Selective Cell Surface Biotinylation  
Cells were plated on 12 mm Transwell inserts at a cell density of 1x105 
cells/Transwell. Four days after plating, the transepithelial electrical resistance 
(TEER) for each Transwell was confirmed to be >200 Ω/cm2. Cells were then 
treated with 5 mM sodium butyrate overnight. On day five, the cells were washed 
three times with cold PBS containing 0.1 mM CaCl2 and 1.0 mM MgCl2 (1xPBS-
CM) on ice. All subsequent steps were done on ice or at 4oC. Either the apical or 
BL cell surface was biotinylated with 0.5 mg/ml biotin in 1xPBS-CM. Cells were 
incubated with biotin for 20 minutes, then used biotin was removed and replaced 
with fresh biotin for an additional 20 minutes. The biotin was quenched with five 
washes of 1xPBS-CM, 0.2% BSA, 100 mM glycine followed by two washes with 
1xPBS-CM. Filters were cut from the inserts and placed in 250 µl 1%NP-40 lysis 
buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% NP40, 2 mM EDTA) plus 
protease inhibitors (Sigma P2714) and rotated for 30 minutes. Cell lysates were 
transferred to new eppendorf tubes and centrifuged for 15 minutes at 13,000 
	   55	  
RPM. Supernatants were transferred to new tubes and rotated for 1 hour with 10 
µl 50% slurry recombinant Protein G agarose beads to pre-clear the samples. 
The protein concentration of each sample was determined using a BCA protein 
assay.  Equal protein concentration of each sample was transferred to a new 
tube with 1 µg of mouse anti-AREG antibody (6R1C2.4) and rotated overnight. 
20 µl of recombinant Protein G agarose bead slurry was added to each sample 
and rotated for 3 hours. Beads were gently pelleted and washed three times with 
1 ml lysis buffer. The final pellet was resuspended in 20 µl 1x sample buffer (2x 
sample buffer: 125 mM Tris-HCl pH 6.8, 2% Glycerol, 4% SDS (w/v), 0.05% 
bromophenol blue) and heated at 75oC for 10 minutes. Sample proteins were 
separated by 12.5% SDS-PAGE and transferred to nitrocellulose membranes. All 
subsequent steps were performed with filtered PBS. Membranes were blocked 
overnight with 1xPBS, 3% BSA. Membranes were probed for 30 minutes at room 
temperature (RT) with IR-Dye680 streptavidin diluted 1:25000 in 1xPBS, 3% 
BSA, 0.1% Tween20, 0.01% SDS. Membranes were then washed three times 
with 1xPBS, 0.1% Tween and two times with 1xPBS before imaged on an 
Odyssey infrared imaging system (LI-COR Biosciences). Odyssey software 
(version 3.0) was used to determine the integrated intensity of each band. The 
integrated intensities for all the bands in both the apical and BL lanes were 
added together to obtain a “total cell surface” value [(apical integrated 
intensity)+(BL integrated intensity)=total]. The integrated intensities of the bands 
in either the apical or BL lanes were divided by the total cell surface value to give 
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the percentage of total value [(apical integrated intensity/total)x100= percentage 
of total on apical surface].   
 
Immunofluorescence and Confocal Microscopy  
LLC-PK1 cells were stained as previously described (Folsch et al., 1999). 
Cells were plated on 12 mm Transwell inserts at a cell density of 1x105 
cells/Transwell. Cells were grown on Transwells for four days and reached 
appropriate TEER (MDCK >200 Ω/cm2, LLC-PK1 >400 Ω/cm2) before staining.  
MDCK cells were washed three times with ice cold PBS-CM then stained for 1 
hour on ice with primary antibody diluted in 1xPBS-CM.  Cells were washed six 
times with ice-cold 1xPBS-CM prior to fixation with 4% paraformaldehyde/PBS-
CM for 15 minutes on ice then quenched with 50 mM ammonium chloride in 1x 
PBS-CM for 10 minutes. Cells were washed and blocked in 1x PBS-CM, 1% 
BSA, 0.2% fish skin gelatin (blocking buffer) three times over 1 hour. Secondary 
antibodies were diluted 1:200 in blocking buffer and incubated on cells for 1 hour. 
Cells were washed three times followed by a 10 minute wash with blocking buffer 
plus 0.1% Triton X-100. Cells were incubated with labeled phalloidin diluted 
1:200 in blocking buffer for 30 minutes prior to three washes with blocking buffer 
and mounting in ProLong® Gold (Invitrogen P36934). Immunofluorescence 
imaging was acquired on a Zeiss LSM 510 confocal microscope (Zeiss 
Microscope Imaging, Inc., Thornwood, NY) using a 40x objective with a 2x zoom 
at 1024x1024 resolution. Contents of image window were exported as Tiff files 
using LSM Image Browser software (Version 4.2.0.121, Carl Zeiss GmbH Jena 
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1997-2006; Zeiss Microscope Imaging, Inc., Thornwood, NY). Tiff files were 
processed and cropped using Adobe Photoshop software (Version 12.0). Levels 
for each channel were independently modified and include all available data.  
 
Transcytosis Assay 
LLC-PK1 cells were plated on 12 mm Transwell inserts at a cell density of 
1x105 cells/Transwell. Cells were grown on Transwells for six days and reached 
appropriate TEER (>400 Ω/cm2). Integrity of the monolayer was confirmed using 
3000 MW dextran Texas Red® (Invitrogen D3328) diluted to 63 µg/ml in phenol 
red-free complete media. Labeled dextran was added to the apical compartment 
of the Transwell only and incubated at 37oC for 30 minutes. 100 µl of media was 
removed from the BL compartment and replaced with fresh media every five 
minutes. The diffusion of the dextran across the monolayer was measured using 
a Synergy 4 BioTek plate reader and Gen5 OLE Automation software (Version 
1.06.10) (BioTek Instruments, Inc., Winooski, VT). Once the monolayer was 
determined to be intact, mouse anti-AREG antibody (6R1C2.4) diluted 4 µg/ml in 
serum free media was added to the BL compartment only for 30 minutes at 37oC. 
Cells were washed three times with RT 1xPBS-CM, 1% BSA to remove unbound 
antibody. In 1xPBS-CM, 1% BSA, Alexa-488 conjugated anti-mouse secondary 
antibody (1:200) was added to the BL compartment only and Cy5 conjugated 
anti-mouse secondary antibody (1:200) was added to the apical compartment 
only. Cells were incubated with secondary antibodies for 10 minutes at RT, 
washed three times with 1xPBS-CM, 1% BSA, then fixed with 4% 
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paraformaldehyde/PBS-CM for 15 minutes at RT. Cells were washed three times 
with 1xPBS-CM, 1% BSA then one 15 minute wash with 1xPBS-CM, 1% BSA, 
0.1% Triton X-100.  F-actin was stained with phalloidin- Texas Red® diluted 
1:200 in 1xPBS-CM, 1% BSA for 30 minutes followed by three washes with 
1xPBS-CM, 1% BSA then mounted with ProLong® Gold. Images were acquired 
as described above.  
 
Quantitative RT-PCR 
Two sets of primers were used to determine the mRNA level of canine 
µ1B in µ1B knockdown MDCK cells. Primer set 1 (RealTimePrimers.com) 
(annealing and extension: 61oC, 45 seconds) contained the forward primer 5’-
ACA AGA CGG TGG AGG TTT TC -3’ and reverse primer 5’-CCT GCT GCG 
TGA TGT ACT CT -3’. Primer set 2 (Sigma) (annealing and extension: 65oC, 45 
seconds) was self-designed and contained the forward primer 5’-CCT GAT CAG 
CCG CAA CTA CAA GG -3’ and reverse primer 5’-GTA CTC AGA GAA AAC 
CTC CAC CG -3’. Primers for canine beta-actin (RealTimePrimers.com) 
(annealing and extension: 61oC, 45 seconds) contained the forward primer 5’-
CCC AGA TCA TGT TCG AGA CT -3’ and reverse primer 5’-CAT GAG GTA 
GTC GGT CAG GT -3’. Platinum SYBR Green qPCR supermix-UDG 
(Invitrogen Cat # 11733-038) was used as per manufactures instructions. 
Samples were run and analyzed on a StepOnePlus real-time PCR system with 
StepOne software version 2.1 (Applied Biosystems).  
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Statistical Analysis 
We used analysis of variance to compare apical distribution of AREG in 
polarized MDCK cells. Tukey’s honestly significant difference was used for pair-
wise comparisons. Statistical significance was declared for p<0.05. 
 
Results 
 
The cytoplasmic domain of AREG contains a dominant BL sorting motif  
The cytoplasmic domain of AREG controls its delivery to the BL surface of 
polarized epithelial cells using information within the last 27 amino acids of its 31 
amino acid cytoplasmic domain, such that deletion of these amino acids results 
in a non-polar surface distribution of AREG in MDCK cells (Brown et al., 2001). 
By contrast, NGFR, which contains an extracellular apical sorting determinant 
consisting of an O-glycosylated region, is normally localized to the apical surface 
of polarized MDCK cells and removal of the NGFR cytoplasmic domain does not 
affect apical localization (Le Bivic et al., 1991; Yeaman et al., 1997). To confirm 
that the cytoplasmic domain of AREG contains BL sorting information, a chimeric 
protein consisting of the extracellular and transmembrane domains of NGFR and 
the cytoplasmic domain of AREG (NGFR-ACD) was generated and stably 
expressed in MDCK cells. Cell surface immunofluorescence for the ectodomain 
of NGFR showed NGFR on the apical surface while NGFR-ACD was present on 
the BL surface of polarized MDCK cells (Figure 9A). Selective cell surface 
biotinylation was used to compare the distribution of NGFR with the NGFR-ACD  
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Figure 9. The cytoplasmic domain of AREG redirects NGFR from the apical 
(Ap) to the basolateral (BL) surface of polarized MDCK cells.  MDCK cells 
stably expressing either full-length NGFR or the NGFR extracellular and 
transmembrane domains fused to the AREG cytoplasmic domain (NGFR-ACD) 
were polarized on Transwell filters (TEER>200 Ω/cm2) and then analyzed for 
steady state cell surface distribution of NGFR using an NGFR ectodomain-
specific antibody (ME20.4). (A) Polarized cells were stained for NGFR (green) 
under non-permeabilized conditions followed by permeabilization with 0.1% 
Triton and F-actin (red) staining. Analysis was performed by confocal 
microscopy. Bar, 10 µm. (B) Polarized cells were selectively biotinylated on the 
Ap or BL surface, immunoprecipitated with ME20.4, separated by SDS-PAGE, 
transferred to nitrocellulose and then probed with streptavidin-HRP, or (C) with 
streptavidin-IRDye680. Results were scanned on an Odyssey scanner and 
quantitated using Odyssey software (n=3). Columns marked with an * are 
significantly different (p<0.05). 
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chimera. At steady state, 75% of NGFR was distributed to the apical surface of 
polarized MDCK cells whereas 78% of the NGFR-ACD chimera was distributed 
to the BL surface (Figure 9C). The BL redistribution of the NGFR ectodomain via 
the cytoplasmic domain of AREG demonstrates it contains a dominant BL sorting 
motif, over-riding the NGFR apical sorting determinant. Interestingly, CD147, 
which contains a canonical mono-leucine BL sorting motif (EDDXXXXXL) (Deora 
et al., 2004), was unable to redirect NGFR to the BL surface (Castorino et al., 
2010). 
 
Determining the amino acids within the cytoplasmic domain necessary for 
the BL localization of AREG  
Having established the presence of a dominant BL sorting motif within the 
cytoplasmic domain of AREG, we set out to determine the specific amino acids 
that contain necessary BL sorting information. Sequential cytoplasmic domain 
truncation mutants of AREG were constructed using PCR and were C-terminally 
fused to EGFP (Figure 10A). These chimeras were transfected into MDCK cells, 
selected for G418 resistance and enriched using flow cytometry to generate a 
stable population of cells expressing high levels of the mutants. The localization 
of the truncation mutants was analyzed by cell surface immunofluorescence 
(Figure 10B) and selective cell surface biotinylation (Figure 10C).  Full-length 
AREG and AREG with 6-amino acids removed from the cytoplasmic domain (25 
aa) were 95% and 93% localized to the BL surface, respectively. However, 
truncating the cytoplasmic domain by 17-amino acids (14 aa) resulted in only  
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Figure 10. AREG cytoplasmic domain (ACD) truncations reveal that 
residues 236-246 contain BL sorting information. (A) Amino acid composition 
of ACD and points of truncation. MDCK cells stably expressing EGFP-tagged 
ACD truncations were generated and used to determine the region of the tail that 
contains BL sorting information. Cells were polarized on Transwell filters and (B) 
surface stained for AREG (green) followed by permeabilization and F-actin (red) 
staining. Analysis was performed by confocal microscopy. Bars, 10 µm. (C) 
Polarized cells were selectively biotinylated on the Ap or BL surface, 
immunoprecipitated with anti-AREG mAb, separated by SDS-PAGE, transferred 
to nitrocellulose and then probed with IRDye680-streptavidin. Results were 
scanned on an Odyssey scanner and quantitated using Odyssey software (n≥3).  
Columns marked with an * are significantly different from WT (p<0.05). 
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57% of total surface AREG localized to the BL surface. The difference in 
distribution between full-length and 14 aa AREG is statistically significant, 
whereas the difference in distribution of 14 aa and a 4-amino acid cytoplasmic 
domain (4 aa) is not statistically significant. These results indicate that important 
BL sorting information resides within amino acids 236 (14 aa) thru 246 (25 aa) of 
AREG within the cytoplasmic domain. 
 
Identification of a mono-leucine-based BL sorting motif  
Analysis of amino acids 236 thru 246 (EERKKLRQENG) revealed no 
obvious canonical BL sorting motifs.  Comparison across species showed this 
region of the domain to be 73% identical and 91% similarly conserved, making 
this the most highly conserved region of the cytoplasmic domain (Figure 7). This 
region contains an acidic cluster, a basic cluster and a mono-leucine.  Mono-
leucine BL sorting motifs consisting of an acidic cluster N-terminal of a mono-
leucine (EDDXXXXXL) have been reported for two other BL proteins, SCF and 
CD147 (Deora et al., 2004; Wehrle-Haller and Imhof, 2001).  Although this exact 
motif is not present in the cytoplasmic domain of AREG, we further analyzed the 
possibility of AREG containing a variation of the consensus mono-leucine BL 
sorting motif.  Using PCR site-directed mutagenesis, individual amino acids were 
changed to alanine (A) residues (Figure 11A).  When the single leucine (L) 
residue was changed to alanine (L241A [LA]), AREG polarity was lost with 45% 
of total surface AREG distributed to the apical surface at steady state (Figure 
11B and 11C).  When the two conserved acidic glutamine (E) residues were  
	   65	  
 
 
	   66	  
 
Figure 11. Amino acid substitutions within residues 236-246 identify a 
mono-leucine-based sorting signal.  
(A) Amino acid composition of AREG cytoplasmic domain (ACD) between 
residues 236 and 246. Specific amino acid mutations are indicated in red. MDCK 
cells stably expressing the ACD mutants were generated and used to determine 
the BL sorting motif. Cells were polarized on Transwell filters and (B) surface 
stained for AREG (green) followed by permeabilization and F-actin (red) staining. 
Analysis was performed by confocal microscopy. Bars, 10 µm. (C) Polarized cells 
were selectively biotinylated on the Ap or BL surface, immunoprecipitated with 
anti-AREG mAb, separated by SDS-PAGE, transferred to nitrocellulose, and then 
probed with IRDye680-streptavidin. Results were scanned on an Odyssey 
scanner and quantitated using Odyssey software (n≥3). Columns marked with an 
* are significantly different from WT. Columns marked with a † are significantly 
different from each other (p<0.05). 
 
 
 
 
 
 
Table 2. AREG cytoplasmic domain and mutations. The 31-amino acid 
cytoplasmic domain of AREG (222-252) is aligned with the different alanine 
substitution mutants. Residues that are substituted with alanine are highlighted in 
red. Whether the mutant is delivered to the basolateral (BL) surface or to both 
surfaces (Ap/BL) of the cell in a non-polarized fashion is indicated on the right. 
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changed to alanine residues (EE236,237AA [EEAA]), the amount of AREG 
detected on the apical surface at steady state was 33% (Figure 11C). These 
changes in AREG apical distribution are both significantly different from the 7% 
of steady state wild-type AREG detected on the apical surface. Combining the 
two mutations (EEAA/LA) resulted in 59% of total surface AREG to be apical at 
steady state (Figure 11C). In order to rule out the possibility that the charge of 
the region played a role in BL sorting (Wolff et al., 2010), we mutated the two 
positive lysine (K) residues (KK239,240AA [KKAA]) to alanine residues. This 
mutant exhibited normal BL localization of AREG with 98% present on the BL 
surface (Figure 11C). These results indicate both the acidic cluster and the 
mono-leucine, which are both highly conserved across species (Figure 7), are 
important components to the BL sorting motif in the cytoplasmic domain of 
AREG.  
 
Loss of AP-1B affects the polarized distribution of AREG at steady state  
Heterotetrameric adaptor protein complexes (AP-1A, AP-1B, AP-2, AP-3A, 
AP-3B, AP-4) selectively incorporate cargo proteins and facilitate vesicle 
formation (Nakatsu and Ohno, 2003). Of the known AP complexes, only AP-1B 
and AP-4 have been implicated in BL sorting (Folsch, 2005). AP-1B expression is 
epithelial cell-specific and only differs from the ubiquitous AP-1A by the medium 
(µ1B) subunit (Ohno et al., 1999). AP-1B is localized to recycling endosomes and 
plays a role in biosynthetic delivery and recycling of BL proteins (Cancino et al., 
2007; Folsch et al., 2003; Gan et al., 2002; Gravotta et al., 2007). LLC-PK1 cells 
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are a polarizing epithelial cell line that does not express AP-1B and missorts 
proteins that are dependent on AP-1B for BL delivery (Folsch et al., 1999). In 
order to determine the role of AP-1B in AREG BL delivery, clonal lines of LLC-
PK1 cells expressing either pCB6::µ1A (LLC-PK1::µ1A) or pCB6::µ1B (LLC-
PK1::µ1B) were transiently transfected with AREG and then analyzed by cell 
surface immunofluorescence (Figure 12A). In the LLC-PK1::µ1A cells, which lack 
AP-1B, AREG was detected on the apical and BL surface, indicating a role for 
AP-1B in maintaining the polar distribution of AREG (Figure 12A). In the LLC-
PK1::µ1B cells,  AREG was restricted to the BL surface and no longer present on 
the apical surface (Figure 12A). Since AREG was detected on both surfaces in 
LLC-PK1::µ1A cells at steady state, we wanted to further characterize the AREG 
distribution using selective cell surface biotinylation. However, LLC-PK1 cells are 
not suitable for use in selective cell surface biotinylation (Folsch et al., 1999); 
therefore, we used a clonal line of MDCK cells expressing shRNA against µ1B 
(Gravotta et al., 2007). This clonal line was transfected with AREG, selected with 
G418 and enriched by flow cytometry to produce a pool of MDCK µ1B 
knockdown cells expressing AREG. Knockdown of µ1B in the clonal line has 
been previously characterized (Gravotta et al., 2007); this was confirmed in these 
AREG-expressing cells by quantitative RT-PCR, which showed a 93% reduction 
in µ1B message compared to control MDCK cells (Figure 12C). AREG 
immunoreactivity was detected on the apical surface of polarized µ1B knockdown 
MDCK cells (Figure 12A). To quantitate the cell surface distribution of AREG in 
the µ1B knockdown MDCK cells at steady state, cells were polarized on 
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Figure 12. Loss of AP-1B results in apical distribution of AREG. µ1B-
deficient LLC-PK1 cells stably expressing either the µ1B or µ1A subunit or 
MDCK cells stably expressing shRNA against the µ1B subunit of AP-1B were 
used to demonstrate the role of AP-1B in the cell surface distribution of AREG. 
The cells were transiently transfected with AREG and then polarized on 
Transwell filters. (A) The polarized monolayer was surface stained for AREG 
(green) followed by permeabilization and F-actin (red) staining. Analysis was 
performed by confocal microscopy. Bars, 10 µm. (B) AREG-expressing parental 
and µ1B knockdown MDCK cells polarized on Transwell filters were selectively 
biotinylated on the Ap or BL surface, immunoprecipitated with AREG mAb, 
separated by SDS-PAGE, transferred to nitrocellulose, and then probed with 
IRDye680-streptavidin. Results were scanned on an Odyssey scanner and 
quantitated using Odyssey software (n≥3). Columns marked with an * are 
significantly different (p<0.05). (C) Knockdown of µ1B was confirmed by 
quantitative RT-PCR using two different primer sets. Relative quantity= RQ.  
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Transwell filters and selectively biotinylated on either the apical or BL surface. 
The µ1B knockdown MDCK cells expressed 30% of the total cell surface AREG 
on the apical surface at steady state, a two-fold increase over control MDCK cells 
with µ1B (Figure 12B). This result, along with the presence of AREG on the 
apical surface of LLC-PK1::µ1A cells, demonstrates a role for AP-1B in the polar 
distribution of AREG.  
 
Loss of AP-1B results in inappropriate recycling of post-endocytic AREG to 
the apical surface in fully polarized LLC-PK1 cells 
The presence of AREG on the apical and BL surface of polarized epithelial 
cells lacking AP-1B led us to ask what role AP-1B plays in the polar distribution 
of AREG. Previous studies have shown that AP-1B is localized to the recycling 
endosomes and participates in both biosynthetic delivery and recycling of 
proteins to the BL surface (Cancino et al., 2007; Folsch et al., 2003; Gan et al., 
2002; Gravotta et al., 2007). Since the majority of steady state cell surface AREG 
was detected on the BL surface of polarized MDCK cells with reduced AP-1B, we 
hypothesized that the AREG biosynthetic route was AP-1B-independent, but 
recycling of post-endocytic AREG was AP-1B dependent. To test this hypothesis 
we used LLC-PK1::µ1A and LLC-PK1::µ1B cells transfected with AREG. These 
cells were polarized on Transwell filters and the integrity of the monolayer was 
determined by transepithelial electrical resistance (TEER) (>400 Ω/cm2) and 
inhibited diffusion of 3000 MW dextran Texas Red across the monolayer. Once 
the monolayer was determined to be intact, the cells were incubated for 30 
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minutes at 37oC with a primary mouse antibody against AREG in the BL 
compartment only. This provided the antibody access to only the AREG on the 
BL surface and ample time for the antibody bound AREG to be endocytosed and 
transit through the recycling endosomes back to the cell surface.  The cells were 
then washed and incubated for 10 minutes at room temperature with two 
separate secondary antibodies, anti-mouse-Cy5 on the apical surface only and 
anti-mouse-Alexa488 on the BL surface only. The LLC-PK1::µ1A cells, which 
lack AP-1B, had recycled AREG bound with the primary antibody to the apical 
surface in 80% of cells with positive BL staining for AREG (Figure 13A). The 
LLC-PK1::µ1B cells restricted the AREG primary antibody to the BL surface in 
65% of AREG positive cells (Figure 13B). These data support our hypothesis that 
AREG is endocytosed from the BL surface and inappropriately recycled to the 
apical surface in AP-1B deficient cells. 
 
 
 
	   72	  
 
 
 
 
 
Figure 13. BL labeled AREG appears at Ap surface of  µ1B-deficient LLC-
PK1 cells. AREG primary antibody was added only to the BL compartment of 
polarized LLC-PK1 cells stably expressing µ1A or µ1B and incubated at 37oC for 
30 minutes. Cells were washed and then selectively incubated with Alexa488-
conjugated secondary antibody in the BL compartment and Cy5-conjugated 
secondary antibody in the Ap compartment for 10 min at RT. (A) BL primary 
antibody-bound AREG was detected at the Ap surface of LLC-PK1 cells that lack 
µ1B using a Cy5 secondary antibody. This occurred in 80% of the cells with BL 
Alexa488 secondary antibody staining (n=100). (B) LLC-PK1 cells that express 
µ1B retained the primary antibody bound to AREG on the BL surface in 65% of 
cells with BL Alexa488 secondary antibody staining (n=93).  The individual 
channels of the X-Z axis are displayed. Bar, 10 µm.  
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Discussion 
Our earlier work demonstrated the importance of the cytoplasmic domain 
for polar distribution of AREG (Brown et al., 2001). The present study extends 
those observations to show that the AREG cytoplasmic domain contains a 
dominant-acting BL sorting motif consisting of a mono-leucine preceded by an 
acidic cluster and show that the adaptor protein, AP-1B, is necessary to maintain 
the proper polar distribution of AREG.  
The 31-amino acid cytoplasmic domain of AREG is 35% identical across 
species (Figure 7). Using cytoplasmic domain truncation mutants, we identified 
that amino acids 236-246 contain essential information needed for the polarized 
distribution of AREG. These amino acids constitute the most conserved region of 
the cytoplasmic domain that is 73% identical and 91% similar across species 
(Figure 7). In the 14 aa truncation mutant, the remaining amino acids in this 
region are only 14% identical across species. Removal of this region (4 aa) did 
not significantly disrupt the polarized distribution of AREG (Figure 10C). 
However, we cannot rule out the possibility that additional information within this 
juxtamembrane region contributes to the steady state BL localization of AREG. 
We previously reported that the juxtamembrane region of TGFα was sufficient to 
maintain its BL distribution (Dempsey et al., 2003). There are similarities between 
the amino acid composition of the AREG (QLRRQYVRK) and TGFα 
(HCCQVRKH) juxtamembrane regions. However, in contrast to TGFα, the 
presence of this region alone in AREG does not maintain polar distribution 
(Figure 10) (Dempsey et al., 2003). Also unlike TGFα, AREG BL delivery is not 
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dependent on NKD2, which, in part, binds the juxtamembrane region of TGFα (Li 
et al., 2004a).  The AREG juxtamembrane region does contain tyrosine residues 
at positions 227 and 231.  Since tyrosine residues are established constituents of 
BL sorting motifs (Bonifacino and Traub, 2003; Carmosino et al., 2010), we 
mutated these tyrosine residues individually and together to alanine residues, but 
no change in AREG polarity was observed (Table 2). In addition, we confirmed 
that removal of all but 4-amino acids from the cytoplasmic domain still resulted in 
35% of total surface AREG being distributed to the BL surface (Brown et al., 
2001).  We believe this indicates the absence of an apical sorting determinant 
within the ectodomain of AREG.   
Canonical BL sorting motifs (YXXΦ, FXNPXY, [DE]XXXL[LI]) (Bonifacino 
and Traub, 2003; Rodriguez-Boulan and Musch, 2005) are not present within 
amino acids 236-246 (EERKKLRQENG) of AREG. However, a less well-
characterized BL sorting motif consisting of a mono-leucine is present.  The 
consensus motif for a mono-leucine BL sorting signal consists of a single leucine 
five residues C-terminal to an acidic cluster (EEDXXXXXL) and is present in the 
only other two proteins identified to contain mono-leucine BL sorting motifs, 
CD147 and SCF (Deora et al., 2004; Gonzalez and Rodriguez-Boulan, 2009; 
Wehrle-Haller and Imhof, 2001).  Although AREG does not contain this exact 
consensus motif, it does contain a mono-leucine C-terminal to an acidic cluster 
(EEXXXL). The AREG BL sorting motif differs from CD147 not only in the 
consensus motif, but also in its dominance over the NGFR apical sorting 
determinant. CD147 and SCF can both redirect the apical reporter Tac to the BL 
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surface, but CD147 is incapable of redirecting NGFR to the BL surface 
(Castorino et al., 2010; Deora et al., 2004; Wehrle-Haller and Imhof, 2001). 
CD147 also has a much more pronounced apical distribution compared to AREG 
after mutation of the mono-leucine, with 80% of L252A CD147 distributed apically 
compared to 45% of L241A AREG (Figure 11C) (Deora et al., 2004). This may 
indicate additional BL sorting information is present in the AREG cytoplasmic 
domain, although removal of the AREG cytoplasmic domain results in only 65% 
apical distribution (Figure 10C). Also, removal of the AREG cytoplasmic domain 
does not result in a statistically significant difference in apical distribution 
compared to the 59% apical distribution of the complete mono-leucine motif 
mutant (EEAA/LA) (Figure 11C).  Another commonality between SCF and CD147 
is their formation of homo- and heterodimers, respectively.  SCF 
homodimerization is necessary for efficient surface expression while CD147 
heterodimerization with the proton- coupled monocarboxylate transporter 1 
(MCT1) directs the localization of MCT1 (Castorino et al., 2010; Paulhe et al., 
2009).  It is unknown if AREG dimerizes.  
The dependence on AP-1B for proper localization of AREG also 
differentiates AREG from CD147, which is delivered to the BL surface in both 
LLC-PK1 cells and µ1B knockdown MDCK cells (Castorino et al., 2010; Deora et 
al., 2004). We have demonstrated a dependence on AP-1B for the polar 
distribution of AREG (Figure 12) and future studies will seek to identify the motif 
recognized by AP-1B. Currently, µ1B is thought to mainly interact with tyrosine-
based sorting motifs (Carmosino et al., 2010; Fields et al., 2007; Folsch, 2005). 
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However, mutation of the only two tyrosine residues in the AREG cytoplasmic 
domain does not disrupt AREG BL distribution in MDCK cells (Table 2). Since 
knockdown of µ1B in MDCK cells disrupts AREG polarity, mutation of the sorting 
motif recognized by AP-1B should also disrupt AREG polarity in MDCK cells. 
AREG may be interacting with AP-1B through a linker/adaptor protein, as has 
been recently reported for LDL receptor and the autosomal recessive 
hypercholesterolemia protein (ARH) (Kang and Folsch, 2011). In the case of LDL 
receptor, ARH interacts with the proximal FXNPXY motif in the LDL receptor 
cytoplasmic domain (Traub, 2009).  Extensive efforts by our group have yet to 
identify and confirm an interacting protein for the AREG cytoplasmic domain.  An 
alternative explanation may be that the tyrosine residues are involved in 
endocytosis of AREG and mutation of these residues prevents post-endocytic 
AREG from reaching recycling endosomes where missorting to the apical 
membrane can occur in AP-1B-deficient cells (Figure 13). However, the AREG 
tyrosine motifs do not resemble the well-characterized NPXY internalization motif 
or the YXXΦ motif demonstrated to interact with the medium subunit, µ2, of AP-2 
(Chen et al., 1990; Matter et al., 1994; Ohno et al., 1995; Owen and Evans, 
1998).  AREG does contain a YXXXXEE motif, similar to the proximal BL sorting 
motif in LDL receptor, but mutation of the acidic residues in the LDL receptor 
motif did not affect endocytosis (Matter et al., 1994). Mutation of the tyrosine in 
the LDL receptor proximal motif results in apical distribution of truncated LDL 
receptor (Matter et al., 1992), while the Y231A mutation in AREG did not affect 
BL delivery. Also, if this YXXXXEE motif in AREG acts as a BL signal, we would 
	   77	  
expect the L241A mutant to maintain polar BL distribution, as is the case if only 
one BL motif in LDLR is mutated (Matter et al., 1992). Future work to determine 
the critical residues involved in AREG endocytosis and identification of 
interacting proteins for the cytoplasmic domain of AREG will address these 
questions.  
Although polar distribution of AREG is AP-1B-dependent, some AREG is 
still delivered to the BL surface in AP-1B-deficient cells and subsequently 
delivered to the apical membrane after internalization (Figure 12 and Figure 13). 
This suggests a role for AP-1B in the recycling of AREG and not in the 
biosynthetic delivery in fully polarized MDCK cells, as previous studies have 
demonstrated for LDL receptor, transferrin receptor, and CAR (Cancino et al., 
2007; Diaz et al., 2009; Gonzalez and Rodriguez-Boulan, 2009; Gravotta et al., 
2007). These previous studies demonstrated an AP-1B-independent biosynthetic 
route for transferrin receptor in fully polarized cells, but also showed an AP-1B-
dependent trans-endosomal biosynthetic route in recently confluent MDCK cells 
(Gravotta et al., 2007). It should be noted that all our experiments were 
performed on fully polarized cells. To investigate the possibility of AP-1B 
affecting AREG polar distribution in a recycling capacity, we performed an 
antibody binding and transcytosis assay in LLC-PK1::µ1A and LLC-PK1::µ1B 
cells transfected with AREG. Because the integrity of the monolayer is important 
in this type of assay and LLC-PK1 cells have notoriously incomplete monolayers, 
we used stringent criteria to validate the monolayer was fully intact, performing 
the assay only on monolayers that prevented the diffusion of a molecule 50 times 
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smaller than mouse IgG (3000 MW dextran Texas Red) across the monolayer. 
Our results support the hypothesis that post-endocytic AREG is missorted to the 
apical surface in AP-1B-deficient cells (Figure 13), as has been shown for CAR 
(Diaz et al., 2009). Future work will determine the biosynthetic route taken by 
AREG to the BL surface and the adaptor protein(s) involved.  
The main focus of this study was to identify the components necessary for 
the polarized distribution of AREG. We have demonstrated the presence of a 
dominant-acting BL sorting motif in the cytoplasmic domain of AREG that 
consists of a mono-leucine and an acidic cluster (EEXXXL). This motif differs 
from previously described mono-leucine motifs. We have also revealed a role for 
AP-1B in the maintenance of AREG polarity. However, additional studies are 
needed to identify the AREG biosynthetic route, adaptor proteins in the 
biosynthetic route, and the motif recognized by AP-1B within the AREG 
cytoplasmic domain. 
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CHAPTER III 
 
AREG IN EXOSOMES 
 
Introduction 
 Exosomes are nano-vesicles (40-100 nm in diameter) produced by 
intralumenal budding into multivesicular bodies (MVB) and are released from 
most cell types after fusion of the MVB with the plasma membrane (Simons and 
Raposo, 2009). Our initial understanding of how cells communicated with each 
other was via the exchange of individual proteins like neurotransmitters, 
hormones, or receptor ligands. Exosomes provide an additional method of 
communication that facilitates the transfer of large amounts of information in one 
vehicle. The protein composition of exosomes is dependent on the donor cell and 
can relay “quanta” of information instead of just one piece of information 
contained in a single protein such as a receptor ligand.  The diversity of 
information in exosomes makes them valuable tools in intercellular 
communication.  
The definition of exosomes is an area of debate because of the variety of 
vesicles released from the cell into the extracellular milieu. Extracellular vesicles 
include exosomes and microvesicles (aka microparticles) and are classified by 
size, method of origin, and protein composition. Microvesicles are heterogeneous 
cytoplasmic protrusions that shed from the cell surface into the extracellular 
space and range in size from 100-200 nm in diameter. How proteins are sorted 
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into these protrusions is unclear, but the process is regulated and can be 
stimulated by Ca2+ and application of phorbol esters (Cocucci et al., 2009). While 
the content of microvesicles is dependent on the donor cell, integrins and 
metalloproteases are common constituents of shed microvesicles (Cocucci et al., 
2009). The functions of microvesicles indentified to date include important roles 
in coagulation and inflammation	   (Ardoin et al., 2007; Falati et al., 2003). The 
importance of microvesicles will become more apparent as we learn more about 
how their content and shedding is regulated. 
Exosomes are smaller and uniform in size, ranging between 40-100 nm in 
diameter. Exosomes originate from endosomes through the formation of 
intralumenal vesicles (ILV) within a late endosome, forming a MVB	  (Denzer et al., 
2000). Exosomes are enriched in ILV proteins, supporting the origin of exosomes 
from MVBs	  (Simons and Raposo, 2009). A MVB can take two pathways, fusion 
with a lysosome and degradation of the lipids and proteins contained within the 
ILVs, or fusion with the cell surface to release the ILVs as exosomes. The 
regulation of what causes a MVB to fuse with the lysosome or fuse with the cell 
surface to release exosomes is unclear.   
The mechanism by which an ILV is formed may provide a level of 
regulation that determines if the ILV is degraded in the lysosome or secreted as 
an exosome. ILV biogenesis for lysosomal degradation has been shown to 
involve the ESCRT (endosomal sorting complex required for transport) 
machinery, which recognizes ubiquitylated proteins and clusters them into ILVs 
destined for the lysosome	   (Hurley, 2008). The presence of ESCRT and 
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ubiquitylated proteins in exosomes suggests a possible role for the ESCRT 
machinery in exosome biogenesis	  (Simons and Raposo, 2009).  However, more 
recent studies have demonstrated certain proteins are still present in exosomes 
in the absence of ESCRT machinery, but instead require the sphingolipid 
ceramide (Trajkovic et al., 2008). Ceramide is enriched in exosomes and is 
formed by sphingomyelinases, inhibition of which can reduce the release of 
exosomes	  (Trajkovic et al., 2008). A possible ESCRT-independent model for ILV 
biogenesis involves the formation of lipid microdomains enriched in sphingolipids, 
which are converted to ceramide by sphingomyelinases. The structure of 
ceramide, clustered in the microdomain, induces the inward curvature of the 
endosomal membrane to form ILVs	  (Trajkovic et al., 2008). Proteins that are not 
clustered by the ESCRT machinery may cluster within these lipid microdomains 
and become enriched in exosomes. This would be one level of regulation to 
generate two populations of ILVs within a single MVB.  
Just as there are different endosomes with distinct protein and lipid 
compositions, the formation of different MVB subpopulations may be another 
method to regulate the destination of ILVs	   (Simons and Raposo, 2009). The 
enrichment of certain lipids within a particular organelle membrane allows for the 
recruitment of specific proteins, such as phosphatidylinositol 3,4,5-trisphosphate 
[PI(3,4,5)P3]  enrichment at the recycling endosome enhances recruitment of 
AP-1B	  (Fields et al., 2010). Enrichment of particular phosphoinositides along with 
sphingolipids in a population of MVBs may create a distinct population of MVBs 
that produce exosomes. One membrane component already demonstrated to 
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differentiate distinct populations of MVBs is cholesterol, which in B lymphocytes	  
is present in one population of MVBs but absent in another (Mobius et al., 2002). 
Different subpopulations of MVBs have been observed in the tumor cell line 
HEp2	   (White et al., 2006). Analysis of EGF stimulated EGFR and the late 
endosomal/lysosomal marker lyso-bisphosphatidic acid (LBPA) in HEp2 cells 
revealed two distinct populations of MVBs. After stimulation with EGF, the EGFR 
and LBPA were detected in distinct MVBs well past the time in which EGFR is 
reported to be localized in the lysosome (White et al., 2006). This phenomenon 
with EGFR and LBPA was observed in numerous cell lines indicating it may be a 
common occurrence. EGFR is detected in exosomes, and EGF stimulates EGFR 
positive exosome secretion (Sanderson et al., 2008). It may be possible the 
EGFR positive, LBPA negative, MVB subpopulation is a distinct MVB population 
destined for fusion with the cell surface. Comparison of the ILV protein 
compositions within these two MVB subpopulations with the protein composition 
of exosomes may provide evidence of an exosomal MVB population. 
Ubiquitylation, addition of the 76-amino acid globular protein ubiquitin to a 
lysine residue, is a reversible post-translational modification that can mark a 
protein for a variety of purposes, including delivery to a MVB. Ubiquitin can be 
added to a single lysine residue on a protein for monoubiquitylation or to multiple 
lysine residues on a single protein for polyubiquitylation. Ubiquitin contains seven 
lysine residues itself where additional ubiquitins can be added (K11, K28, K48 
and K63) to form a multi-ubiquitin chain	  (Weissman, 2001).  The structure of the 
final ubiquitin tag depends on which lysine on ubiquitin is modified and the 
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number of ubiquitins added. A multi-ubiquitin chain of four or more ubiquitins on a 
membrane protein typically results in protein degradation, whereas a 
monoubiquitylation results in endocytosis (Hicke, 2001). 
Monoubiquitylation and K63 multi-ubiquitylation can target a membrane 
protein to the MVB (Lauwers et al., 2009; Urbanowski and Piper, 2001). The role 
of ubiquitin in protein delivery to exosomes is unclear, although ubiquitylated 
proteins are present in exosomes	  (Buschow et al., 2005). It has been proposed 
that ubiquitin is removed from proteins targeted for degradation to prevent 
depletion of ubiquitin from the cell (Swaminathan et al., 1999). Since 
ubiquitylated proteins are present in exosomes, ubiquitin may function to first 
mark a protein for delivery to the MVB and secondly mark the protein for sorting 
into exosomes, while deubiquitylated proteins are sorted for degradation. Another 
possibility is modification of the ubiquitin chain at the MVB	   (Raiborg and 
Stenmark, 2009). In this model one form of ubiquitin could mark the protein for 
delivery to the MVB and be removed at the MVB. Then a different ubiquitin chain 
could be added to mark the protein for sorting into an exosome. Further 
understanding of how an exosome is differentiated from an ILV destined for 
degradation may reveal a role for ubiquitin. 
 The role of exosomes in cell signaling is still being unraveled. Our recent 
publication on exosomal signaling reveals a new mode of EGFR signaling 
through exosomes (Higginbotham et al., 2011). This study was the first to 
demonstrate the presence of biologically active EGFR ligands in exosomes. 
Exosomes containing EGFR ligands stimulate cellular invasion through Matrigel, 
	   84	  
with AREG-containing exosomes inducing four fold higher rates of invasion than 
TGFα or HB-EGF exosomes. Colorectal cancer (CRC) cell lines containing 
mutant KRAS produce exosomes with increased amounts of AREG and 
increased invasiveness of recipient cells compared to CRC cell lines with wild-
type KRAS. This difference in exosomal composition and function between cells 
with or without mutant KRAS could contribute to such diverse cancer phenomena 
as field effect and priming the metastatic niche. 
Our analysis of exosomes began with the observation by Ada Braun that 
full-length HB-EGF was present in cell culture conditioned medium. Isolation of 
exosomes from conditioned medium and analysis by sucrose gradient 
fractionation confirmed the presence of HB-EGF in exosome abundant fractions. 
Using fluorescence-activated vesicle sorting (FAVS), an approach developed for 
purifying small (<100 nm) vesicles, we confirmed the presence of HB-EGF, 
TGFα, and AREG in exosomes	   (Cao et al., 2008b; Higginbotham et al., 2011).  
FAVS recognizes the extracellular domains of these EGFR ligands, indicating the 
topology of the ligands was such that the receptor binding domains were present 
on the outside of the exosome. However, the presence of a heparin-binding 
domain in AREG and HB-EGF would allow for cleaved soluble ligand to be 
present on an exosome and detected by FAVs. To determine whether full-length 
AREG is present in exosomes, I performed western blotting analysis on exosome 
preparations. Analysis of the western blots revealed the presence of post-
translational modified forms of AREG not seen in regular whole cell lysate or 
immunoprecipitation (IP) western blots. Suspecting this post-translational 
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modification to be ubiquitin, I demonstrated with HA-tagged ubiquitin that AREG 
could be ubiquitylated. However, I was unable to detect endogenous ubiquitin on 
AREG in lysates or exosomes. To determine if ubiquitylation was necessary for 
delivery of AREG to exosomes, I generated a mutant form of AREG (AREG-K2A) 
that does not contain any lysine residues within the cytoplasmic domain. Western 
blotting analysis of exosomes from MDCK cells expressing wild-type AREG or 
the lysine mutant AREG-K2A showed a reduction of AREG in the AREG-K2A 
mutant compared to wild-type, suggesting a role for ubiquitylation in AREG 
delivery to exosomes.  These data provide a strong foundation for future work to 
determine how AREG is delivered to exosomes.      
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Materials and Methods 
 
Generation of AREG-K2A Mutant 
The following quick change primers were designed to change K239 and K240 to 
alanine residues: 
KK to AA fw QC (oligo# 37516386-010) 
 5’-ggagaagccgaggaacgaGCgGCacttcgacaagagaatgg-3’ 
KK to AA rv QC (oligo# 37516386-020) 
 5’-ccattctcttgtcgaagtGCcGCtcgttcctcggcttctcc-3’ 
QC PCR mixture: AREG-pCB6 template at 15ng/µl = 30ng; 5µl 10x Pfu Turbo 
Buffer; 1µl 10mM DNTPs; 1.25 µl at 100ng/µl (125ng final) KK to AA fw QC 
primer; 1.25 µl at 100ng/µl (125ng final) KK to AA rv QC primer; 38.5 µl H2O; 1µl 
Pfu Turbo enzyme. 
PCR Cycles: 95oC 3 min; 95oC 30 sec; 55oC 1 min; 68oC 7 min 30 sec; 17 
cycles; 68oC 10 min; 4oC Hold. 
1µl of DpnI enzyme was added to the reaction and incubated at 37oC for 45 min. 
5µl was transformed into DH5α cells and plated on ampicillin (amp) plates. Two 
colonies from the transformation were picked and grown in amp medium 
overnight. The minipreps were sequenced and clone #1 was determined to be 
correct. 072407 pCB6 KK2AA ART clone #1 is correct. 
The following quick change primers were used to change K-230 to alanine. 
K230A QC Fw primer: 5’ GACAATACGTCAGGgcATATGAAGGAGAAGC 3’ 
K230A QC Rv primer: 5’ GCTTCTCCTTCATATgcCCTGACGTATTGTC 3’ 
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The template used was the pCB6 KK2AA ART mutant.  This quick change 
removes all lysine residues from the AREG cytoplasmic domain. 
QC PCR reaction mixture: 3.3µl template = 50ng; 5µl 10x Pfu Buffer; 1µl 25mM 
DNTPs; 1.25µl Fw primer at 100ng/µl; 1.25µl Rv primer at 100ng/µl; 37.2µl H2O; 
1µl Pfu turbo 
PCR cycles: 95oC 3min; 95oC 30 sec; 53oC 30 sec; 68oC 8min; 20 cycles; 68oC 
10min; 4oC Hold 
The entire PCR reaction was digested with 1µl Dpn1 at 37oC for 4 hrs. 
Four µl of the digested reaction was transformed into 50µl DH5α competent cells 
and plated on an amp plate. The following day 6 colonies were collected from the 
plate and minipreped. All of the minipreps were sequenced. Miniprep #2 was 
analyzed four ways, pCB6FW, pCB6RV, ARIFW, ARIRV (internal primers for 
AREG), all indicating it is correct. pCB6 K230A mini #2 082309 is correct.  
 
Isolation of Exosomes 
Exosomes were isolated by James Higginbotham (Higginbotham et al., 2011). 
Native and ionomycin elicited exosome pellets were subjected to sucrose 
gradient fractionation as described previously (Sanderson et al., 2008; Thery et 
al., 2006). 
 
Fluorescence-Activated Vesicle Sorting (FAVS)  
All FAVS was performed by James Higginbotham and previously described (Cao 
et al., 2008b). 
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Amphiregulin Western Blot of Cell Lysates and Exosome Preparations.  
Cells were resuspended in 1% NP-40 lysis buffer (50mM Tris-HCl pH 8.0, 
150mM NaCl, 1% NP40, 2mM EDTA, and protease inhibitor cocktail Sigma 
P2714) and incubated for 30 min at room temperature (RT). Lysates were 
centrifuged at 20,000xg for 15 min at 4oC and supernatants were transferred to 
fresh tubes. Prior to use, protein concentrations of each lysate were determined 
with a MicroBCA protein reagent kit (Pierce, Rockford, USA).  A 12.5% SDS 
PAGE gel was used to separate cell lysate or exosomal preparations (10µg total) 
under non-reducing conditions. After separation, samples were transferred at 4oC 
overnight at 50mA to nitrocellulose membranes (0.2 µm, Whatman Optitran BA-S 
83). Membranes were rinsed 3x in PBS-T (1xPBS 0.05% Tween 20) and blocked 
overnight at 4oC in 5% milk PBS-T. Subsequent steps were performed at RT. 
Membranes were probed with the anti-AREG mouse monoclonal antibody 
6R1C2.4 at 2µg/ml in 5% milk PBS-T for 1.5 hrs and then washed 3x in PBS-T. 
Membranes were incubated with secondary donkey anti-mouse IgG-HRP 1:2000, 
in 5% milk PBS-T for 1hr. Membranes were washed 3x in PBS-T. The ECL 
western blotting kit (Western Lighting plus ECL, Perkin Elmer, Waltham, USA) 
was used as per manufacturer’s instructions to visualize AREG protein bands.      
 
HA-Ubiquitin AREG co-Transfection, AREG IP, anti-HA Western Blot 
293T cells were plated at a cell density of 500,000 cells/well in a six well dish and 
transfected the following day with wild-type AREG alone, HA-ubiquitin alone, 
wild-type AREG and HA-ubiquitin together, or AREG K2A and HA-ubiquitin 
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together. Two days following transfection, the cells were washed 3x with cold 
1xPBS. The cells were lysed for 1hr on the 4oC shaker in 500µl 1%NP-40 lysis 
buffer with protease inhibitor (same as above). Lysates were kept cold during the 
entire protocol. The lysates were centrifuged in the tabletop centrifuge at max 
speed at 4oC for 15 min. The supernatants were transferred to fresh tubes 
containing 20µl of a 50% slurry of recombinant protein G agarose beads 
(Invitrogen Catalog no. 15920-010) to pre-clear the lysates. Lysates were cleared 
for 1.5hrs.  The protein concentration of each sample was determined using the 
MicroBCA protein reagent kit and equal amounts of protein were transferred to 
fresh tubes. 20µl of the AREG-K2A + HA-ubiquitin cleared lysate was removed 
and set aside for a western blot positive control. 50µl of 6R1C2.4 (≈2.5µg) was 
added to each lysate and rotated in the cold room overnight. 20µl of a 50% slurry 
of recombinant protein G agarose beads was added and incubated on the cold 
room rocker for 4 hrs to IP AREG. The beads were gently centrifuged and 
washed 5x with 1ml lysis buffer. After the last wash as much lysis buffer as 
possible was removed using a loading tip and 20µl 1x sample buffer without DTT 
was added (2x sample buffer = 125mMTris-HCl pH6.8, 2%Glycerol, 4%SDS 
(w/v), 0.05% bromophenol blue). The positive control sample had equal volume 
2x sample buffer without DTT added. The samples were heated for 5min at 72oC 
then stored at RT until ready to run gel. The proteins were separated by a 7.5% 
SDS PAGE gel at 80v until the dye front reached the bottom of the gel. The 
samples were transferred to a nitrocellulose membrane at 18v overnight in the 
cold room. After removing the membrane from the transfer apparatus, the top 
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was immediately cut off at the 130 kDa mark to remove any antibody at the top of 
the membrane. The membrane was washed with 1xTBS 0.05% Tween then 
blocked with 1xTBS pH8 0.05% Tween 5% milk (TBS blocking buffer) overnight 
in the cold room. The next day, the membrane was blotted with mouse anti-HA 
antibody (Clone HA-7 Sigma H 9658) diluted 1:1000 in TBS blocking buffer for 2 
hrs at RT. The membrane was washed for 1.5 hrs with multiple changes of 
1xTBS 0.05% Tween. The membrane was blotted with Mouse TrueBlot® 
ULTRA: Anti-Mouse Ig HRP (eBiosciences 18-8817) diluted 1:1000 in TBS 
blocking buffer for 1.5 hrs at RT. Subsequently, the membrane was washed for 1 
hr with multiple changes of 1xTBS 0.05% Tween. The ECL chemiluminescent 
reagent was added for 1 min and the blot was exposed to film for 1 min, 3 min 
and overnight (max). 
 
HA Blot of Exosome Preparations 
Exosomes were collected from MDCK cells expressing either HB-EGF or AREG-
HA. 30µg of each exosome preparation was diluted 1:1 with 2x sample buffer, 
without DTT, and heated at 95oC for 5 min. The samples remained at RT for a 
few days before being run. Half of each exosome preparartion (15µg) was run on 
a 4-20% gradient gel until the dye front reached the bottom of the gel. The 
samples were transferred to a nitrocellulose membrane overnight. The PBS used 
in this protocol was a premade bottle purchased from Sigma. The membrane 
was blocked overnight in the cold room with 5% milk in 1xPBS. The remaining 
steps were all performed at RT. The membrane was washed 3x 5 min with 
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1xPBS 0.05% Tween then blocked for 10 min with 1xPBS 1% BSA. The 
membrane was blotted with the primary anti-HA antibody (Clone HA-7 Sigma H 
9658) diluted 1:1000 in 1xPBS 1%BSA 0.05% Tween for 2.5 hrs. Our antibody 
stocks are already diluted 1:10; therefore, I diluted 1:100 to get a final 1:1000 
dilution. The membrane was washed 3x 15 min with 1xPBS 0.05% Tween. The 
membrane was blotted with secondary donkey anti-mouse HRP-conjugated 
antibody diluted 1:2000 in 1xPBS 0.05% Tween for 1 hr. The membrane was 
washed 3x 5 min with 1xPBS 0.05% Tween. ECL chemiluminescent reagent was 
added for 1 min and film was exposed for 1 min, 5 min, and overnight (max). 
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Results 
 
 AREG is present in exosomes with the extracellular domain on the outside 
of the exosome.  
 The observation by Ada Braun that full-length HB-EGF is present in the 
conditioned medium of MDA-MB-231 breast cancer cells raised the possibility 
that EGFR ligands are present in exosomes. To address this possibility, 
exosomes were isolated from the conditioned medium of MDA-MB-231 cells and 
the CRC cell line HCA-7 cells. FAVS revealed the presence of HB-EGF and 
TGFα in MDA-MB-231 and HCA-7 exosomes, while AREG was detected only in 
HCA-7 exosomes (Higginbotham et al., 2011). It should be noted that HCA-7 
cells endogenously express very high amounts of AREG	  (Damstrup et al., 1999). 
Detection of these ligands by FAVS indicates the topology of the ligand displays 
the extracellular domain on the outside of the exosome. To confirm this is the 
only topology of AREG in exosomes we used an MDCK cell line expressing 
AREG fused to a HA-tag on the cytoplasmic domain (AREG-HA) as a negative 
control. Analysis by FAVS revealed the exosomes were positive for the 
extracellular domain of AREG but negative for HA on the cytoplasmic domain. 
Western blot analysis for HA confirmed the HA-tag was present; demonstrating 
the HA-tagged cytoplasmic domain of AREG is inside of the exosome (Figure 
14). These experiments established the presence of AREG in exosomes with a 
topology displaying the receptor-binding domain on the outside of the exosome.  
	   93	  
 
 
 
Figure 14. AREG is present in exosomes with a signaling competent 
topology. 
To confirm the presence of AREG in exosomes we used FAVS to detect and 
quantitate AREG-containing exosomes. Exosomes were isolated from MDCK 
cells expressing AREG-HA. A) Mouse anti-AREG, 6R1C2.4 (AREG N-terminal 
Ab), which recognizes the EGF-like motif in AREG was used to detect the 
extracellular domain on the outside of the exosomes. Mouse anti-HA (AREG C-
terminal Ab) was used to detect the HA-tag on the cytoplasmic domain of AREG. 
The histograms demonstrate the N-terminal extracellular domain is present on 
the outside of the exosome while the C-terminal cytoplasmic domain is inside the 
exosome, inaccessible to the anti-HA antibody. B) Western blot analysis for HA 
confirms the presence of membrane-bound AREG-HA within exosomes. The 
arrow marks full-length AREG-HA while the lower bands are processed forms of 
AREG that are still integrated into the membrane. The smear suggests some 
form of post-translational modification, which is detected with the anti-HA 
antibody and the anti-AREG antibody. HB-EGF exosomes were used as a 
negative control for the anti-HA blot. 
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AREG is enriched in exosomes derived from donor cells containing mutant 
forms of KRAS. 
Having established the presence of signaling competent AREG in 
exosomes we contemplated the clinical relevance of this discovery. If EGFR 
ligands are present in exosomes released from transformed cancer cells, do non-
transformed cells also release exosomes? To address this question, we used 
isogenically matched cell lines, DLD-1, DKO-1, and DKs-8 cells	  (Shirasawa et al., 
1993). These three lines were derived from the transformed CRC line DLD-1, 
which contains one copy of wild-type KRAS and one copy of mutant active 
KRAS. Using homologous recombination, the wild-type copy was removed to 
generate DKO-1 cells or the mutant copy was removed to generate DKs-8 cells. 
The resulting cell lines are isogenic for all other genes except KRAS for which 
DLD-1 cells contain one wild-type copy and one mutant copy, DKO-1 cells only 
contain a mutant copy, and DKs-8 cells only contain a wild-type copy	  (Shirasawa 
et al., 1993). Having lost the mutant copy, DKs-8 cells are no longer transformed 
and do not grow in soft agar or nude mice. DLD-1 and DKO-1 cells are 
transformed and grow in both soft agar and nude mice	  (Shirasawa et al., 1993).  
Exosomes were isolated from the conditioned medium of the isogenic cell 
lines and compared with lysates of each line by ELISA and western blot. ELISA 
was used to quantitate the amount of AREG present in the lysates and 
exosomes. The results revealed AREG was enriched in the exosomes of all three 
lines compared to the matched lysates. AREG was enriched in DKO-1 exosomes 
4-fold compared to lysate, while DLD-1 and DKs-8 cells had 3-fold more AREG in 
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exosomes compared to lysates (Figure 15C). The cells with mutant KRAS had 
considerably more AREG present than DKs-8 cells that only express wild-type 
KRAS. These results suggests mutant KRAS not only increases the overall 
expression of AREG, but also increases the amount of AREG loaded into 
exosomes to be released into the surrounding extracellular space. 
ELISA is an excellent quantitative technique that uses the anti-AREG 
antibody 6R1C2.4, which recognizes an epitope in the EGF-like domain within 
the mature ligand. This is why the antibody does not recognize the reduced 
forms of AREG; the di-cysteine bonds that make up the EGF-like motif are 
necessary for the structure of the epitope. This also allows the antibody to 
recognize all the membrane and soluble forms of AREG. Because the antibody 
recognizes all forms of AREG that contain the EGF-like motif, quantitative 
techniques like FAVS and ELISA that use this antibody provide solid data for 
quantification of total AREG, but not valuable information on which forms of 
AREG are present. Only western blotting analysis provides data on the relative 
abundance of different soluble or membrane forms of AREG.  
In order to confirm the presence of membrane AREG and not soluble 
AREG in exosomes a western blotting analysis was performed on exosomes 
isolated from the conditioned medium of DLD-1, DKO-1, and DKs-8 cells (Figure 
15B). Western blotting analysis confirmed the presence of membrane-bound 
forms of AREG, and not soluble AREG in the exosomes. The western blots also 
supported the ELISA data demonstrating increasing amounts of AREG in 
exosomes derived from cells with mutant KRAS. Interestingly, the most 
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prominent forms of AREG in the exosomes are the 26 kDa and 28 kDa 
processed forms. While the lysates appear to have similar levels of the full-length 
50 kDa and 26-28 kDa forms (Figure 15A), exosomes have considerably more 
26-28 kDa AREG (Figure 15B). (Forms referred to as 26 kDa and 28 kDa were 
initially described by Brown et al. as 26 kDa and 28 kDa, but run as a doublet 
below 25 kDa in my blots. This may be the result of running the samples under 
non-reduced conditions compared to reduced as done by Brown (Brown et al., 
1998). These forms run below 25 kDa in lysates as well and I have confirmed 
them to be membrane forms. See Appendix B for a detailed explaination).	  	  
Even more interesting is the presence of the smear detected in exosomes 
and not in lysates. A smear pattern in western blots results from various sizes of 
the protein being created by some sort of post-translational modification and 
detected by the antibody. This smear increases in size, indicating it is not a result 
of degradation but from the addition of something to the AREG. The same smear 
was also detected in the HA blot in Figure 14, suggesting it is not an artifact of 
the AREG antibody. Since the smear is not present in lysates, it may result from 
the modification responsible for delivery of AREG to exosomes, possibly 
ubiquitin.   
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Figure 15. AREG is enriched in exosomes compared to lysates, with the 26 
kDa and 28 kDa processed forms being most prominent in exosomes.  
A) AREG western blot of the indicated cell lysates. 10µg of each lysate was run 
on a 12.5% SDS-PAGE gel, transferred to nitrocellulose and blotted for AREG 
using the mouse anti-AREG antibody 6R1C2.4. MDCK II cells were used as a 
negative control because 6R1C2.4 cannot detect canine AREG. The positive 
control is HCA-7 cells, a human CRC cell line that expresses high levels of 
endogenous AREG. DKs-8, DLD-1, and DKO-1 cells are isogenic, with the 
exception of their KRAS gene. B) AREG western blot of exosomes isolated from 
the isogenic cell lines DKs-8, DLD-1, and DKO-1. 10µg of exosomes were run on 
a 12.5% SDS-PAGE gel, transferred to nitrocellulose, and blotted for AREG with 
6R1C2.4. These exosome preparations were collected from cells treated with or 
without ionomycin, which does not appear to affect the amount of AREG or the 
forms of AREG loaded into exosomes. C) Results from an ELISA assay 
quantitating the amount of AREG in cell lysates or exosomes collected from the 
isogenic cell lines DKs-8, DLD-1, and DKO-1 (n=3).  
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AREG can be ubiquitylated in vitro.  
 Analysis of the exosome AREG western blots revealed a smearing pattern 
not seen in previous AREG blots of total cell lysates or AREG IP samples (Figure 
15B). Since the smear pattern increases in size compared to the defined sizes of 
AREG, I speculated that the AREG in exosomes contains a post-translational 
modification. Others have already demonstrated monoubiquitylation and K63 
multi-ubiquitylation can target a membrane protein to the MVB (Lauwers et al., 
2009; Urbanowski and Piper, 2001). It has also been shown that ubiquitylated 
proteins are present in exosomes	   (Buschow et al., 2005). This led me to 
investigate if the AREG contained within exosomes is ubiquitylated.  
Since the smear pattern suggesting ubiquitylation is only seen in 
exosomes and not in cell lysates, the modified AREG appears to be enriched in 
exosomes. This would make exosomes a good source of material to isolate and 
characterize this post-translational modification. However, I was unable to IP 
AREG from the exosomes due to technical difficulties. I suspect due to the small 
size of the exosomes the detergent in my lysis buffer (1% NP-40) was unable to 
integrate into the exosomal lipid membrane and dissociate the proteins from the 
exosomes. Another possibility is that the lipid composition of the exosome may 
make the exosomes insoluble in 1% NP-40 lysis buffer; similar to the way 
different membrane lipid domains are Triton-soluble or Triton-insoluble. While I 
could effectively detect AREG in a total exosome preparation, I could not isolate 
AREG from the exosomes in order to determine if it is ubiquitylated.  
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I can IP AREG from cell lysates, so as an alternative approach to detect 
ubiquitylated AREG I attempted to detect endogenous ubiquitin on AREG 
isolated from cell lysates. However, detection of ubiquitin on a protein is 
technically challenging because ubiquitylation is such a dynamic process. Once a 
protein is ubiquitylated by an ubiquitin ligase, the ubiquitin can be immediately 
removed by a de-ubiquitylating enzyme (DUB). This requires the use of DUB 
inhibitors to allow for the ubiquitylated protein to be modified long enough for 
isolation and detection. However, inhibition of DUBs will cause the protein to be 
degraded more quickly, so protease inhibitors must be used as well. The 
protease inhibitor pepstatin A can inhibit the cathepsin proteases in the 
lysosome, however the protease inhibitor cocktail used in my experiments did not 
contain pepstatin A and may not have effectively inhibited protein degradation by 
the lysosome. The ubiquitin antibody is another technical challenge because it is 
not very robust and provides considerable background. In addition to the 
challenges of detecting ubiquitin, because the vast majority of AREG in the lysate 
is not ubiquitylated, the AREG IP protocol would need to be close to 100% 
efficient to isolate enough of the ubiquitylated AREG to be detected by the anti-
ubiquitin antibody. Due to time constraints and all the technical difficulties needed 
to be overcome I was not able to detect endogenous ubiquitin on AREG. 
An alternative approach to detecting endogenous ubiquitin is to use a HA-
tagged form of ubiquitin. HA-tagged ubiquitin has a couple of advantages: it is 
not as easily removed by DUBs, and it can be detected by a robust anti-HA 
antibody with less background. The disadvantage of using the HA-tagged 
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ubiquitin is that it is an artificial system. However, HA-tagged ubiquitin is an 
accepted tool to demonstrate a protein can be ubiquitylated.  
I used HA-tagged ubiquitin to demonstrate AREG can be ubiquitylated. 
Wild-type AREG contains three lysine residues within the cytoplasmic domain 
that can be ubiquitylated (Figure 16A). I generated a lysine-free AREG mutant 
(AREG-K2A) by changing all three lysine residues to alanine (Figure 16A). 293-T 
cells were transiently co-transfected with HA-ubiquitin and either wild-type AREG 
or AREG-K2A. Two days after transfection the cells were lysed, AREG was 
isolated by IP, run on a 7.5% SDS-PAGE gel, and transferred to nitrocellulose. 
The nitrocellulose membrane was blotted for HA. The anti-HA antibody did not 
detect the AREG-K2A mutant but did detect the wild-type AREG in a smearing 
pattern similar to the exosomes (Figure 16B). However, the wild-type AREG 
sizes were larger. The prominent bands detected below 25 kDa in exosomes 
were above the 25 kDa marker in the anti-HA blot. Full-length AREG runs around 
50 kDa but a prominent band around 68 kDa was present in the anti-HA blot. 
Addition of a mono-ubiquitin to a protein results in a 9 kDa increase in size on a 
gel. Detection of these larger bands by the anti-HA antibody could represent the 
ubiquitylated AREG. These results clearly demonstrate AREG can be 
ubiquitylated.  
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Figure 16. AREG can be ubiquitylated by HA-tagged ubiquitin. 
A) Amino acid composition of wild-type AREG (WT) and the lysine-free AREG 
mutant (K2A). The alanine residues highlighted in red represent the lysine 
residues changed to alanine to generate the mutant. B) Western blotting analysis 
of 293-T cells co-transfected with HA-ubiquitin and either WT or K2A AREG. 
AREG was isolated by IP, run on a 7.5% SDS-PAGE gel, transferred to 
nitrocellulose, and blotted for HA. The Ub-HA lane represents cells transfected 
only with HA-ubiquitin. The AREG lane represents cells transfected only with 
AREG. These two controls demonstrate the anti-HA antibody is not detecting 
significant background. There is one 36 kDa background band present in all 
lanes. 
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Ubiquitylation is necessary for efficient delivery of AREG to exosomes. 
 Having established that AREG can be ubiquitylated, I next wanted to 
determine the role ubiquitylation plays in delivery of AREG to exosomes. 
Exosomes were isolated from MDCK cells expressing either wild-type AREG or 
the AREG-K2A mutant. An equal amount of exosomes, as determined by BCA 
protein concentration, was run on a 12.5% SDS-PAGE gel and transferred to 
nitrocellulose. The membrane was blotted for AREG to determine any differences 
between wild-type and K2A in the amount and forms of AREG present in 
exosomes. The results clearly demonstrate there is much less of the AREG-K2A 
present in the exosomes (Figure 17). There is a small amount of the 26-28 kDa 
doublet detected in the AREG-K2A sample, but not nearly as much as in the 
wild-type AREG exosomes. This experiment was conducted only one time but 
was later confirmed by Michelle Demory Beckler. Future studies will determine 
the overall AREG levels between the two lines to demonstrate the difference in 
exosomal AREG is really due to the lack of lysine residues and not because the 
AREG-K2A line expresses less AREG. While these results should be regarded 
as preliminary, they provide some foundation to the hypothesis that AREG 
ubiquitylation may be involved in delivery of AREG to exosomes. 
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Figure 17. AREG must be ubiquitylated to be efficiently loaded into 
exosomes. 
Western blotting analysis of exosomes isolated from MDCK cells expressing 
wild-type AREG (WT) or mutant AREG-K2A (K2A). 10µg of exosomes, as 
determined by BCA assay, were run on a 12.5% SDS-PAGE gel, transferred to 
nitrocellulose, and blotted for AREG. The AREG-K2A mutant does not contain 
any lysine residues within the cytoplasmic domain and cannot be ubiquitylated, 
possibly inhibiting its loading into exosomes.   
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Discussion 
 The data I have produced provide a solid foundation on which to build our 
understanding of AREG in exosomes. It is clear that full-length AREG is present 
in a signaling competent topology within exosomes. The most prominent forms of 
AREG present in exosomes are the 26-28 kDa forms. Exosomal AREG appears 
to contain a post-translational modification not detected on AREG isolated from 
total cell lysate. AREG containing this modification is enriched in exosomes 
indicating a role for this modification in delivery of AREG to exosomes. While I 
was unable to identify the modification, AREG can be ubiquitylated and lysine-
free AREG is not efficiently loaded into exosomes. These data provide clues on 
how AREG delivery to exosomes might be regulated.  
 One of the questions still remaining is the route taken to the exosome by 
AREG. One clue to the answer of this question is the forms of AREG most 
prominent in exosomes. Our current understanding of AREG is that full-length 
glycosylated AREG runs around 50 kDa on a SDS-PAGE gel. Proper secretion of 
AREG from the cell requires the N-terminal pro-protein domain to shield the 
heparin-binding domain of AREG during exocytosis	   (Thorne and Plowman, 
1994). Once at the cell surface, there are multiple forms of AREG present, 
including the full-length 50 kDa form as well as 28 kDa and 26 kDa processed 
forms	  (Brown et al., 1998). The 28 kDa and 26 kDa forms do not contain the N-
terminal pro-protein domain, which if required for secretion must be removed 
post arrival at the cell surface. The 26 kDa and 28 kDa AREG forms are the most 
prominent exosomal forms of AREG. If removal of the pro-protein domain takes 
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place at the cell surface, then the majority of exosomal AREG must have been at 
the cell surface prior to arrival in the exosome. These data suggest the route to 
the exosome is via the cell surface. 
 Assuming AREG transits the cell surface prior to delivery to exosomes, 
what distinguishes an AREG molecule for delivery to the exosome verses 
cleavage or recycling back to the cell surface? Western blot analysis indicates 
AREG has some form of post-translational modification that could mark AREG 
for delivery to the exosomes. Using HA-tagged ubiquitin, I have demonstrated 
AREG can be ubiquitylated. However, the size of the HA-ubiquitylated AREG 
was larger then exosomal AREG. The size difference may result from removal of 
the ubiquitin prior to invagination of the ILV, while the remaining smear pattern in 
exosomal AREG western blots that indicates a post-translational modification 
may simply result from inefficient removal of the modification. Identification of the 
actual modification causing the smear would provide clarity on how AREG 
delivery to exosomes is regulated.  
An alternative explanation to ubiquitin modification of AREG is 
sumoylation. Sumo (small ubiquitin-related modifier) proteins are added to 
proteins in a similar fashion as ubiquitin and can form multi-sumo chains	  (Geiss-
Friedlander and Melchior, 2007).  The smear pattern in the exosomal AREG 
western blots indicates addition of a protein chain and the function of multi-
sumoylation chains is unknown.  AREG does not contain a classical consensus 
sumoylation acceptor site, but does contain a similar sequence. The consensus 
sumoylation site is ΨKxE, where Ψ is an aliphatic branched amino acid and x is 
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any amino acid	   (Geiss-Friedlander and Melchior, 2007). The site in AREG that 
closely matches the consensus sumoylation site is RKYE, where the aliphatic 
amino acid is replaced with the basic arginine residue.  If the amino acid 
sequence of AREG were extended it would include an acidic patch C-terminal to 
the possible sumoylation site (RKYEGEAEE). In addition to the classical 
consensus sumoylation site, acidic clusters C-terminal to the accepting lysine 
residue have been shown to enhance sumoylation	   (Yang et al., 2006). The 
presence of a tyrosine residue in this site is interesting because it adds an 
additional level of possible regulation.  Analysis of this region of the AREG 
cytoplasmic domain may reveal critical residues in the regulation of AREG in 
exosomes and beyond.    
The observation that mutant active KRAS increases the amount of AREG 
expressed in cell lysate and loaded into exosomes has clinical relevance. KRAS 
is downstream of EGFR activation in the EGFR signaling cascade, so cancer 
treatment directed against the EGFR is only effective in patients with wild-type 
KRAS	   (Peeters et al., 2009). If KRAS is active regardless of EGFR activation, 
blocking EGFR activation is ineffective. However, the results of mutant KRAS on 
increasing exosomal AREG composition may increase EGFR signaling in 
surrounding cells, which could affect the tumor microenvironment. The increase 
in exosomal AREG within the tumor microenvironment could increase 
inflammation and disrupt tissue homeostasis (Nishimura et al., 2008). It is 
possible that EGFR targeted treatment early in cancer progression could block 
the effect of AREG exosomes on the tumor microenvironment, possibly 
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preventing metastasis and increasing a patients overall survival. Unfortunately, 
since clinical trials are only conducted on patients who have failed to respond to 
standard care and have progressed disease, the effects of EGFR targeted 
treatment in early cancer progression cannot be observed under the current 
clinical trial methodology.  
The role of exosomes in cancer is still to be determined. The potency of 
exosomal AREG on cancer cell invasion in vitro provides us with clues to the 
importance of this signaling vehicle in disease (Higginbothem J, et. al. 2011). 
Understanding the regulation of AREG delivery to exosomes could provide a 
point of attack from which to prevent aberrant EGFR signaling via exosomes. 
Future work on how exosomes and their cargo are regulated is critical to 
understanding this important cell signaling process. 
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CHAPTER IV 
 
IDENTIFICATION OF AREG INTERACTING PROTEINS 
 
Introduction 
 Prior to my joining the Coffey laboratory, studies were already underway 
to identify interacting proteins for the EGFR ligands TGFα and AREG. The goal 
of these studies was to identify proteins involved in the delivery of these ligands 
to the basolateral (BL) cell surface. Two proteins were identified to interact with 
TGFα: Naked2 (NKD2) and membrane associated guanylate kinase inverted-3 
(MAGI-3) (Franklin et al., 2005; Li et al., 2004a). Similar studies did not elucidate 
AREG interacting proteins. As a consequence, a major aspect of my dissertation 
proposal was to identify interacting proteins for AREG.  
 TGFα is delivered to the BL surface of polarized epithelial cells where it is 
rapidly cleaved by the metalloprotease TACE and avidly bound by the EGFR 
(Dempsey and Coffey, 1994; Peschon et al., 1998). The cleavage of TGFα at the 
cell surface is so rapid that expression of a membrane-fixed form is necessary to 
detect the ligand on the lateral membrane by indirect immunofluorescence 
(Dempsey and Coffey, 1994). The released ligand is efficiently consumed by the 
EGFR such that soluble TGFα cannot be detected in the conditioned media 
without using an EGFR blocking antibody (Dempsey and Coffey, 1994). 
Combined, these results strongly suggest the rate-limiting step in TGFα 
activation of the EGFR is the delivery to the cell surface.  
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 A yeast two-hybrid screen was performed to identify proteins that regulate 
the rate-limiting cell surface delivery of TGFα through interaction with the 
cytoplasmic domain of TGFα. The 39-amino acid TGFα cytoplasmic domain was 
screened against a cDNA library generated from polarized HCA-7 cells, a 
polarizing human CRC cell line. This screen identified the myristoylated protein 
NKD2, a mammalian homolog of Drosophila Naked Cuticle (Li et al., 2004a). In 
Drosophila, others have shown Naked Cuticle to antagonize the Wnt pathway via 
interaction with Dishevelled (Rousset et al., 2001). Our laboratory demonstrated 
in zebra fish and mammalian HEK293 cells that NKD2 can also antagonize Wnt 
signaling, in a myristoylation-dependent manner, through mutual ubiquitin-
mediated proteasomal degradation	  of Dishevelled at the cell surface (Hu et al., 
2010). TGFα plays an important role in NKD2 antagonism of Wnt signaling by 
stabilizing NKD2 and ensuring its delivery to the cell surface where it can interact 
with Dishevelled	   (Ding et al., 2008). In turn, NKD2 coats TGFα containing 
vesicles and escorts them to the BL surface of polarized epithelial cells	   as 
previously described in Chapter 1 (Li et al., 2004a)	   (Li et al., 2007). Increased 
expression of NKD2 in MDCK cells accelerates the cell surface delivery of TGFα, 
revealing NKD2 as an important regulator of TGFα activation of the EGFR	  (Li et 
al., 2004a).  
 The identification of NKD2 and its role in TGFα cell surface delivery 
provided the foundation for the idea that AREG must also interact with a protein 
during delivery to the cell surface. Just as the cytoplasmic domain of TGFα was 
used as bait to identify NKD2, the 31-amino acid cytoplasmic domain of AREG 
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was used to screen the same HCA-7 library. However, no proteins were 
identified to interact with the AREG cytoplasmic domain.  
 I hypothesized that the traditional yeast two-hybrid screen was 
inappropriate to identify interacting proteins for AREG because the screen did not 
express the cytoplasmic domain in its native location within the cell. The 
traditional yeast two-hybrid screen utilizes the GAL4 transcriptional activator that 
consists of two essential domains for proper function, a DNA binding domain and 
activating domain (Fields and Song, 1989). In a yeast two-hybrid screen the bait 
protein is tagged with one of these domains while the prey protein is tagged with 
the other. When the two proteins interact they bring the two GAL4 domains 
together to form a functional transcriptional activator that activates transcription 
of a reporter gene (Fields and Song, 1989). However, the two interacting proteins 
are tethered to the transcriptional activator and must be able to translocate to the 
nucleus in order to activate transcription. In the case of transmembrane proteins 
such as AREG and TGFα this allows for only the expression of the cytoplasmic 
domain and does not allow for the full-length protein to be integrated into the 
membrane where it would normally be expressed. This was not a problem for 
identifying TGFα interacting proteins, but may have inhibited identification of 
AREG interacting proteins.  
 An alternative to the traditional yeast two-hybrid screen that allows for full-
length proteins to be expressed in their native location is the split ubiquitin yeast 
two-hybrid screen. This screen utilizes the protein ubiquitin, which is 
endogenously expressed as a single domain protein. Ubiquitin can form fusions 
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with itself on the last glycine residue (Gly-76), which are rapidly cleaved by 
ubiquitin specific proteases (UBP) (Baker et al., 1992). While ubiquitin is a 
monomer protein, it can be divided into N-terminal (NUB) and C-terminal (CUB) 
portions that will fuse to reconstitute a complete ubiquitin protein (Johnsson and 
Varshavsky, 1994). NUB and CUB fused to interacting proteins will reconstitute 
during protein interactions to form a complete ubiquitin protein that will be 
recognized by UBPs. If a reporter protein is fused to the CUB at Gly-76, 
reconstitution of a complete ubiquitin will result in cleavage of the reporter 
protein, which can then be detected on a SDS-PAGE gel by radiolabeling or 
western blotting (Johnsson and Varshavsky, 1994). This split ubiquitin 
phenomenon can be used to detect protein interactions between integral 
membrane proteins expressed in their native localizations in the cell.  
 A split ubiquitin membrane yeast two-hybrid screen uses the reconstitution 
of ubiquitin to indentify interacting proteins for transmembrane proteins (Figure 
18)	   (Iyer et al., 2005). Instead of using a reporter protein separated on a SDS-
PAGE gel, this screen works by fusing a transcription factor for a reporter gene to 
Gly-76 of CUB. The CUB is fused to the bait protein and the NUB is fused to the 
prey protein. When the bait and prey proteins interact the NUB and CUB 
reconstitute a complete ubiquitin that is then recognized by a UBP. The UBP will 
cleave the transcription factor from the CUB allowing it to translocate to the 
nucleus and activate the reporter gene. The bait and prey proteins stay 
integrated into the membrane and do not need to translocate to the nucleus to  
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Iyer et al Sci STKE. 2005 Mar 15;2005(275):pl3 
 
Figure 18. Illustration of a split ubiquitin membrane yeast two-hybrid 
screen.  Illustration of how the split ubiquitin yeast two-hybrid screen used to 
identify AREG interacting proteins works. A) AREG would be tagged with the 
CUB-LexA-VP16 transcription factor and the prey library would be tagged with 
the NUB. B) Upon interaction of AREG with a tagged prey protein the ubiquitin 
would reconstitute and be recognized by the UBP, releasing the LexA-VP16 
transcription factor from AREG. The transcription factor can then translocate to 
the nucleus and activate the HIS3, ADE2, and LacZ reporter genes	   (Iyer et al., 
2005).  
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activate transcription. Removing the requirement for interacting proteins to 
translocate to the nucleus to activate the reporter gene allows for the proteins to 
be expressed in their proper location and increases the chances of identifying 
interacting proteins.  
 Yeast two-hybrid screens are good tools for identifying interacting 
proteins, but these screens do not always produce results. A yeast two-hybrid 
screen relies on expression of the interacting proteins in the prey library. If the 
library does not express an interacting protein then it cannot be identified in a 
yeast two-hybrid screen. During construction of the prey library a protein may not 
be included or the cDNA may not translate a full-length protein. Many things may 
go wrong that cause an important protein to be absent from a prey library.  
One approach to the problems caused by use of a prey library is to look 
for interactions with endogenously expressed proteins. This can be accomplished 
through immunoprecipitation (IP) of the protein of interest followed by mass 
spectral analysis. If two proteins have a strong interaction that is stable over time 
then the interaction could be maintained during an IP at 4oC. However, most 
protein interactions are transient and do not fall under this criteria, particularly 
interactions involved in protein trafficking. To maintain the interaction through the 
IP process crosslinking reagents can be used. These reagents will covalently link 
the interacting proteins and prevent them from separating during the IP 
procedure. The resulting pellet from a crosslinked IP can then be digested into 
small peptides with trypsin and analyzed by mass spectrometry.  
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 Just as a yeast two-hybrid screen is not perfect, neither is a crosslinked 
IP. The main problem resulting from crosslinking is background. The crosslinking 
reagent has a 12-angstrom spacer arm and will crosslink proteins that come 
within that distance of each other. While this is a very small distance, in a 
densely packed cytoplasm non-interacting proteins may come this close to each 
other, leading to a false-positive result. The large amount of background noise 
created by crosslinking may drown out genuine signals from interacting proteins 
during the mass spectral analysis. The problem of background is amplified by the 
lack of sensitivity of mass spectrometry. While mass spectrometry is generally 
accepted to be extremely sensitive, my own experience with the procedure has 
revealed it to be rather insensitive. For example, detection of AREG in exosomes 
by mass spectrometry has been elusive, even though AREG has been confirmed 
in exosomes by three other methods: western blotting, ELISA, and FAVs. The 
inability to detect an abundant protein in exosomes by mass spectrometry raises 
questions about the number of other proteins not detected in a mass 
spectrometry analysis.  
 To identify interacting proteins for AREG, I employed both the split 
ubiquitin yeast two-hybrid screen and a crosslinked AREG IP. The split-ubiquitin 
yeast two-hybrid screen was more successful then the traditional yeast two-
hybrid screen in identifying a number of possible interacting proteins. However, 
none of the identified proteins are reported to be involved in protein trafficking. 
Efforts to verify these interacting proteins outside of the yeast two-hybrid system 
also proved difficult, leading me to attempt the crosslinked AREG IP. The 
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crosslinked AREG IP was successful in identifying one interesting protein 
possibly involved in protein trafficking, but was not pursued due to the time frame 
of my graduate studies and the lack a publishable story. While the proteins 
identified by these two screens did not advance my graduate work, they may 
shed light on future studies of AREG.   
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Material and Methods 
 
Isolation of the RNA Used to Generate the Split Ubiquitin Prey cDNA 
Library.  
Total RNA was isolated from polarized HCA-7 cells. The cells were plated 
in 24mm Transwell filters at a cell density of 500,000 cells per Transwell. The 
cells were determined to be polarized on day six after plating with a TEER 
between 350-420 Ω/cm2. The RNA was isolated using the Qiagen RNA easy kit. 
The protocol in the manual was followed, using 350µl of collection buffer for each 
Transwell. Each Transwell (total of 3) was treated as a separate sample. Two 
30µl elution steps were performed and all samples were combined at the end. 
The final concentration was determined to be 500 ng/µl in a total volume of 
180µl.  This RNA was sent to Dualsystems Biotech for generation of the prey 
library. The generated prey library was an N-terminally tagged library, meaning 
the NUB is on the N-terminus. It was suggested by the company to use an N-
terminally tagged library to ensure the NUB was present on each protein. If the 
NUB is placed on the C-terminus, there is a chance it would not be included due 
to incomplete translation of the cDNA during library expression. If the NUB is 
absent, there is no chance of detecting an interaction, however, if the NUB is 
present but the protein is truncated, there is still a chance the portion of the 
protein fused to the NUB can mediate an interaction.  
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Split Ubiquitin Yeast Two-Hybrid Screen. 
 The split ubiquitin yeast two-hybrid screen was performed following the 
Dualsystems DUALmembrane kit 2 protocols. In order to obtain a high 
transformation efficiency of the library, high quality bottled water was used.  
To create the signal sequence minus AREG for the screen, AREG was 
cloned into the pCCW-SUC vector using the following primers: 
Forward Primer 2: 5’ aaaaaaatggccattacggcctcaggccattatgctgctg 3’ 
Reverse Primer 2: 3’ cctttacatgtacgatatcgtttccggcggagccggaaaaaaaaa 5’ 
The following PCR reaction was used to generate the signal sequence minus 
AREG PCR fragment: 
1µl diluted hAREG = 25ng, 5µl 10x buffer w/ MgCl, 1µl Forward primer 2 at 
100ng/µl, 1µl Reverse primer 2 at 100ng/µl, 2.5µl 10mM DNTPs = 500uM final, 
38.5µl H2O, 1µl Pfu turbo enzyme 
PCR Program used: 
940C for 2 min, 940C for 1 min, 580C for 1 min, 720C for 1.5 min, cycle 20 times, 
720C for 10 min, 40C hold. 
The PCR product was digested with SfiI then ligated into pCCW-SUC also 
digested with SfiI. The pCCW-SUC-AREG Clone#3 was determined to be correct 
and was transformed into the yeast strain NMY32 for screening of the prey 
library. Following protocol 4 in the DUALmembrane kit 2 user manual, the 
expression of the AREG-CUB-LexA-VP16 construct was confirmed in the AREG-
SUC yeast clone#4 by western blotting for LexA (Figure 19F). The positive 
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control in this blot was yeast transformed with pCCW-Alg5 and the negative 
control was non-transformed NYM32 yeast. 
After concluding that AREG was being expressed in the AREG-SUC yeast 
clone 4, I went forward with clone 4 because it had the highest protein 
concentration in the lysate. The next step was to determine the correct topology 
of the protein in the membrane by co-transforming clone 4 with a positive and 
negative control. The positive control is pAI-Alg5 which is Alg5 fused to the wild-
type NUB protein. This wild-type NUB should spontaneously reconstitute with the 
CUB on AREG. The negative control is pDL2-Alg5 which is Alg5 fused to the 
NUBG which will not reconstitute with CUB unless a protein-protein interaction 
brings them together. The results of the co-transformations were growth with pAI-
Alg5 and no growth with pDL2-Alg5 (Figure 19A-E). The growth with pAI-Alg5 
demonstrates the CUB is correctly oriented in the cytoplasm. The lack of growth 
with pDL2-Alg5 demonstrates the AREG-CUB-LexA-VP16 protein is integrated 
into the membrane and is not self-activating. There was very little growth on the 
SD-LWHA plates indicating the level of stringency with the SD-LWH is enough. 
The total lack of growth on SD-LWH plates with pDL2-Alg5 indicates no 
background and no need for 3-AT. 
 
 
 
	   120	  
 
 
Figure 19. Split ubiquitin yeast two-hybrid screen controls for expression, 
topology and self-activation of AREG-CUB-LexA-VP16 clone 4.  
Positive controls for the correct topology of the AREG-CUB-LexA-VP16 clone 4 
(A-C). A) Growth on the SD-LW plate shows the transformation of Clone 4 with 
pAI-Alg5 was successful. B) Growth on the SD-LWH plate shows the CUB-LexA-
VP16 is in the cytoplasm and available to interact with the NUB. This 
demonstrates AREG is in the proper topology. C) The reduced growth seen on 
the SD-LWHA plate shows the stringency of the SD-LWH plate is best for 
screening the library. Negative controls for self-activation of CUB-LexA-VP16 (D-
E). D) Growth on the SD-LW plate shows the transformation of Clone 4 with 
pDL2-Alg5 was successful. E) Lack of growth on the SD-LWH plate 
demonstrates the AREG-CUB-LexA-VP16 is not self-activating and is properly 
integrated into the membrane and unable to translocate to the nucleus. F) 
Western blot for LexA to demonstrate the expression of the AREG-CUB-LexA-
VP16 protein in the AREG-SUC yeast clone 4. This clone was used for 
transformation and screening of the prey library. The positive control in this blot 
was yeast transformed with pCCW-Alg5 and the negative control was non-
transformed NYM32 yeast. 
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Crosslinked AREG Immunoprecipitation and Mass Spectrometry Analysis. 
Bead Preparation 
The beads used for the IP were protein G Dynal beads (Invitrogen) prepared as 
follows: 
1350µl of beads were removed from the stock solution (6x108 beads/ml) and 
washed 3x with 1xPBS 0.1%BSA. These beads have a binding capacity of 1µg 
IgG/107 beads (1350µl beads = 8.1x108 beads which can bind 81µg IgG). The 
mouse anti-AREG 6R1C2.4 stock is at 40ng/µl (2025µl x 40ng/µl = 81µg IgG). 
2025µl of 6R1C2.4 stock was added to the 1350µl of beads. The beads were 
incubated with IgG antibody overnight in the cold room rotator. The IgG bound 
beads were washed 3x with 1xPBS 0.1% BSA followed by two washes with 1ml 
0.2M triethanolamine pH 8.2. To crosslink the antibody to the beads, 1ml 20mM 
DMP (0.0054g/ml) in 0.2M triethanolamine pH 8.2 was used. The beads were 
incubated with this crosslinking reagent for 40min at RT in the rotator. The 
crosslinking reaction was quenched with 1ml 50mM Tris pH 7.5 for 15min in the 
rotator at RT then washed 3x with 1xPBS 0.1% BSA. In order to elude any un-
crosslinked antibody, the beads were washed 2x 2min with 1ml 0.1M Citrate pH 
3.1 in the rotator at RT, then washed 3x with 1xPBS 0.1% BSA. The final product 
was resuspended in 1350µl 1xPBS 0.1% BSA plus 13µl 2% Sodium Azide and 
stored at 4oC.	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Crosslinking of Cells and Preparation of Cell Lysates for IP 
Fresh DSP was prepared immediately prior to use. The protocol is as follows: 
Stock solution of 10mM: 0.0142g DSP + 3.5ml DMSO = 10mM stock 
1.0mM working solution: 1.0mM -> 3ml 10mM stock + 27ml 1xPBS 
The cells used in this experiment were CC3 cells (a derivative of HCA-7 cells) 
grown in seven 150x25mm dishes. Four of these dishes were treated with DSP, 
while three were not treated. The cells were washed 3x with ice cold 1x PBS.  
The PBS was removed and 7ml 1.0mM DSP was added to each of the four 
treated dishes.  The cells were incubated with the crosslinking reagent for 30min 
at RT. The crosslinking reaction was quenched with 7ml 20mM Tris pH7.5 for 
15min at RT then washed 3x with 1xTBS. At this point the three dishes that were 
not treated were washed with cold 1xTBS. From this point on the crosslinked and 
non-crosslinked cells were treated equally.  The cells were scraped from the dish 
using a cell lifter in 1xTBS. Cells were then transferred to a 50ml conical and 
centrifuged at 1000 rpm for 5min. Cells were lysed with 4ml 1%NP-40 (50mM 
Tris-HCl pH 8.0, 150mM NaCl, 1% NP40, 2mM EDTA) plus protease inhibitor 
cocktail (Sigma) for 20min on the RT rocker. The lysates was divided evenly 
between eppendorf tubes and centrifuged at 16000g for 15min at 4oC. Pellets 
were saved and 25µl 1x sample buffer (2x sample buffer = 125mM Tris-HCl 
pH6.8, 2% Glycerol, 4% SDS (w/v), 0.05% bromophenol blue) added to each. 
The supernatant was transferred to fresh tubes and a BCA assay was used to 
determine protein concentration. 12.5µl of each sample was reserved as a Total 
Lysate (TL) sample. The protein concentration for each sample was determined: 
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The DSP	   treated lysate had a protein concentration of 2µg/µl. The untreated 
lysate had a protein concentration of 3µg/µl. I transferred 2ml of each sample to 
fresh tubes for the IP.   	  
Immunoprecipitation 
For the untreated lysate: 3µg/µl x 2000µl = 6000µg so added 600µl anti-AREG 
conjugated dynabeads. 
For the DSP treated lysate: 2µg/µl x 2000µl = 4000µg so added 400µl anti-AREG 
conjugated dynabeads. 
The lysates were incubated with the dynabeads for 1hr 25min in the coldroom. 
The tubes were put on the magnet and 12.5µl from each sample was removed 
for a cleared lysate (CL) sample. 
The samples were transferred to eppendorf tubes to make working with the 
magnet easier. Each sample was consolidated in one eppendorf tube and 
washed 6x with 1000µl lysis buffer. The antigens were eluted off the beads with 
25µl 1x sample buffer without DTT and heated at 95oC for 5min.  5µl from each 
elution (E) was removed for analysis.  All samples were stored at –80oC until 
delivered to mass spectrometry core for analysis. 
Eluted proteins were briefly run by SDS-PAGE (~ 1cm) using a 10% 
NuPAGE gel.  After staining with colloidal coomassie blue, the area 
corresponding to the proteins was excised and subjected to in-gel trypsin 
digestion.  The resulting peptides were analyzed by a 90min data dependent LC-
MS/MS analysis.  Briefly, peptides were resolved using an Eksigent 1D+ 
ultraHPLC equipped with an AS1 autosampler on an 18cm Jupiter (3 micron, 
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300A) 100 µm internal diameter, self-packed analytical column coupled directly to 
an LTQ-orbitrap (ThermoFisher) via a nanoelectrospray source.  A full scan mass 
spectrum followed by 5 data-dependent tandem mass spectra (MS/MS) were 
collected throughout the run using dynamic exclusion to minimize acquisition of 
redundant spectra.  MS/MS spectra were searched against a human protein 
database (IPI) using SEQUEST 
(http://www.ncbi.nlm.nih.gov/pubmed/7741214) and results filtered and collated 
using IDPicker (http://www.ncbi.nlm.nih.gov/pubmed/19522537). Dr. Hayes 
McDonald, Associate Director in the Vanderbilt Proteomics Laboratory and Mass 
Spectrometry Research Center performed the LC-MS/MS. 
 
Western Blot Analysis 
Western blot analysis was performed on the different samples before sending to 
the MS core. I wanted to load equal percentages of the total sample on the gel so 
the samples would be comparable. For the TL and CL I removed 12.5µl from 
2000µl or 0.6%. For the elution samples, 0.6% of 25µl = 0.15µl. Since 0.15µl 
would be impossible to remove I did 0.3µl, which would make it 2x compared to 
the TL and CL. However pipetting accuracy of 0.3µl is still very poor.  The 
samples were loaded on a 12.5% SDS-PAGE gel in the following order: 
 M/TL(+)/TL(-)/CL(+)/CL(-)/E(+)/E(-) 
(+=with DSP, -=without DSP) The gel was run until the dye front reached the 
bottom of the gel then transferred to nitrocellulose overnight. When I came in the 
next morning the power supply had been shut off and since I did not know when 
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this happened I increased the amps to 0.1 and transferred for an additional 5hrs. 
The membrane was washed with 1x PBS 0.05% Tween then blocked in 5% milk 
1xPBS 0.05% Tween overnight. The membrane was blotted with mouse anti-
AREG 6R1C2.4 primary antibody diluted 1:50 in blocking buffer for 1hr at RT 
then washed 3x with 1xPBS 0.05% Tween. The membrane was blotted with 
TrueBlot anti-mouse HRP secondary antibody diluted 1:1000 in blocking buffer 
for 1hr at RT then washed 3x with 1xPBS 0.05% Tween. The 
chemiluminescence reagent was added for 1min then exposed film to the 
membrane for 30sec and 1min 30sec. 
  
AREG-Kinectin Co-Immunoprecipitation. 
One confluent 100mm dish of HCA-7 cells was used.  The dish was 
washed 3x with cold 1xPBS, and the cells were scrapped from dish and spun into 
a pellet. The pellet was resuspended in 2ml 1%NP40 lysis buffer plus protease 
inhibitor. The lysate was divided between two eppendorf tubes.  The cells were 
incubated in lysis buffer for 1hr in the cold room. The lysates were centrifuged for 
15min at max speed then the supernatant was transferred to new tubes. Each 
lysate was cleared with 25µl of a 50% slurry of recombinant protein G agarose 
beads (Invitrogen Catalog no. 15920-010) for 1hr in cold room followed by a 5min 
centrifugation at max speed. The supernatants were transferred to fresh tubes. 
25µl was removed from one tube for a total lysate (TL) sample. 7.5µg of either 
goat anti-kinectin antibody(Santa Cruz sc-19909) or mouse anti-AREG antibody 
(6R1C2.4) was added to one of the lysates then incubated for 1hr in the cold 
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room. 25µl of a 50% slurry of recombinant protein G agarose beads was added 
to each IP and incubated in the cold room for 1hr. The beads were centrifuged 
and 25µl removed for a cleared lysate (CL) sample.  The supernatant was 
removed and the beads washed 4x with 1ml lysis buffer. 40µl of 1x sample buffer 
without DTT was added to each pellet. Equal volume 2x sample buffer was 
added to the TL and CL samples and all samples heated at 70oC for 5min. The 
samples were loaded onto two 10% SDS-PAGE gels with the gel for the anti-
kinectin blot run out much further to provide greater separation of the higher 
molecular weight proteins. The samples were transferred to nitrocellulose and 
blotted as described above. The anti-kinectin antibody was used at 1:200 and the 
anti-AREG was used at 1:50. The secondary rabbit anti-goat HRP antibody was 
diluted 1:10000.  
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Results 
 
Split ubiquitin yeast two-hybrid screen 
 The screening of the split ubiquitin library generated from polarized HCA-7 
cells using full-length AREG tagged with CUB-LexA-VP16 produced 37 unique 
hits (Table 3). These hits were confirmed by binary transformations and a LacZ 
assay. Unfortunately, none of the identified proteins are reported to be involved 
in protein trafficking to the cell surface and many of the proteins have no 
indentified functions whatsoever.  
Because there was not a clear candidate to investigate, 
immunofluorescence co-localization was used to further verify which of the 
identified proteins would be most promising to pursue. At this point the cDNA for 
each of the hits was in the prey library vector. The prey library was generated 
using SfiI restriction sites within the multiple cloning site (MCS) to easily clone 
the cDNA into the prey vector. This SfiI cloning strategy was utilized to release 
each of the cDNAs from the prey vectors and clone into pCMV-Myc. The pCMV-
Myc vector contains a single Myc tag N-terminal to the MCS. Because the prey 
library was also N-terminally tagged, I was able to modify pCMV-Myc using quick 
change PCR to introduce SfiI sites that would keep the cDNA in frame with the 
N-terminal Myc tag. Using the SfiI sites, each of the positive hits from the yeast 
two-hybrid screen was released from the prey vector and inserted into the pCMV-
Myc vector. 
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Table 3. List of confirmed hits from the split ubiquitin yeast two-hybrid 
screen of AREG. The protein IDs and pubmed nucleotide identifier numbers are 
listing in the protein ID column. The number of hits column is the number of times 
the protein was identified in the screen. All hits listed were confirmed by binary 
transformations and lac Z assays. The cellular localization column indicates 
where the protein is reported or predicted to localize in the cell.  
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Once the cDNAs were successfully cloned into pCMV-Myc, they were 
transiently transfected into MDCK cells stably expressing AREG-GFP, which was  
used to simplify the staining procedure. Using indirect immunofluorescence and 
confocal microscopy each of the Myc-tagged constructs was screened for co-
localization with AREG-GFP. The most promising hit was transmembrane protein 
165 (TM165), which appears to co-localize with AREG in a Golgi-like structure 
(Figure 20A). However, Golgi markers were not used to confirm the structure, but 
the co-localization appears to be perinuclear. Because TM165 is a multi-pass 
transmembrane protein, there was concern that placement of the tag on the N-
terminus could result in false positive co-localization. Therefore, TM165 was 
cloned into a pCherry-N1 vector to fuse a cherry fluorescent protein on the C-
terminus of TM165. The C-terminally tagged version of TM165 co-localized with 
AREG-GFP in a similar perinuclear region as the N-terminal Myc-tag, 
demonstrating the co-localization to be genuine (Figure 20B).  
 The final criterion for establishing a true interacting protein was the ability 
to co- immunoprecipitate (co-IP) the protein with AREG. Attempts to co-IP AREG 
and Myc-tagged TM165 through an AREG IP and an anti-Myc blot could not be 
interpreted due to background issues with the anti-Myc blot. Using the Cherry-
tagged TM165 instead to IP AREG and blot for cherry produced negative results, 
with the cherry tag detected in the total lysate samples, but not in the AREG IP 
samples. I concluded after multiple attempts that I could not co-IP AREG and 
TM165, either due to the technical difficulty of immunoprecipitating a multi-pass 
transmembrane protein or because they do not physically interact.  
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Figure 20. Co-localization of AREG and TM165. A) N-terminally Myc-tagged 
TM165 was transiently transfected into MDCK cells expressing AREG-GFP. 
Indirect immunofluorescence for the Myc tag (Red) suggests co-localization with 
AREG-GFP (Green) in a perinuclear region of two different cells. B) C-terminally 
Cherry-tagged TM165 (Red) was transiently transfected into MDCK cells 
expressing AREG-GFP (Green). Detection of the two proteins by confocal 
microscopy demonstrates co-localization in a perinuclear region. The upper 
image shows a field image while the lower image is a magnification of the 
perinuclear region of one cell and shows puncta of co-localization.  
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Table 4. Condensed list of proteins identified from the crosslinked AREG IP 
mass spectral analysis. Protein identification numbers and descriptions are 
listed in descending order of peptide coverage. See appendix A for the full list. 
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Crosslinked AREG immunoprecipitation, mass spectral analysis, and 
kinectin co-immunoprecipitation.  
 The second approach taken to identify interacting proteins for AREG was 
a technique developed by Andrew Smith (Smith et al., 2011). This technique 
uses crosslinking reagents to stabilize transient protein interactions and increase 
the chances of isolating interacting proteins during an IP of the protein of interest. 
Using this approach a number of proteins were identified by mass spectral 
analysis, including the protein kinectin as a possible interacting protein for AREG 
(Table 4).  
Kinectin was first identified as a kinesin-binding protein of motile vesicles 
that localized to the endoplasmic reticulum (ER) (Toyoshima et al., 1992). 
Kinesin, the binding partner for kinectin, is a molecular motor involved in 
anterograde movement along microtubules and plays a role in delivery of 
endocytic vesicles from the cell surface to endosomes (Bomsel et al., 1990; 
Schroer et al., 1988). The association between kinectin and the molecular motor 
kinesin prompted me to further investigate the possible interaction between 
AREG and kinectin.   
 To determine if AREG and kinectin interact, two co-IP experiments were 
performed, an IP of AREG followed by a western blot for kinectin and an IP of 
kinectin followed by a western blot for AREG. The kinectin blot of the AREG IP 
produced a band at 160 kDa, the same size detected in the TL sample and the 
predicted size for kinectin (Figure 21A).  The AREG blot of the kinectin IP 
resulted in a 25 kDa doublet and a band at approximately 45 kDa (Figure 21B). 
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The 25 kDa doublet ran at the same size in the TL sample and corresponds to 
what was previously described as a 26-28 kDa doublet	   (Brown et al., 1998). 
However, the 45 kDa band was clearly smaller then the predominant 50 kDa 
band in the TL sample indicative of full-length, mature AREG (Figure 21B). The 
45 kDa band was previously characterized as an immature ER form of AREG 
that is endo H-sensitive and is not fully processed by the Golgi	   (Brown et al., 
1998). It is interesting that the 45 kDa band, not the predominant post-Golgi 50 
kDa band, co-IPs with kinectin (Figure 21B). These results demonstrate that 
AREG and kinectin do interact and suggest this happens in the ER.  
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Figure 21. Co-immunoprecipitation of AREG and kinectin.  Because of the 
varying intensities of the IP verse the TL samples, different exposure times are 
shown side by side for size comparison. The actual size marker marks are shown 
for an accurate indication of size. A) An IP of AREG followed by an anti-kinectin 
blot detects a band at 160 kDa in the TL and IP samples. B) An IP of kinectin 
followed by an anti-AREG blot detects a band at 45 kDa and a doublet at 25 kDa. 
The 25 kDa doublet is the same size in both the IP and TL sample. The 45 kDa 
band in the IP sample represents an immature ER form of AREG.  
 
	   135	  
Discussion 
 While I was unsuccessful in conclusively determining interacting proteins 
for AREG, the data produced by this work may be beneficial to future members 
of the Coffey lab. Two areas of study that could benefit from these screens are 
the exosome and trafficking projects. The mechanism of how proteins are 
delivered and sorted into exosomes is unclear and may involve proteins 
indentified in these screens that currently have no known function. The 
identification of TM165 and localization to the perinuclear region could reveal an 
unknown role in protein trafficking. As the science progresses and we gain a 
better understanding of how receptor ligands are trafficked within and between 
cells, some of the proteins identified in these two screens may become relevant.   
 TM165, a protein identified in the split ubiquitin yeast two-hybrid screen 
and verified by co-localization, should be followed up with further experiments. 
As a nascent and naive graduate student I set strict criteria for confirming an 
authentic interacting protein, including the ability to co-IP. Now at the end of my 
graduate education, I understand the difficulties of a co-IP and the inability to co-
IP two proteins should not rule out the possibility of an interaction. If given the 
chance I would pursue different methods to confirm an interaction between 
TM165 and AREG.  
Small interference RNA (siRNA) is one method I would use to investigate 
the possible role of TM165 in the trafficking of AREG. The co-localization of 
AREG and TM165 in the perinuclear region and the punctate co-localization 
pattern could indicate these two proteins are co-localizing in an endosomal 
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compartment (Figure 20). Since identifying TM165, I have demonstrated the 
dependence on AP-1B for the proper recycling of AREG, a function that would 
take place in the recycling endosome. Knockdown of TM165 in polarized cells 
may have dramatic effects on the recycling or biosynthetic delivery of AREG.   
Additionally, I would use organelle markers to identify where AREG and 
TM165 are co-localizing. While perinuclear staining can specify Golgi 
localization, AREG and TM165 were never confirmed to be co-localizing in the 
Golgi. Staining for golgin 97 is commonly used as a Golgi marker and could be 
used to determine whether TM165 is localized in this organelle. As mentioned 
earlier, the puncta revealed by immunofluorescence (Figure 20B) could be 
recycling endosomes, which could be identified with labeled transferrin. The 
presence of AREG in exosomes is another discovery since the identification of 
TM165 as a possible AREG interacting protein, making MVBs a possible 
localization. Identifying the organelle where AREG and TM165 co-localize could 
reveal the consequences of their possible interaction.  
 In addition to TM165, the interaction between AREG and kinectin is 
another avenue of study I would devote further work. The identification of kinectin 
as a possible AREG interacting protein was a late discovery in my graduate 
education and the development of a publishable story with kinectin and AREG 
was not possible within the timeframe for my graduation. However, if I were to 
continue in the Coffey lab I would pursue this interaction.   
A role for kinectin in vesicle and organelle delivery to the cell surface has 
already been established. In pancreatic islet β-cells, kinectin has been shown to 
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participate in the delivery of hormone containing vesicles to the cell periphery for 
secretion	  (Bai et al., 2006).  In COS-7 cells, overexpression of kinectin facilitates 
the microtubule-dependent transport of lysosomes to the cell periphery, while 
overexpression of kinectin-kinesin interacting domain fragments inhibited 
lysosomal redistribution	  (Ong et al., 2000; Vignal et al., 2001). Given these recent 
reports, further investigation of the kinectin-AREG interaction would be of 
interest.   
The role kinectin plays in lysosomal delivery to the cell periphery is 
particularly interesting considering our recent findings regarding AREG and 
exosomes	  (Higginbotham et al., 2011). It is unclear what regulatory mechanisms 
determine if a MVB fuses with a lysosome for degradation or the cell membrane 
to release exosomes. The connection between kinectin and lysosomal transport 
begs the question, could kinectin be involved in MVB transport to the cell 
periphery? Kinectin associates with two forms of AREG, the 45 kDa immature ER 
form and the 25 kDa doublet forms (Figure 21B). The 45 kDa ER form may 
associate with kinectin during the elongation step of protein synthesis while 
kinectin anchors elongation factor-1δ to the ER membrane (Ong et al., 2003). 
Interestingly, elongation factor-1 was identified in the crosslinked AREG IP 
screen for interacting proteins (Table 4 and Appendix A). The 25 kDa AREG 
doublet that associates with kinectin is also the most abundant form of AREG 
detected in exosomes, an observation that could shed light on how AREG is 
delivered to exosomes. Could the processing event that generates the 25 kDa 
AREG forms take place in the ER instead of the cell surface? Could the 25 kDa 
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forms originate from the 45 kDa immature ER form of AREG that may be 
improperly folded and processed in the ER before being delivered to a MVB for 
degradation or exosome release? These are just a few questions that arise from 
the observed association of AREG and kinectin that should be pursued in the 
future.  
Hopefully the data generated from the AREG split ubiquitin yeast two-
hybrid screen and the crosslinked AREG IP screen will be useful in future studies 
by the Coffey lab. Expansion from a protein trafficking focus to other areas of 
interest, such as exosome generation, could make the data more relevant. As 
more is learned about AREG, this data could provide a missing piece of 
information to complete future work. 
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CHAPTER V 
 
DISCUSSION AND FUTURE DIRECTIONS 
 
Polar Distribution of AREG 
 AREG delivery to the BL surface of polarized epithelial cells is dependent 
on a novel mono-leucine-based BL sorting motif. Only one mono-leucine BL 
sorting motif has been previously described and has been identified in only two 
other proteins, SCF and CD147, both of which contain the canonical motif 
EEDXXXXXL (Deora et al., 2004; Gonzalez and Rodriguez-Boulan, 2009; 
Wehrle-Haller and Imhof, 2001).  The AREG motif is different and consists of 
EEXXXL (Figure 11). Identification of a novel sorting motif increases the 
opportunities for identifying other proteins that also use this motif for BL 
distribution. One such protein may be HB-EGF, which contains an EEXXXL 
sequence with a similar amino acid composition to the AREG motif (Table 1). 
Both proteins contain the amino acid sequence EEbXbL, where “b” represents a 
basic residue, within a similar distance from the membrane. The similarity in 
charged residues associated with a mono-leucine, located in a region of the HB-
EGF cytoplasmic domain similar to the location of the AREG motif, suggests this 
sequence could be the HB-EGF BL sorting motif. This is a future line of 
investigation that has been opened by the discovery of the novel AREG BL motif.   
 The steady state polarized distribution of AREG is dependent on the 
epithelial specific adaptor protein AP-1B (Figure 12). My data suggest AREG 
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biosynthetic delivery to the BL surface is independent of AP-1B because of the 
amount of AREG present on the BL surface in LLC-PK1 cells and µ1B KD MDCK 
cells. However, I demonstrated AREG is dependent on AP-1B after endocytosis 
for proper recycling back to the BL surface in LLC-PK1 cells (Figure 13). 
Interestingly, AREG is the most rapidly endocytosed of the EGFR ligands, 
suggesting the proper recycling of AREG is important for its function (personal 
communication with Steve Wiley, unpublished data).  AREG is the only EGFR 
ligand known to date to be dependent on AP-1B for polarized distribution. TGFα 
is delivered to the BL surface by the CaRT protein NKD2 and is independent of 
AP-1B for polarized distribution	   (Li et al., 2007). EGF is delivered to both the 
apical and BL surface and selectively cleaved from the BL surface	  (Dempsey et 
al., 1997). EGF does contain a BL sorting motif, which if mutated impairs BL 
delivery	  (Groenestege et al., 2007). The role AP-1B plays in BL delivery of EGF 
has not been investigated. EREG is the most recent EGFR ligand to be 
investigated in the Coffey laboratory and has been shown to contain a tyrosine-
based BL sorting motif that is AP-1B-independent (unpublished data). Future 
studies will discern if other EGFR ligands rely on AP-1B for polarized distribution. 
 The EGFR is dependent on AP-1B for polarized distribution in a similar 
manner as AREG. In LLC-PK1 cells, the EGFR is present on both the apical and 
BL surface	  (Ryan et al., 2010). The EGFR was shown to bind AP-1B via a non-
canonical di-leucine motif in an in vitro peptide pulldown assay. Interestingly, 
when an acidic residue was introduced to create a canonical di-leucine motif, the 
EGFR was still delivered on the BL surface but absent from the apical surface in 
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LLC-PK1 cells. The authors concluded the EGFR is delivered to the BL surface 
via multiple routes, both AP-1B-depenent and independent	  (Ryan et al., 2010). I 
draw a different conclusion; the EGFR is delivered to the BL surface via an AP-
1B-independent route but is recycled via an AP-1B-dependent route, just like 
AREG. Introduction of the canonical di-leucine motif created a lysosomal 
targeting signal that may have diverted the EGFR from the recycling endosome 
and prevented mis-recycling to the apical surface (Letourneur and Klausner, 
1992). If I am correct, AREG and the EGFR are both delivered to the BL surface 
via AP-1B-independent routes but are both dependent on AP-1B for proper 
recycling back to the BL surface.  
 Future studies of the signal recognized by AP-1B in AREG could shed 
light on how the EGFR is recycled by AP-1B. Analysis for similarities between the 
EGFR non-canonical di-leucine signal demonstrated to bind AP-1B and the 
AREG mono-leucine motif reveals some commonalities. The EGFR di-leucine 
and AREG mono-leucine motifs are surrounded by similarly charged residues 
(RRLLQE vs KKLRQE). Comparisons of the AREG cytoplasmic domain structure 
with the previously described EGFR structure of this region my reveal similarities 
between the AREG and EGFR cytoplasmic domains	   (Hobert et al., 1997). It 
would also be interesting to know if both of the leucine residues in the EGFR di-
leucine motif are necessary for binding to AP-1B. While mutation of the two basic 
lysine residues in the AREG cytoplasmic domain did not affect BL distribution, 
mutation of the single leucine did and may have disrupted the AP-1B interaction. 
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This recent report on EGFR interaction with AP-1B via leucine residues may 
provide important clues into how AREG interacts with AP-1B	  (Ryan et al., 2010). 
 
Post-Translational Modification of AREG 
 Analysis of AREG in exosomes revealed a possible post-translational 
modification of AREG not previously observed in AREG IP or cellular lysate 
samples. AREG is known to be N-glycosylated during its transit through the Golgi 
to the cell surface	   (Brown et al., 1998). However, the modifications detected in 
the exosome preparations were much more extensive and created a smearing 
pattern more indicative of ubiquitylation than glycosylation (Figure 15). The 
enrichment of the modified AREG in exosomes suggests the modification could 
be important for delivery to exosomes, a process that is currently poorly 
understood.  
 I could not identify the modification on the exosomal AREG due to the 
technical difficulties of isolating the transmembrane AREG from the exosomes. 
However, I was able to identify ubiquitin as a possible modification of AREG 
using HA-tagged ubiquitin (Figure 16). While ubiquitin may not be the 
modification seen in the exosomes, it is still interesting to know AREG does 
contain sites suitable for ubiquitylation. This information could be useful in future 
studies of how AREG is regulated at the cell surface, especially considering 
AREG is the most rapidly endocytosed EGFR ligand and is recycled in an AP-
1B-dependent process (Figure 13 and personal communication with Steve Wiley, 
unpublished data).  Analysis of the AREG cytoplasmic domain, which only 
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contains three lysine residues, may reveal an unknown consensus ubiquitylation 
site present in other proteins important in disease.   
 I was able to support the hypothesis that ubiquitylation regulates exosomal 
AREG without directly demonstrating ubiquitylation is the modification seen in 
exosomes. This was accomplished analyzing exosome preparations from MDCK 
cells expressing wild-type AREG and lysine-free AREG-K2A. The data suggest 
AREG-K2A was not incorporated into the exosomes as efficiently as wild-type 
AREG (Figure 17). These preliminary data provide a foundation for future 
investigations into the role ubiquitylation may play in regulating exosomal AREG. 
Ubiquitylated proteins are present in exosomes	   (Buschow et al., 2005). 
However, the data suggest the majority of AREG in exosomes is not 
ubiquitylated. Addition of one ubiquitin monomer to a protein increases the 
molecular weight of that protein by approximately 9 kDa, but the prominent 
AREG bands detected in exosomes do not represent an increased molecular 
weight. My hypothesis is ubiquitylation regulates delivery to exosomes followed 
by deubiquitylation prior to ILV formation, a hypothesis supported by the literature	  
(Hurley, 2008; Swaminathan et al., 1999). The smear seen in exosomes could 
result from inefficient deubiquitylation prior to ILV formation.  Future studies will 
clarify the role ubiquitin plays in regulating AREG.  
 
AREG Interacting Proteins 
Two proteins, TM165 and kinectin, were identified as possible interacting 
proteins for AREG and both have the potential to play important roles in AREG 
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trafficking. Kinectin interacts with the molecular motor kinesin and has been 
demonstrated to play a role in vesicular secretion and organelle trafficking to the 
cell periphery	  (Bai et al., 2006; Ong et al., 2000). There is no reported function for 
TM165, but it co-localizes with AREG in a region of the cell possibly involved in 
proteins sorting and trafficking (Figure 20). While these two proteins cleared the 
most hurdles of all the proteins identified in the two screens for AREG interacting 
proteins, the remaining identified proteins should not be completely ignored.  The 
complete list of all the proteins identified in these screens is included in this 
thesis for future reference, as they may become relevant in future studies of 
AREG (Table 3, Table 4, and Appendix A).  
 
My graduate studies have focused on the EGFR ligand AREG and how it 
is trafficked within polarized epithelial cells. The EGFR signaling pathway is often 
dysregulated in cancer, so understanding each aspect of this pathway provides 
us with additional knowledge to develop effective treatments. My work has 
expanded this knowledge by revealing the critical elements involved in delivery of 
AREG to the BL surface of polarized epithelial cells. I have demonstrated that 
AREG contains a mono-leucine-based BL sorting motif and depends on AP-1B 
for steady state polar distribution. Ubiquitylation has been revealed as a possible 
level of AREG regulation. Kinecitn and TM165 have been uncovered as potential 
interacting proteins for AREG. Additional studies are needed, but our 
understanding of how AREG is trafficked and regulated has been expanded. 
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APPENDIX A 
 
Complete list of proteins identified in the crosslinked AREG co-IP screen 
for AREG interacting proteins. Protein identification numbers are listed in the left 
column, protein descriptions in the center column and peptide coverage in the 
right column. Proteins are listed in descending order of peptide coverage. 
  
Protein Description Coverage 
IPI:IPI00026272.2 Histone H2A type 1-B 42 
IPI:IPI00031562.3 Histone H2A type 3 42 
IPI:IPI00081836.3 Histone H2A type 1-H 42 
IPI:IPI00216456.5 Histone H2A type 1-C 42 
IPI:IPI00220855.3 H2A histone family 42 
IPI:IPI00255316.5 Histone H2A type 1-D 42 
IPI:IPI00291764.5 Histone H2A type 1 42 
IPI:IPI00552873.2 Histone H2A type 1-J 42 
IPI:IPI00008530.1 60S acidic ribosomal protein P0 40 
IPI:IPI00453473.6 Histone H4 39 
IPI:IPI00794746.1 24 kDa protein 38 
IPI:IPI00008529.1 60S acidic ribosomal protein P2 37 
Cntm_P13645|K1C10_HUMAN Keratin 35 
IPI:IPI00009865.2 Keratin 35 
IPI:IPI00102165.3 H2A histone family member J 35 
Cntm_Q65ZC0|Q65ZC0_MOUSE Kappa light chain C_region (Fragment) - Mus musculus (Mouse). 34 
IPI:IPI00030179.3 60S ribosomal protein L7 32 
IPI:IPI00141938.4 H2A histone family 32 
IPI:IPI00219156.7 60S ribosomal protein L30 32 
IPI:IPI00217030.10 40S ribosomal protein S4 31 
IPI:IPI00013415.1 40S ribosomal protein S7 31 
IPI:IPI00215719.6 60S ribosomal protein L18 30 
IPI:IPI00216587.9 40S ribosomal protein S8 30 
IPI:IPI00413324.6 60S ribosomal protein L17 30 
IPI:IPI00478208.2 hypothetical protein LOC645296 30 
IPI:IPI00514874.1 hypothetical protein LOC645441 30 
IPI:IPI00644171.1 hypothetical protein LOC642250 30 
IPI:IPI00010153.5 60S ribosomal protein L23 30 
IPI:IPI00742805.1 15 kDa protein 30 
IPI:IPI00795408.1 15 kDa protein 30 
IPI:IPI00783060.1 Ubiquitin 30 
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IPI:IPI00003918.6 60S ribosomal protein L4 29 
IPI:IPI00012023.1 Amphiregulin precursor 29 
IPI:IPI00470657.1 Anti-colorectal carcinoma heavy chain 28 
IPI:IPI00470528.5 60S ribosomal protein L15 28 
IPI:IPI00550032.1 Ribosomal protein L15 pseudogene 3 28 
IPI:IPI00847986.1 Isoform 2 of 40S ribosomal protein S24 28 
IPI:IPI00018278.3 Histone H2AV 28 
IPI:IPI00218448.4 Histone H2A.Z 28 
IPI:IPI00651660.1 ribosomal protein L3 isoform b 27 
IPI:IPI00220740.1 Isoform 2 of Nucleophosmin 27 
IPI:IPI00029750.1 Isoform 1 of 40S ribosomal protein S24 27 
IPI:IPI00008527.3 60S acidic ribosomal protein P1 27 
IPI:IPI00026271.5 40S ribosomal protein S14 27 
IPI:IPI00221092.8 40S ribosomal protein S16 27 
IPI:IPI00640929.1 Ribosomal protein S6 27 
IPI:IPI00795465.1 Protein 27 
IPI:IPI00796075.1 20 kDa protein 27 
IPI:IPI00414860.6 60S ribosomal protein L37a 27 
IPI:IPI00554723.5 60S ribosomal protein L10 26 
IPI:IPI00853161.1 ribosomal protein L10 26 
IPI:IPI00247583.5 60S ribosomal protein L21 26 
IPI:IPI00788010.1 similar to 60S ribosomal protein L21 26 
IPI:IPI00444262.3 CDNA FLJ45706 fis 25 
IPI:IPI00472171.2 RPL7 protein 25 
IPI:IPI00412579.6 60S ribosomal protein L10a 25 
IPI:IPI00827508.1 Ribosomal protein L1 25 
IPI:IPI00069693.4 Uncharacterized protein ENSP00000350479 25 
IPI:IPI00219486.2 40S ribosomal protein S24. Isoform 2 25 
IPI:IPI00845507.1 Ribosomal protein L21 variant (Fragment) 25 
IPI:IPI00024933.3 60S ribosomal protein L12 25 
IPI:IPI00550021.4 60S ribosomal protein L3 24 
IPI:IPI00013485.3 40S ribosomal protein S2 24 
IPI:IPI00479366.1 Uncharacterized protein ENSP00000351543 24 
IPI:IPI00549248.4 Isoform 1 of Nucleophosmin 24 
IPI:IPI00031812.3 Nuclease sensitive element-binding protein 1 24 
IPI:IPI00385699.3 Uncharacterized protein YBX1 24 
IPI:IPI00450235.1 Nuclease sensitive element binding protein-1 24 
IPI:IPI00646899.1 Ribosomal protein L10 24 
IPI:IPI00555841.2 15 kDa protein 24 
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IPI:IPI00329389.8 60S ribosomal protein L6 23 
IPI:IPI00790342.1 60S ribosomal protein L6 23 
IPI:IPI00419880.6 40S ribosomal protein S3a 23 
IPI:IPI00472119.2 Uncharacterized protein ENSP00000343748 23 
IPI:IPI00221089.5 40S ribosomal protein S13 23 
IPI:IPI00216153.7 40S ribosomal protein S15 23 
IPI:IPI00827674.1 Isoform 2 of Nucleolin 22 
IPI:IPI00794734.1 13 kDa protein 22 
IPI:IPI00219155.5 60S ribosomal protein L27 22 
IPI:IPI00550247.2 11 kDa protein 22 
IPI:IPI00221093.7 40S ribosomal protein S17 22 
IPI:IPI00414603.3 similar to 40S ribosomal protein S17 isoform 1 22 
IPI:IPI00604620.3 Isoform 1 of Nucleolin 21 
IPI:IPI00299573.12 60S ribosomal protein L7a 21 
IPI:IPI00479315.2 Uncharacterized protein ENSP00000351738 21 
Cntm_P00761|TRYP_PIG Trypsin - Sus scrofa (Pig). 21 
IPI:IPI00382885.1 60S ribosomal protein L27 21 
IPI:IPI00550766.1 RRP1-like protein 20 
IPI:IPI00021266.1 60S ribosomal protein L23a 20 
IPI:IPI00793523.1 18 kDa protein 20 
IPI:IPI00794894.1 Protein 20 
IPI:IPI00023048.4 Elongation factor 1-delta 20 
IPI:IPI00398135.2 hypothetical protein LOC389435 20 
IPI:IPI00456758.4 60S ribosomal protein L27a 20 
IPI:IPI00827619.1 16 kDa protein 20 
IPI:IPI00477179.1 Isoform 2 of Nucleolar RNA helicase 2 19 
IPI:IPI00218592.5 Isoform ASF-3 of Splicing factor 19 
IPI:IPI00186712.5 OTTHUMP00000018641 19 
IPI:IPI00401819.2 Putative uncharacterized protein RPS26 19 
IPI:IPI00655650.2 40S ribosomal protein S26 19 
IPI:IPI00295992.4 Isoform 2 of ATPase family AAA domain-containing protein 3A 18 
IPI:IPI00007188.5 ADP/ATP translocase 2 18 
IPI:IPI00005589.1 Uncharacterized protein ENSP00000275524 18 
IPI:IPI00395998.5 60S ribosomal protein L32 18 
IPI:IPI00456429.3 ubiquitin and ribosomal protein L40 precursor 18 
IPI:IPI00012493.1 40S ribosomal protein S20 18 
IPI:IPI00015953.3 Isoform 1 of Nucleolar RNA helicase 2 17 
IPI:IPI00003881.5 Heterogeneous nuclear ribonucleoprotein F 17 
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IPI:IPI00012772.8 60S ribosomal protein L8 17 
IPI:IPI00412607.6 60S ribosomal protein L35 17 
IPI:IPI00014230.1 Complement component 1 Q subcomponent-binding protein 17 
IPI:IPI00791426.1 13 kDa protein 17 
IPI:IPI00026302.3 60S ribosomal protein L31 17 
IPI:IPI00856058.1 ribosomal protein L31 isoform 3 17 
IPI:IPI00025091.3 40S ribosomal protein S11 17 
IPI:IPI00328753.1 Isoform 1 of Kinectin 16 
IPI:IPI00789159.1 22 kDa protein 16 
IPI:IPI00215884.4 Isoform ASF-1 of Splicing factor 16 
IPI:IPI00021924.1 Histone H1x 16 
IPI:IPI00848331.1 ribosomal protein L31 isoform 2 16 
IPI:IPI00795717.1 19 kDa protein 16 
IPI:IPI00037070.2 Isoform 2 of Heat shock cognate 71 kDa protein 15 
IPI:IPI00795040.1 Heat shock 70kDa protein 8 isoform 2 variant (Fragment) 15 
IPI:IPI00217465.5 Histone H1.2 15 
IPI:IPI00217467.3 Histone H1.4 15 
IPI:IPI00465361.4 60S ribosomal protein L13 15 
IPI:IPI00797230.1 32 kDa protein 15 
IPI:IPI00218606.7 40S ribosomal protein S23 15 
IPI:IPI00787131.1 similar to 60S ribosomal protein L35 15 
IPI:IPI00179330.6 ubiquitin and ribosomal protein S27a precursor 15 
IPI:IPI00784990.2 Ubiquitin C splice variant 15 
IPI:IPI00794659.1 16 kDa protein 15 
IPI:IPI00217466.3 Histone H1.3 14 
IPI:IPI00515047.1 Actin 14 
IPI:IPI00815690.1 Leucocyte antigen A precursor 14 
IPI:IPI00221088.5 40S ribosomal protein S9 14 
IPI:IPI00739952.2 similar to ribosomal protein S23 14 
IPI:IPI00793102.1 11 kDa protein 14 
IPI:IPI00031691.1 60S ribosomal protein L9 14 
IPI:IPI00218591.2 Isoform ASF-2 of Splicing factor 13 
IPI:IPI00745955.2 Probable rRNA-processing protein EBP2 13 
IPI:IPI00003865.1 Isoform 1 of Heat shock cognate 71 kDa protein 12 
IPI:IPI00816229.1 ACTA2 protein (Fragment) 12 
IPI:IPI00306332.4 60S ribosomal protein L24 12 
IPI:IPI00025329.1 60S ribosomal protein L19 12 
IPI:IPI00029731.8 60S ribosomal protein L35a 12 
IPI:IPI00735961.2 similar to ribosomal protein L35a 12 
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IPI:IPI00005978.8 Splicing factor 12 
IPI:IPI00796848.1 24 kDa protein 12 
IPI:IPI00328840.9 THO complex subunit 4 12 
IPI:IPI00742905.1 146 kDa protein 11 
IPI:IPI00844578.1 ATP-dependent RNA helicase A 11 
IPI:IPI00410017.1 Isoform 2 of Polyadenylate-binding protein 1 11 
IPI:IPI00478522.1 61 kDa protein 11 
IPI:IPI00216237.5 60S ribosomal protein L36 11 
IPI:IPI00644631.3 HLA class I histocompatibility antigen 11 
IPI:IPI00005198.2 Interleukin enhancer-binding factor 2 11 
IPI:IPI00793696.1 19 kDa protein 11 
IPI:IPI00396321.1 Leucine-rich repeat-containing protein 59 11 
IPI:IPI00550239.4 Histone H1.0 11 
IPI:IPI00024684.1 Interferon-induced GTP-binding protein Mx2 10 
IPI:IPI00402391.3 Isoform 3 of Heterogeneous nuclear ribonucleoprotein U-like protein 1 10 
IPI:IPI00736859.1 Isoform 4 of Heterogeneous nuclear ribonucleoprotein U-like protein 1 10 
IPI:IPI00021840.1 40S ribosomal protein S6 10 
IPI:IPI00008708.5 Ribosomal L1 domain-containing protein 1 10 
IPI:IPI00642046.1 Putative uncharacterized protein 10 
IPI:IPI00735318.1 similar to ribosomal protein L13a isoform 2 10 
IPI:IPI00418813.2 CDNA FLJ46113 fis 10 
IPI:IPI00719280.2 ubiquitin B precursor 10 
IPI:IPI00798155.3 Ubiquitin C splice variant 10 
IPI:IPI00015838.3 Cell growth-regulating nucleolar protein 10 
IPI:IPI00413611.1 DNA topoisomerase 1 9 
IPI:IPI00644079.2 heterogeneous nuclear ribonucleoprotein U isoform a 9 
IPI:IPI00008524.1 Isoform 1 of Polyadenylate-binding protein 1 9 
IPI:IPI00796945.1 70 kDa protein 9 
IPI:IPI00013070.2 Isoform 1 of Heterogeneous nuclear ribonucleoprotein U-like protein 1 9 
IPI:IPI00167147.1 Isoform 2 of Heterogeneous nuclear ribonucleoprotein U-like protein 1 9 
IPI:IPI00218609.2 Isoform Short of Double-stranded RNA-binding protein Staufen homolog 1 9 
IPI:IPI00641873.1 Staufen 9 
IPI:IPI00643664.1 staufen isoform c 9 
IPI:IPI00000875.6 Elongation factor 1-gamma 9 
IPI:IPI00747497.1 50 kDa protein 9 
IPI:IPI00642971.3 eukaryotic translation elongation factor 1 delta isoform 1 9 
IPI:IPI00304612.9 60S ribosomal protein L13a 9 
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IPI:IPI00398949.1 Uncharacterized protein ENSP00000349505 9 
IPI:IPI00398964.2 similar to ribosomal protein L13a 9 
IPI:IPI00398983.3 OTTHUMP00000018470 9 
IPI:IPI00003362.2 HSPA5 protein 8 
IPI:IPI00215637.5 ATP-dependent RNA helicase DDX3X 8 
IPI:IPI00000001.2 Isoform Long of Double-stranded RNA-binding protein Staufen homolog 1 8 
IPI:IPI00328715.4 Protein LYRIC 8 
IPI:IPI00793729.1 UBC protein 8 
IPI:IPI00000494.6 60S ribosomal protein L5 8 
IPI:IPI00513959.3 RNA binding motif protein 39 8 
IPI:IPI00843773.1 Putative uncharacterized protein DKFZp686A11192 8 
IPI:IPI00027107.5 Tu translation elongation factor 8 
IPI:IPI00011253.3 40S ribosomal protein S3 8 
IPI:IPI00005416.3 NICE-4 protein (Fragment) 8 
IPI:IPI00005492.2 WD repeat-containing protein 5 8 
IPI:IPI00102815.1 Nucleolar complex protein 3 homolog 7 
IPI:IPI00843861.1 Uncharacterized protein NOC3L 7 
IPI:IPI00012341.1 Isoform SRP40-1 of Splicing factor 7 
IPI:IPI00009328.4 Eukaryotic initiation factor 4A-III 7 
IPI:IPI00555602.1 CD68 antigen variant (Fragment) 7 
IPI:IPI00746554.2 48 kDa protein 7 
IPI:IPI00027831.1 Glutamate-rich WD repeat-containing protein 1 7 
IPI:IPI00005024.3 Isoform 1 of Myb-binding protein 1A 6 
IPI:IPI00607584.1 Isoform 2 of Myb-binding protein 1A 6 
IPI:IPI00383296.5 Isoform 2 of Heterogeneous nuclear ribonucleoprotein M 6 
IPI:IPI00555857.1 CS0DF038YO05 variant (Fragment) 6 
IPI:IPI00556297.1 Arginine/serine-rich splicing factor 6 variant (Fragment) 6 
IPI:IPI00025491.1 Eukaryotic initiation factor 4A-I 6 
IPI:IPI00032374.3 Isoform 2 of RRP1-like protein B 6 
IPI:IPI00290952.6 Isoform 1 of RRP1-like protein B 6 
IPI:IPI00220834.8 ATP-dependent DNA helicase 2 subunit 2 6 
IPI:IPI00479630.3 Isoform 3 of Fragile X mental retardation syndrome-related protein 1 6 
IPI:IPI00554715.2 Isoform 2 of Fragile X mental retardation syndrome-related protein 1 6 
IPI:IPI00163505.2 Isoform 1 of RNA-binding protein 39 6 
IPI:IPI00215801.1 Isoform 2 of RNA-binding protein 39 6 
IPI:IPI00556364.1 Interleukin enhancer binding factor 3 isoform c variant (Fragment) 6 
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IPI:IPI00017617.1 Probable ATP-dependent RNA helicase DDX5 5 
IPI:IPI00023785.6 DEAD box polypeptide 17 isoform 1 5 
IPI:IPI00651653.1 Isoform 3 of Probable ATP-dependent RNA helicase DDX17 5 
IPI:IPI00651677.1 Isoform 2 of Probable ATP-dependent RNA helicase DDX17 5 
IPI:IPI00012726.4 Isoform 1 of Polyadenylate-binding protein 4 5 
IPI:IPI00555747.1 Isoform 2 of Polyadenylate-binding protein 4 5 
IPI:IPI00642944.1 Poly 5 
IPI:IPI00414676.6 Heat shock protein HSP 90-beta 5 
IPI:IPI00796844.1 Full-length cDNA clone CS0CAP007YF18 of Thymus of Homo sapiens 5 
IPI:IPI00171903.2 Isoform 1 of Heterogeneous nuclear ribonucleoprotein M 5 
IPI:IPI00328293.2 Serine/arginine repetitive matrix 1 5 
IPI:IPI00647720.1 Isoform 1 of Serine/arginine repetitive matrix protein 1 5 
IPI:IPI00012345.2 Isoform SRP55-1 of Splicing factor 5 
IPI:IPI00215879.1 Isoform SRP55-3 of Splicing factor 5 
IPI:IPI00016249.2 Isoform 1 of Fragile X mental retardation syndrome-related protein 1 5 
IPI:IPI00018971.7 52 kDa Ro protein 5 
IPI:IPI00025447.8 Elongation factor 1-alpha 5 
IPI:IPI00396485.3 Elongation factor 1-alpha 1 5 
IPI:IPI00472724.1 Elongation factor 1-alpha 5 
IPI:IPI00847435.1 EEF1A1 protein 5 
IPI:IPI00642904.1 Poly 4 
IPI:IPI00334775.6 85 kDa protein 4 
IPI:IPI00604607.2 Hsp89-alpha-delta-N 4 
IPI:IPI00797482.1 CDNA FLJ32377 fis 4 
IPI:IPI00219330.2 Isoform 5 of Interleukin enhancer-binding factor 3 4 
IPI:IPI00298789.2 Isoform 2 of Interleukin enhancer-binding factor 3 4 
IPI:IPI00414335.1 Isoform 3 of Interleukin enhancer-binding factor 3 4 
IPI:IPI00556173.1 Isoform 6 of Interleukin enhancer-binding factor 3 4 
IPI:IPI00015808.3 Nucleolar GTP-binding protein 2 4 
IPI:IPI00797590.2 NOL1 protein 4 
IPI:IPI00025874.2 
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase 67 kDa subunit 
precursor 
4 
IPI:IPI00382470.3 heat shock protein 90kDa alpha (cytosolic) 3 
IPI:IPI00784295.2 Isoform 1 of Heat shock protein HSP 90-alpha 3 
IPI:IPI00789847.1 Protein 3 
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IPI:IPI00798127.1 ubiquitin C 3 
IPI:IPI00298788.4 Isoform 1 of Interleukin enhancer-binding factor 3 3 
IPI:IPI00418313.3 Isoform 4 of Interleukin enhancer-binding factor 3 3 
IPI:IPI00029019.5 Isoform 2 of Ubiquitin-associated protein 2-like 3 
IPI:IPI00181306.3 Isoform 3 of Ubiquitin-associated protein 2-like 3 
IPI:IPI00412535.2 115 kDa protein 3 
IPI:IPI00514856.4 Isoform 1 of Ubiquitin-associated protein 2-like 3 
IPI:IPI00294891.4 Isoform 2 of Putative RNA methyltransferase NOL1 3 
IPI:IPI00654555.2 Isoform 1 of Putative RNA methyltransferase NOL1 3 
IPI:IPI00177817.4 
Isoform SERCA2A of 
Sarcoplasmic/endoplasmic reticulum 
calcium ATPase 2 
2 
IPI:IPI00219078.5 
Isoform SERCA2B of 
Sarcoplasmic/endoplasmic reticulum 
calcium ATPase 2 
2 
IPI:IPI00747443.1 Uncharacterized protein ATP2A2 2 
IPI:IPI00792389.1 115 kDa protein 2 
IPI:IPI00794296.1 110 kDa protein 2 
IPI:IPI00644127.1 Isoleucyl-tRNA synthetase 2 
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APPENDIX B 
 
 
This figure demonstrates the accuracy of the 6R1C2.4 anti-AREG mouse 
monoclonal antibody used throughout my work. Previous work published by the 
Coffey lab described the main AREG bands detected on SDS-PAGE gels to be 
50 kDa, a 28-26 kDa doublet, and 16 kDa (Figure 8)	  (Brown et al., 1998). These 
bands were detected from samples metabolically labeled with Tran35S-label and 
run under reduced conditions. In order to use the 6R1C2.4 antibody for western 
blotting, I determined the samples must be run under non-reduced conditions in 
order to preserve the epitope in the extracellular domain recognized by the 
antibody. The 6R1C2.4 antibody cannot detect reduced AREG. The main bands 
detected on AREG western blots using 6R1C2.4 are 50 kDa, a doublet below 25 
kDa, and a16 kDa band. The size of this doublet is different from the previously 
described size, so therefore, I set out to confirm I was indeed detecting the 
membrane forms of AREG in my western blots.  
The AREG western blot below is of four different cell lines (from left to 
right): MDCK II cells, which contain no detectible AREG and act as a negative 
control; HCA-7 cells, which express high levels of endogenous AREG and act as 
a positive control for wild-type endogenous AREG; MDCK-ARTL, which express 
a truncated form of AREG lacking all but four residues of the cytoplasmic 
domain; MDCK-AR, which over express full-length wild-type AREG. TL is the 
total lysate sample and IP is an immunoprecipitation of AREG using the 6R1C2.4 
antibody. The samples were separated on a 12.5% SDS-PAGE gel and 
transferred to a nitrocellulose membrane. The membrane was blotted with 
6R1C2.4 and an anti-mouse TrueBlot secondary HRP-conjugated antibody.  
This blot demonstrates the accuracy of the antibody and confirms the 
detection of membrane AREG because of the shift seen in the ARTL lanes. The 
ARTL form of AREG does not contain the cytoplasmic domain so it should run 
slightly smaller then the wild-type membrane AREG. Slightly smaller forms of all 
the wild-type AREG forms can be seen in the ARTL samples, confirming these 
bands to be actual membrane forms of wild-type AREG. If these were not 
membrane forms, but instead soluble forms, the ARTL bands would be the same 
size as the wild-type bands. The absence of signal in the MDCK II negative 
control demonstrates the lack of background. The wild-type AREG bands 
detected in the MDCK-AR samples are the same size as the AREG bands 
detected in the HCA-7 samples, which are endogenously produced AREG. 
Combined, the results in this blot demonstrate the accuracy of the 6R1C2.4 
mouse anti-AREG antibody in detecting membrane AREG in total cell lysate and 
IP samples.  
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